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Abstract 
    The modular polyketide synthase responsible for biosynthesis of the antibiotic mupirocin 
occupies 75 kb of Pseudomonas fluorescens NCIMB 10586, while a hybrid of PKS/NRPS is 
responsible for biosynthesis of the antibiotic thiomarinol located on a 97 kb plasmid pTML1 
in Pseudoalteromonas spp SANK 73390. Biosynthesis of the acyl side chains in mupirocin 
and thiomarinol are thought to be either through esterification of the fully synthesised fatty 
acid (C9 or C8) or through extension of the PK derived ester starter unit which is predicted to 
be carried out on MmpB and TmpB. mupU/O/V/C/F and macpE are proposed to be sufficient 
for the conversion of pseudomonic acid B to pseudomonic acid A. Mupirocin is regulated via 
quorum sensing, while regulation of thiomarinol was not identified.  
    Production of thiomarinol was determined to occur after 8 hours of growth, while acidic 
conditions and use of acetone with ethyl acetate improved the extraction. TmlU, the 
thiomarinol amide ligase, did not complement a mupU mutant in mupirocin, and was found to 
block the biosynthesis of 9-hydroxynonanoic acid, causing truncation of 9-HN. This suggests 
that MupU, prevents MmpB from being an iterative PKS. KS-B2/ACP-B2 was shown to be 
involved in the removal of C8-OH from thiomarinol. Genetically manipulated mupU 
increased the production of mupirocin to 3 to 4 fold without abolishing PA-B production. 
Fused mupU-macpE complemented the NCIMB10586∆mupU∆macpE double mutant. 
However, insertion of this fusion into MmpB blocked the biosynthesis of mupirocin, while 
insertion after MmpA did not changed the pathway. Attempts to mobilise pTML1 revealed 
that a hybrid plasmid of RK2-R6K γ-ori was integrated into pTML1 but recovery of this 
cointegrate has not yet been recovered in E. coli.         
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1. Introduction 
1.1 Polyketide natural products 
    The worldwide distribution of antibiotic resistance, especially the emergence of diverse 
clones of methicillin resistant Staphylococcus aureus (MRSA) is threatening the scientific 
revolution of antibiotic therapy (Gould, 2009). Therefore, to overcome such problems, many 
scientists are involved in the search for new antibiotics effective against multiply drug 
resistant bacteria. Effective biological activities have been investigated with several natural 
products of novel structure (Sujatha et al., 2005). Among the most important microbial 
secondary metabolites in medicine are polyketides, represented in clinical uses by antibiotics 
(erythromycin A, rifamycin S), antifungals (amphotericin B), antiparasitics (avermectin), as 
agents lowering blood cholesterol (lovastatin), and rapamycin as an example of 
immunosuppressants (Weissman and Leadlay, 2005). Structurally, polyketides include a very 
diverse family of natural products (Hranueli et al., 2001), and have been divided into two 
groups: those that contain one to six aromatic rings designated as aromatic polyketides, while 
the second group is subdivided according to their chemical diversity into macrolides and 
ansamycins (having both lactone and lactam rings), polyethers and polyenes, designated as 
complex polyketides (OʹHagan, 1991). Structures of a small selection of polyketides with 
biological activites and pharmacological properties are presented (Figure 1.1). The size of 
polyketide gene clusters ranges from 20 to more than 100 kb and DNA sequencing of many 
of these clusters has shown substantial homology, suggesting that they must have emerged by 
evolution from a common ancestor (Hranueli et al., 2001). Moreover, bioinformatic studies 
on modular PKSs in actinomyctes revealed that a single cross over by recombination between 
modules of PKSs could be the major driving force for the evolution of a new PKS with 
chemical diversity (Zucko et al., 2012).  
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    Actinomycetes genera and particularly Streptomyces species are the group of organisms 
that have been manifested to produce the largest number of secondary metabolites: 
actinomycetes synthesize 40% of the total antibiotically active substances, and 40% of that 
total consists of polyketides (Hranueli et al., 2001). In particular, Streptomyces is widely 
known as an important industrial microorganism, since they produce many biologically active 
metabolites, including antibiotics (Williams et al., 1983).  
 
 
Figure 1.1 Examples of polyketides with pharmacological properties (adapted from 
Weissman, 2004). 
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    Mupirocin (Figure 1.11), as an example of a polyketide product, is produced as a mixture 
of pseudomonic acids that exhibit immense structural and functional diversity and possess 
great pharmaceutical potential (Pfeifer and Khosla 2001; Nicolaou et al., 2009). It has been 
used clinically as Bactroban in the UK since 1985 (Cookson, 1990). The main use of 
mupirocin is to control Staphylococcus aureus (especially MRSA) (Wilcox et al., 2003). Low 
toxicity to human and animals made possible the use of this product for various kinds of skin, 
ear and nose infections (Szell et al., 2002). However, mupirocin is unstable in vivo, because 
of the hydrolytic inactivation of the ester-bond between monic acid and 9-hydroxynonanoic 
acid (Sutherland et al., 1985).  
    Thiomarinol (Figure 1.18), an interesting example in the class of naturally hybrid 
molecules (Mancini et al., 2007) with a strong antimicrobial activity, is produced by the 
marine bacterium, Alteromonas rava sp. nov. SANK 733390 (Shiozawa et al., 1993). 
Deduction based on chemical configuration confirmed that is a hybrid of two types of 
antibiotics, pseudomonic acids and pyrrothines (Shiozawa et al., 1995). As for mupirocin, the 
mode of action of thiomarinol is to inhibit bacterial isoleucyl–tRNA synthetase, and the 
inhibition is stronger by thiomarinols A, B and D (Shiozawa et al., 1997). Two other 
antibiotics belonging to the group of pyrrothine antibiotics, holomycin and N-
propionylholothin are produced by a mutant strain of cephamycin C producer, and were 
identified on the basis of activity against a β-lactamase-producing strain of Serratia 
marcescens (Okamura et al., 1977; Kenig and Reading, 1979). Approximately 35% of strains 
of surface associated marine bacteria, in addition to a diverse range of free-living and 
sediment-inhabiting organisms were observed to produce compounds with antimicrobial 
properties (Burgess et al., 1991, 1999).  
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        Polyketide chain building and assembly are catalyzed by polyketide synthases (PKSs), 
which are homologues to fatty acid synthase (FASs) required for the biosynthesis of fatty 
acids (Staunton and Weissman, 2001). Although, all the reactive enzymatic steps involved in 
chain initiation, condensation steps and termination are homologous, PKSs need to be highly 
programmed (Hopwood and Sherman, 1990). However, the insights into the enzymatic 
process of fatty acid assembly will of course help to illuminate the relevant steps carried out 
during polyketide biosynthesis (Staunton and Weissman, 2001).  
 
1.2 Enzymology of fatty acid biosynthesis 
    Biosynthesis of fatty acids involves a sequence of reactions, beginning with a starter acyl 
group, and the extender units that comes from the activated acyl-CoA precursors which are 
assembled by head-to-tail linkage into the growing chain, until the chain reaches the required 
length (Staunton and Weissman, 2001; Smith and Tsai, 2007). The starter unit, which is often 
an acetyl group derived from acetyl-CoA, is condensed with the extender units which are 
acetyl groups derived from malonyl-CoA which is made by carboxylation of acetyl-CoA at 
the α-position so that it can undergo concerted decarboxylation, allowing chain elongation. 
The β-keto ester that is formed is reduced successively to a hydroxy, dehydrated alkene and 
another reduction to give a final alkane chain that is fully reduced (Figure 1.2) (Staunton and 
Weissman, 2001; Kwan and Schulz, 2011). 
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Figure 1.2 Biosynthetic cycle of fatty acid. Malonyl-acetyl transferase (MAT), domains 
presented by acyl carrier protein (ACP); ketosynthase (KS); ketoreductase (KR); dehydratase 
(DH), and enoyl reductase (ER) (Source: Staunton and Weissman, 2001). 
 
    The set of enzymes that are involved in chain extension usually carry the acyl units that 
participate in these chemical reactions as thioesters. The starter acyl unit is tethered to the 
thiol of the cysteine residue of the ketosynthase (KS), the enzyme involved in Claisen 
condensation. Malonate, the chain extender unit is attached to a thiol residue of a protein 
designated as an acyl carrier protein (ACP) (Kwan and Schulz, 2011). This last thiol is the 
terminus of the phosphopantetheine residue that is added to the unique serine residue of the 
ACP by post-translational modification, and it is not part of the primary protein (ACP) chain 
(Figure 1.3). The function of the long flexible phosphopantetheine arm is to carry the 
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growing chain and pass it to the other enzymes that are responsible for chain extension 
(Staunton and Weissman, 2001). Chain elongation is the process of condensation catalysed 
by ketosynthase (KS) which results in an extended acyl chain in the form of a β-ketoacyl 
intermediate that is bound to the ACP. In subsequent steps, the β-ketoacyl thioester 
intermediate can then be reduced at the β-carbon by the ketoreductase (KR-catalysing the 
reduction of the keto ester to a hydroxyl), dehydrated by a dehydratase (DH-catalysing 
dehydration of the hydroxyl group to form a double bond), and then reduction of the double 
bond to a saturated methylene by the enoyl reductase (ER) (Staunton and Weissman, 2001; 
Kwan and Schulz, 2011). The previous sequence of reactions ensures the completion of the 
first round of chain extension. After the transfer of the saturated extended acyl chain 
intermediate from ACP to the KS the cycle is repeated. A number of identical cycles of chain 
extension using the same enzymes successively, eventually lead to a chain of the required 
length (usually consist of 14, 16 or 18 carbons). Then the chain is usually released either as a 
free acid or as an acyl ester after it has been passed to the thioesterase (TE). The set of the 
domains (KS, ACP, KR, DH, and TE) are present as components in all fatty acid synthases 
(FASs) (Staunton and Weissman, 2001) and are available in the active form (Kwan and 
Schulz, 2011). Malonyl-acetyl transferase (MAT), a protein as a seventh partner, has a role in 
the transfer of the building blocks of the fatty acid chain represented by acetate (to start) and 
malonate (to extend) from the particular coenzyme A to the active thiol resides of the 
appropriate domains (Staunton and Weissman, 2001).    
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Figure 1.3 Post-translational modification of the carrier protein mediated by coenzyme 
A. The carrier protein is shown as a helical bundle, with cartoon representation in 
parentheses. Transfer of the 4ʹ-phosphopantetheine prosthetic group to the conserved serine 
residue of the carrier protein (CP) is mediated by PPtase, converting the CP from apo to holo 
form. The thiol at the terminus of the protein can then be used to carry intermediates during 
FAS, PKS, and NRPS biosynthesis (adapted from Meier and Burkart, 2009).  
 
 
1.3 Biosynthesis of polyketides 
    Despite the chemical diversity of polyketides and their classification into two main types 
(type I with multiple catalytic activities contained within large multienzyme complexes that 
are joined covalently and type II with multiple catalytic activities located on discrete, 
separated enzymes) they are synthesized by a uniform biochemistry (Hopwood and Sherman, 
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1990). However, although biosynthesis of type III PKSs, the chalcone synthase superfamily 
(Austin and Noel, 2003) that were identified as the simplest known PKSs (Kwan and Schulz, 
2011), resembles the biosynthesis of type I and type II PKSs superficially, it has a number of 
important differences (Staunton and Weissman, 2001).  
 
  
Figure 1.4 Sequence of events in the biosynthesis of polyketides. Polyketide synthase 
(PKS) carries two thiol groups on two separate enzymes; the first one on the condensing 
enzyme (KS) and the second on the phosphopantetheinylated acyl carrier protein (ACP). 
Successive steps of reactions are labelled: acyl transferase (AT); ketosynthase (KS); 
ketoreductase (KR); dehydratase (DH); enoylreductase (ER) (source: Hranueli et al., 2001).     
 
    Condensation of the starter with an extender unit is the initiation point that ensures the 
growth of the carbon chain of the polyketide.  Both the starter and the extender units are 
available in the host and are derived from the acyl-CoA precursor. Polyketides usually use 
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acetyl-CoA and propionyl-CoA as the starter units, and malonyl-CoA and methylmalonyl 
CoA as extender units (Kwan and Schulz, 2011; Ridley et al., 2008). In addition, PKSs can 
utilize the CoA derivatives of some other carboxylic acids as starters or extender units as 
well. 
    Ketosynthase (KS) is the enzyme responsible for the Claisen condensation by 
decarboxylation of the extender unit. Subsequently, the fate of the diketide that is produced 
depends on whether it undergoes any reduction by the presence of one or more of the 
reductive enzymes (KR, DH, and ER) (Kwan and Schulz, 2011). Condensation of another 
extender unit with the diketide will be the next step, and will end up with the unreduced 
triketide if the keto group of the diketide has not been reduced. For this reason this type of 
synthase is known as polyketide. However, the availability of the essential enzyme activities, 
one or more of the following sequential reactions will take place; β-ketoreduction, 
dehydration and enoylreduction. The consequence of this is the formation of compounds 
having a β-hydroxyl group, unsaturated double bond or completely reduced β-carbon 
(Hranueli et al., 2001). Acyltransferase (AT) is particularly responsible for loading the acyl 
carrier protein (ACP) in the PKS complex with the extender unit for each condensation, and 
the specificity of the AT determines the extender unit (Smith et al., 2003). The triketide 
formed may then pass through a new round of reduction in the β-keto group, depending on 
the presence of the reductive enzymes that are actively able to act on triketides. The level of 
the reduction of that triketide, whether it is full, partial or left unreduced does not correlate 
with the reductive fate of diketide formed in the prior condensation, nor does it depend on 
what will happen to the keto group represented by tetra-, penta-, and hexaketides formed in 
the next accompanying condensation cycles (Figure 1.4) (Hranueli et al., 2001).   
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1.3.1 Modular Type I polyketide synthase 
    Modular type I PKSs are arguably the most important group of polyketide antibiotics, that 
are large multi-modular enzymes ranging from 100- to 10,000 kDa, and each catalytic site 
located on a discrete protein domain, which are optimally arranged to be used only once 
(Hopwood, 1997; McDaniel et al., 2005). The functional units responsible for each 
condensation are named ‘modules’. Each module consists of a set of domains, the core of 
which is represented by ketosynthase (KS), acyltransferase (AT) and acyl carrier protein 
(ACP), which are linked together covalently and responsible for single chain-extension. It 
also includes any reductive domains; ketoreductase (KR), dehydratase (DH), and 
enoylreductase (ER) if the keto group formed by the chain-extension requires any 
modification before handing the intermediate onto the downstream module. Hence, these 
multienzyme complexes have been designated as modular polyketide synthases (PKSs) 
(Weissman, 2004; Weissman and Leadlay, 2005). These modules are further organised into a 
more complex multimodular subunits. For example, in the biosynthesis of erythromycin, 
three polypeptides of the 6-dEB synthases (DEBS) are present, designated as DEBS 1, DEBS 
2, and DEBS 3, respectively (Weissman and Leadlay, 2005). Although a typical subunit 
consists of two to three modules, in other PKSs, such as the synthase that produces the 
polyketide toxin mycolactone, a single polypeptide unusually incorporates nine modules 
(Smith et al., 2003). The individual subunits within the PKSs must recognise the correct 
partners and it must resist making any incorrect associations that might end up with wrong 
products. Docking domains located at the extremity of the PKS proteins, which are present in 
the form of folded structures, act to ensure that such interactions between the subunits occur 
correctly (Broadhurst et al., 2003).    
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    Modular PKSs are preceded by a loading module, which functions in the transfer of the 
starter unit from the CoA enzymes pool to the KS of module 1, while the last module ends 
with a thioesterase (TE), which is responsible for the essential process of removing the 
completed polyketide chain (Hill and Staunton, 2010). The growing PK chains are normally 
tethered on the acyl carrier protein by the long flexible ‘swinging arm’ all the way through 
the synthase, which ensures that they are correctly shepherded when transfered between 
diverse active centres and not allowed to ‘wander off’ into the cell (Weissman et al., 2004). 
Domains within the natural modules are normally joined by linkers. These linkers consist of 
sequences of amino acids ranging from 20 up to more than 250 (Weissman, 2004), thought to 
play an important role in maintaining the correct architecture of the activites along the 
biosynthetic process (Staunton and Weissman, 2001). These linkers may work like rigid 
connectors or may act by providing some sort of flexibility, which will allow and facilitate 
the movement of the multienzymes (Bevitt et al., 1992; Staunton and Wilkinson, 1997). The 
modular biosynthetic arrangement of type I PKS system suggests the possibility of mixing 
and splicing domains and even modules within and between various PKS systems, which 
could create recombinant enzymes that are capable of producing novel, ‘unnatural’ 
polyketide natural products (Kuščer et al., 2005).   
 
1.3.1.1 Erythromycin biosynthetic pathway 
     The biosynthetic gene cluster of erythromycin (ery genes) was discovered after the 
identification of the resistance gene, ermE (Cortesʹ et al., 1990). The expectation that 
synthase genes would cluster around the genes that confer self-resistance to the antibiotic 
increased the probability of the expression of both set of genes at the same time (Hill and 
Staunton, 2010). The biosynthetic core of erythromycin A, 6-deoxyerythronolide B (6-dEB) 
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(Figure 1.5), provided the basis for understanding the function and modularity of PKSs that 
are responsible for the assembly of complex polyketides over the last 15 years (Weissman 
and Leadlay, 2005). Three successive open reading frames (ORFs), eryAI, eryAII and eryAIII 
were identified as genes responsible for biosynthesis of the aglycone core (the intermediate 6-
dEB) of this macrolide antibiotic. These genes encode three giant proteins that dock together 
forming a gigantic multienzyme polypeptide, designated 6-deoxyerythronolide B synthase 
(DEBS) 1, (DEBS) 2, and (DEBS) 3, in the putative enzymatic order that they function in the 
synthetic operations (Figure 1.5) (Staunton and Weissman, 2001; Hill and Staunton, 2010). It 
is obvious from the diagram that each of the DEBS proteins consists of two functional units 
or modules, therefore named as ‘modular’ PKS (Staunton and Weissman, 2001). The core 
component of each module includes KS, acyltransferase (AT), and ACP domains. These 
domains together extend the growing polyketide chain by two carbon atoms. In addition, it 
generates a β-keto group that can be modified through a variable set of reductive domains 
including ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) domains, which 
are typically attached to the core module (Donadio et al., 1991; Ridley et al., 2008). DEBS 1 
at the front of the synthase has a didomain (ATL-ACPL), which was formerly known as the 
loading module (LM), whose function is to accept the starter unit propionate from the 
external pool of propionyl-CoA and to transfer it to the KS of module 1 (Hill and Staunton, 
2010). Co-operation between the three essential domains KS, AT and ACP will catalyse one 
cycle of chain extension through the formation of carbon-carbon bond by Claisen 
condensation, which will end up in a β-ketoacyl thioster intermediate (Staunton and 
Weissman, 2001). The structure of domains in module 1 ensures that the keto group 
undergoes only a partial reduction to hydroxyl intermediate by the KR due to the absence of 
other reductive domains DH and ER. Transfer of this hydroxyl intermediate to the 
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downstream KS of module 2 within DEBS 1 which consists of an equivalent set of reactions 
would generate another hydroxyl acyl intermediate (Hill and Staunton, 2010).  
  
 
 
Figure 1.5 Biosynthesis of erythromycin A.  6-deoxyerythronolide B synthase (DEBS) is 
responsible for the biosynthesis of the aglycone, which subsequently converts to 
erythromycin A by post-translational modifications (source: Kwan and Schulz, 2011). 
 
    Subsequently, the growing chain is passed from DEBS 1 to the KS of module 3 in DEBS 
2, and a new round of chain extension will take place. However, as no reductive domains are 
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present in this module, the keto group should survive intact. Following the transfer of the acyl 
intermediate to module 4, the β-keto group undergoes full reduction as in FAS, and it the 
passes through all the modifications catalysed by the reductive domains (KR, DH and ER), 
resulting in a methylene moiety (Hill and Staunton, 2010). Transfer of the growing chain to 
the KS of module 5 in DEBS 3 is delivered by interprotein transfer. In the two further rounds 
of condensation by modules 5 and 6, the keto groups are partially reduced to hydroxyl, and 
lead to the completed PK chain. TE is the last domain of module 6 within DEBS 3 instead of 
KS of a downstream module. The activity of TE is thought to be through catalysing the 
removal and cyclisation of the fully formed heptaketide (PKS) intermediate to give 6-dEB 
(the aglycone). Then, non-PKS enzymes, encoded by genes on either sides of the resistance 
gene, ermE, act at the late stage of the PKS pathway through the conversion of 6-dEB to the 
active antibiotic erythromycin A (Staunton and Weissman, 2001).   
 
1.3.1.2 Structural model for type I PKS 
    Determining the structural organisation of modular PKSs is valuable for engineering 
applications. Descriptive structural models should consider two very important points. The 
first is the ability of the ACP domain in each module to interact with other domains. The 
second is the interaction between successive modules in a successful fashion to ensure chain 
transfer to the next module (Weissman and Leadlay, 2005). A structural model for the 
erythromycin DEBS (subunits) proteins has been proposed, which proposes that the identical 
PKS subunits are wrapped around each other to form a double helical homodimer associated 
head-to-head and tail-to tail (Figure 1.6) (Staunton et al., 1996). In this model, each protein 
subunit is in the form of a homodimer, and the individual domains, especially the KS-AT 
didomain and the thioesterase (TE) activities remain dimeric even when they have been 
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released as separate proteins from the PKS. On the other hand, the reductive domains 
represented by KR, DH and ER are monomeric. During chain extension, a preferential 
interaction between a particular KS within the ACP domain on the opposite subunit was 
observed (Weissman and Leadlay, 2005). This sort of interaction is facilitated by the angle of 
the coil which brings the ACP of one chain over the KS of the opposite subunit. However, no 
such interaction was detectable between the reductive domains of the complementary chains 
(Staunton and Weissman, 2001). This ‘double helical’ model places the KS (and possibly the 
AT as well) at the core of the helix, while the reductive domains tend to protrude out of the 
loop at the periphery of the structure. Moreover, it appears that all the available domains 
within each module are able to interact with the ACP domain, and the closest such interaction 
that is facilitated by the subunit interface occurs between the KS and ACP domains of the 
same module (Weissman and Leadlay, 2005). According to the crystallographic structure, the 
thioesterases (TEs) have been identified as homodimers and belong to the family of the α/β 
hydrolase (Staunton et al., 1996).  
    NMR was used by Weissman and co-workers to elucidate the structure of the docking 
domains in the DEBS system that brings all the multienzymes together to act in collaboration 
(Broadhurst et al., 2003). Since DEBS consist of three multienzymes and the nascent PK 
chain must transfer to the downstream multienzyme, there must be some mechanism that 
brings them together. Therefore, it was suggested that there must be a docking motif to 
ensure that the multienzymes in charge come together at least for long time enough to permit 
the transfer of the growing PK chain from the terminal ACP of one multienzyme to the first 
KS domain of the next multienzyme. In addition, the docking process requires it to be carried 
out with a highly effective level of discrimination so as to ensure that correct pairs of 
multienzymes become associated. Furthermore, the C-terminal residues of the ACP partner 
17 
 
and the N-terminal residue of the KS partner are considered to be the most likely candidates 
for the position where the docking domains are situated (Hill and Staunton, 2010).    
            
 
Figure 1.6 Double helical model represents the arrangement of domains of modular 
polyketide synthases (adapted from Weissman and Leadlay, 2005). 
 
 
    Experimentally, artificial covalent links were used to join DEBS 1 with DEBS 2 and 
DEBS 2 with DEBS 3. These new systems that are artificially joined retained the ability to 
take part in the biosynthesis of the 6-dEB as a normal metabolite of erythromycin (Squire et 
al., 2003; McDaniel et al., 1997). Exploiting genetic engineering, fragments containing the 
C-terminal part of the ACP from the last module of the upstream multienzyme, were joined 
covalently by artificial linkage with fragments from the N-terminal end of the KS at the start 
of the downstream multienzyme to prepare a short protein. It was anticipated that the linkage 
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must give a higher chance to these isolated fragments to fold properly so as to give domains 
which in turn may associate together in such a way that allows them to be responsible for 
docking (Broadhurst et al., 2003). The success of this strategy was confirmed by 
multidimentional NMR which showed that the docking domain takes the dimerization form 
of a rigid rod-like coiled-coil, which is positioned at the N-terminal end of DEBS3 and 
DEBS2 as well (Figure 1.7). Helping the subunits to associate together, and providing them 
with assistance to become a dimer and to be able to maintain the dimeric state in the first 
place, are two critical and valuable roles played by the docking domains (Weissman, 2004). 
Their role in dimerization has been proved by the successful use of elements from the 
structutre of the docking domains as a dimerziation motif in another system. The portion of 
the prepared protein derived from the C-terminus of the upstream ACP formed three helical 
regions, 1, 2, and 3. A striking structural motif that consists of an intertwined four α-helix 
bundle was formed by the first two helices (1 and 2), which may form the dimerzation motif 
for the tail end of the upstream multienzyme. A mobile linker region is stretched from the 
bundle leading to helix 3, which in turn docks with the rod-like docking domain of the 
downstream KS. Therefore, this manner of association between helices of adjacent 
multenzymes would be regarded as the docking motif. 
    The coiled-coil that is formed at the N-terminal docking domain of DEBS 3, is a well-
known motif that is utilised by proteins to associate together and stabilise each other 
(Branden and Tooze, 1999). The particular hydrophobic residues which hold helices 1, 2, 3, 
and 4 together are shared between several different synthases, which suggests that they may 
use their docking domains for the stabilization of the dimer (Weissman, 2004). Further 
experiments conducted to investigate different aspects of the recognition processes between 
helices 3 and 4, ensure that the correct pairs of multienzymes associate together (Weissman, 
2006a and 2006b). 
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Figure 1.7 Structure of ‘Dock 2-3’ by NMR. A model of docking between DEBS 2 and 
DEBS 3. The structure comprises two separate, non-interacting domains, DEBS 2-ACP (A) 
and DEBS 3-KS (B). The dimerization motif consists of helices 1 and 2, while the docking 
domains include helix 3 of ACP and helix 4 of KS. Coloured spheres represent the two 
residues that possibly define a ‘code for docking’ (Sources: Weissman, 2004; Hill and 
Staunton, 2010).     
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1.3.2 The iterative type II PKSs  
    Aromatic PKSs are iterative type II systems consisting of multienzymes in which the 
active sites are located on discreet polypeptide subunits. The catalytic centres are anticipated 
to work several times in a repetitive manner during the iterative cycles of the polyketide 
chain extension and assembly (Kuščer et al., 2005). The polyfunctional aromatic antibiotics 
such as actinorhodin, tetracycline, doxorubicin, and frenolicin, are among the most widely 
studied type II iterative polyketides (Ridley et al., 2008). Phenolic aromatic compound are 
the characteristic products of this type of PKS. Biosynthetic reactions include the formation 
of polyketone chains during cycles of condensation of the building blocks, which then 
undergo cyclisation and aromatisation processes to produce aromatic compounds (Staunton 
and Weissman, 2001). The heterodimeric ketosynthase (KS), chain length factor (CLF), and 
acyl carrier protein (ACP) in addition to a malonyl-CoA:ACP transacylase (MAT), which are 
believed to be recruited from bacterial fatty acid synthases, all together are considered as the 
core set of enzymes of these types of polyketide synthases (Figure 1.8A). Cooperatively, the 
minimal PKS proteins essential for biosynthesis of a polyketide are the four previously 
mentioned proteins (Hutchinson, 1999; Ridley et al., 2008). Chain extension (and often 
initiation) using malonate as a chain extender unit is cataylzed by KS-CLF to form a poly-β-
ketide intermediate by decarboxylative condensation of malonyl building blocks that are 
delivered by ACP, while MAT provides malonyl groups to the PKS (Hutchinson, 1999; 
Reeves, 2003). A highly reactive polyketide chain of defined length and strength is produce 
by the action of these proteins collectively, that is under the control of a deep pocket in KS-
CLF (Ridley et al., 2008).  
Subsequently, the poly-β-ketone intermediates are changed to compounds containing an 
aromatic ring by the action of unique tailoring enzymes such as ketoreductases (KRs), 
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aromatases (AROS), and cyclases (CYCS). This is consistent with what has been shown by 
Hranueli et al., (2001) about the implication of ketosynthase (KS) α and β, acyl carreir 
protein (ACP), cyclase/aromatase and cyclase (Figure 1.8B) as a set of six proteins required 
for the biosynthesis of actinorhodin by Streptomyces coelicolor.   
    Although that it is still believed that the ACP in this type of PKS needs assistance for 
loading building blocks, it has been observed by Simpson and coworkers that the ACP is able 
to accept a malonate and any other acyl groups from the respective CoA thioesters without 
the need for external assistance (Matharu et al., 1998). Moreover, since no specific gene 
identifed in the actinorhodin (act) cluster encodes a malonyl-CoA: holo-acyl carrier protein 
transacylase (MCAT), there is no clear mechanism for selection of the starter or the extender 
unit within this cluster. Arthur et al., (2005) also proved the ability of ACP in this PKS 
system of self- malonylation by an in vitro study. However, more recently, hexanoate in 
benastatin (Xu et al., 2007), and malonamate in oxytetracyline (Zhang et al., 2006) have been 
identified as examples of building blocks other than acetate units derived from malonyl-CoA 
by decarboxylation.       
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Figure 1.8 General scheme of genes encoding for actinorhodin, as an example of type II 
polyketide synthase. (A) The conserved minimal PKS for all type II PKS gene cluster 
consist of β-ketoacyl synthase (KS) α and β, and acyl carrier protein (ACP). (B) mono- or 
bifunctional proteins that are used iteratively for the assembly of the polyketide backbone   
(source: Hranueli et al., 2001).     
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    The mechanistic actions of PKS enzymes in type II are quite different from similar ones in 
type I, as they generate cyclic and aromatic compounds that do not require further extensive 
rounds of reduction alone, or with dehydration. Consequently, there are several principal 
challenges faced in studying type II PKS, which include trying to determine what controls the 
number of times such chain extensions occur, how the poly-β-ketone intermediates are folded 
into the correct orientation for cyclization, and how to select which carbonyl and methylene 
groups react to form the six-membered rings of the final cyclic compounds (Hutchinson and 
Fujii, 1995). However, the diversity of aromatic polyketides discovered so far could be due to 
the presence or abscence of accessory (tailoring) enzymes which add additional modifications 
to the product (Ridley et al., 2008). Since type II PKS’s are structurally very similar, it is 
impossible to predict the nature of the polyketide synthesized from the structure and the 
architecture of the gene cluster, which is different from other type of PKS’s in some of which 
there is a one-to-one correspondence between active sites and product structure (Hranueli et 
al., 2001).     
 
1.3.3 Type III polyketide synthases 
    This type of polyketide synthases is responsible for the biosynthesis of chalcones and 
stilbenes in plants, as well as polyhydroxyphenols in bacteria. Enzymes of this system, which 
are self contained, are able to form homodimers. Flavonoids are plant-derived natural 
products considered to be derived from an important branch metabolite, 2’, 4, 4’, 6’-
tetrahydroxychalcone which is the product of the chalcone synthase (CHS) (Reimold et al., 
1983). Chalcone synthase (Figure 1.9A) was the first type III enzyme discovered in the 
biosynthetic pathway of flavonoids, followed by the discovery of stilbene synthase a short 
while later as a second enzyme leading to these type III PKSs being collectively termed the 
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‘chalcone synthase/stilbene synthase superfamily’ (Schrӧder, 1999; Austin and Noel, 2003). 
Chalcone synthases provide the starting materials for a variety of secondary metabolites with 
important roles including defence against pathogenic micro-organisms, protection against the 
damage by UV light, and further additional specificities (Schrӧder, 1999). The wide 
distribution of CHS-like proteins in bacteria and fungi has been revealed recently by rapid 
expansion in genome sequence data. For example, they have been found in Saccharomyces 
cerevisiae, Azotobacter oryaze and some other fungi, and even type III PKSs have been 
characterised in some of them (Yu et al., 2012). Nevertheless, the sequence identity is only 
25% between bacterial and plant CHSs, indicating that bacterial type III PKSs may possibly 
be able to perform reactions different from those of classical CHSs (Figure 1.9B) (Li and 
Müller, 2009).    
    Comparatively, type III PKSs, includes a wider and more diverse range of starter 
molecules than those involved in type I and type II PKSs. These consist of different aromatic 
and aliphatic CoA thioesters, for example coumaryl-CoA and methyl-anthraniloyl-CoA, used 
by the classical plant CHSs. In addition, the most recently identified, medium and long-chain 
fatty acyl-CoA esters, which are used by specific bacterial type III enzymes, which are 
involved in the biosynthesis of phenolic lipids (Schrӧder, 1999; Funa et al., 1999). Although, 
chalcone synthases are the most extensively studied type III enzymes, both chalcone and 
stilbene are generated by a similar chain-elongation reaction, which includes a starter unit 
from 4-coumaroyl-CoA followed by three successive decarboxylative condensation reactions 
using malonyl-CoA as the extender. However, bacterial type III PKS is able to utilise other 
acyl-CoAs than malonyl-CoA as extender units (Li and Müller, 2009). Differential aldol-
cyclization and aromatization of the produced linear polyketide intermediate (either C6→C1 
or C2→C7) (Tsai, 2004) occurs within the same enzyme active site to yield 2’, 4, 4’, 6’ –
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tetrahydroxychalcone as a final product for the synthesis of chalcone or stilbene (Baerson and 
Rimando, 2007).  
 
Figure 1.9 Representative reactions catalyzed by type III PKSs. (a) The use of 4-
coumaroyl-CoA as the starter unit and malonyl-CoA as the extender unit by plant type III 
PKSs: BSA, benzalacetone synthase; SPS, styrylpyrone synthase; CTAS, triacetic acid 
synthase; STA, stilbene synthase; CHS, chalcone synthase. (b) RppA, 1, 3, 6, 8-
tetrahydroxynaphthalene synthase, and PhID, phloroglucinol synthase, as examples of 
bacterial type III PKSs  (source: Yu et al., 2012). 
   
    Architecturally, the plant and bacterial type III PKSs are considered the simplest among 
the three types of PKSs, as they consist of homodimeric enzymes that possess subunits 
between 40-45 KDa in size (Tsai, 2004; Baerson and Rimando, 2007). Similar to type II 
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PKSs, type III PKSs catalyse iterative decarboxylative condensation reactions, usually using 
malonyl-CoA as the extender units. Moreover, based on the homodimeric form, the single 
active site cysteine in each monomer catalyses a complex series of reactions iteratively, 
consists of priming, extension, and intramolecular cyclisation to form polyketide products 
(Austin and Noel, 2003; Tsai, 2004; Yu et al., 2012). The crystal structure of CHS2 from 
alfalfa determines four residues encompassing Cys164, Phe215, His303, and Asn336 which 
are conserved between all the CHS2 related enzymes, and these are suggested as the possible 
elements of a single active site to catalyze all the decarboxylative condensation reactions 
collectively (Ferrer et al., 1999). Non-involvement of the acyl carrier proteins and the use of 
free CoA thioesters directly as substrates are considered as the unique character of this family 
of PKS (Baerson and Rimando, 2007). However, bacterial alkylpyrone synthases, such as 
ArsB and ArsC synthase from Azotobacter vinelandii, which are responsible for the 
biosynthesis of phenolic lipids and use a long chain acyl-CoA as starter units rather than 
malonyl-CoAs, transfer the C22-C26 acyl chain starter units directly from the ACP domains 
of the type I FAS to the type III synthase (ArsB and ArsC) (Miyanaga et al., 2008).  
 
1.4 Post –PKS modifications 
    The already synthesized and cyclised polyketides can undergo some modifications through 
hydroxylation, glycosylation, methylation and/or acylation. It was believed that these 
tailoring enzymes, or post PKS modifications, were crucial for the addition of special 
necessary and functional groups to the polyketides skeleton that are important for their 
structural diversity and biological activity (Rix et al., 2002). Using gene knockouts, post-PKS 
enzyme function can be typically investigated, and then checking the characteristics of the 
resulting metabolites, allows a conclusion about the sequence of modification events to be 
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established (Rix et al., 2002; Hong et al., 2004). Changes catalyzed by oxidoreductases, 
which includes oxygenases, peroxidases, oxidases, reductases (i.e ketoreductases), and 
dehydrogenases, are among the most frequently found post-PKS modifications. Introducing 
oxygen-containing functionalities, exemplified by hydroxyl groups (hydroxylases), epoxides 
(epoxidases), aldehyde or keto groups, or modifying such functionalities by either addition or 
removal of hydrogen atoms, such as changing an aldehyed into a carboxylic acid, are general 
reactions carried out by oxidoreductases (Kim and Park, 2008).  
    Transferases are a group of enzymes that act by introducing novel functional groups, which 
subsequently alter the product profiles relative to the substrate. Several important enzymes 
are included in this group including alkyl (usually methyl) transferases, aminotransferases, 
acyl (usually acetyl) transferases, gylcosyltransferases (GTs) and kinases. Both methyl- and 
glycosyltransferses are considered as the most significant post-PKS tailoring enzymes (Kim 
and Park, 2008). GTs functions in the attachment of sugar moieties, most often deoxysugars, 
which confer important and valuable characteristics to a molecule, since they play an 
essential and profound role in the biological activity of many PKs and other natural product-
based drugs (Mendez and Salas, 2001). Methyl-transferases can methylate O, N or C-atoms, 
using S-adenosylmethionine (SAM) as co-factor. Methylation reactions take place either at 
the polyketide-derived aglycone moiety or on the sugar residues, either before or following 
the glycosyl transfer (Rix et al., 2002). The following examples illustrate the power of post-
PKS engineering.  
    In the erythromycin producer Saccharopolyspora erythraea, all the required information 
about the order of the occurrence of the post-polyketide modifications and methodologies for 
gene transfer is available. The deduction that the lactone ring carrying the 6,7 unsaturation is 
a substrate for mycarosyl- and desosaminyltransferases, and C-12 hydroxylase as a post-
polyketide modification enzymes, is the formation of ∆6٫7-anhydroerythromycin C (Donadio 
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et al., 1993). In a genetically modified Saccharopolyspora erythraea, the three previously 
mentioned reactions have thus far been observed within numerous different cyclic structures, 
even when the alterations were quite close to the site of modification (Donadio et al., 1991; 
McAlpine et al., 1987; Weber et al., 1991).  
   Studies on the nystatin (antifungal polyene macrolide) gene cluster identified two genes 
(NysDiii and NysDii) that putatively participate in the biosynthesis of mycosamine, and 
(NysDi) responsible for the mycosamine attachment to the nystatin aglycone. The suggested 
functions of these genes are as mannose dehydratase, aminotransferase and a 
glycosyltransferase, respectively. Furthermore, the deoxysugar mycosamine is suspected to 
have a significant function for nystatin bioactivity (Nedal, 2007).  
    A specific gene disruption of the complex macrocyclic polyketide TA antibiotic produced 
by Myxococcus xanthus identified several genes necessary for post-modification processes 
during its biosynthesis, and in the subsequent production of biologically active TA antibiotic. 
These chemical modifications involve the addition of several carbon atoms originating from 
acetate at C-13, C-17 and C-32, three C-methylations at C-2, C-4 and C-8, O-methylation at 
C-34 and a specific hydroxylation at C-20 (Paitan et al., 1999b). A cytochrome P-450 
hydroxylase is responsible for the unique hydroxylation at C-20 within TA biosynthetic gene 
cluster, which is essential for the production of an active TA molecule (Paitan et al., 1999a).  
 
 
1.5 Non-ribosomal peptide synthetase (NRPS) 
    This vast family of compounds mainly synthesized by micro-organisms constitute the 
peptide based natural products. They exhibit a wide range of biological activities with 
different functions ranging from defending against other micro-organisms like vancomycin, 
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to iron sequestration (yersiniabactin), or cell wall components (gylcopeptidolipids). 
Furthermore, some of these peptides like the antibiotic vancomycin, or the antitumour agent 
bleomycin, have proved to have an important role in medicine. Although some peptides, for 
example lantibiotics are synthesized by the ribosomal machinery, the vast majority are 
confirmed to be biosynthesized by large multifunctional modular enzymes which are known 
as nonribosomal peptide synthetases (NRPSs) (Lautru and Challis, 2004). Molecules 
produced by NRPS are often cyclic, and the amino acids are connected by peptide bonds 
(Challis and Naismith, 2004). The basic difference between PKS and NRPS systems is in the 
selection of the monomers, in which PKSs utilise activated fatty acids monomers (Acyl CoA 
thioesters), while NRPSs consume ATP to activate amino acids in the form of AMP esters 
(Keating, and Walsh, 1999). 
    NRPSs exhibit a modular architecture as large multifunctional enzymes, similar to that in 
the PKSs. Therefore, they consist of repeats of modules as the basic peptide synthetase units 
that are responsible for the activation, covalent attachment as a thioester, and optional 
modification of a single amino acid (Lautru and Challis, 2004). Thus one amino acid is 
incorporated within every single step of peptide synthesis (Kopp and Marahiel, 2007). 
Moreover, the number and the order of the modules within the NRPS depend upon the 
number of the amino acids and the length or the sequence of the peptide being synthesized, 
respectively. Every module consists of structurally different and independent domains, in 
which each fulfills a specific function, and is normally specific to a particular amino acid 
substrate (Challis and Naismith, 2004). A minimal chain elongation module contains three 
core domains: the 50 kDa adenylation (A) domain, the peptidyl carrier protein (PCP) domain 
(or thiolation [T] domain) and the 50 kDa condensation (C) domain (Lautru and Challis, 
2004). However, in some cases the first module has a three-domain organization, which 
occurs in the assembly lines that form N-acylated peptides, for example plipastatin (Steller et 
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al., 1999), in which the C-A-T (PCP) is the typical order of the domains. The adenylation 
domain firstly is responsible for selecting the amino acid monomer and activating it via the 
formation of an aminoacyl adenylate, and then through covalently binding of the activated 
amino acid via a thioester to the 4´-phoshopantetheinyl (4´Ppant) cofactor of the next 
peptidyl carrier domain (Figure 1.10). Phosphopantetheinyl transferase is responsible for the 
post-translational attachement of the mentioned cofactor to the conserved serine of PCP prior 
to binding of the activated amino acid. The C domain is the last essential domain, which is 
responsible for the formation of the peptide bond between the aminoacyl thioester attached to 
the PCP domain of the module in charge and that of the previous module (Lautru and Challis, 
2004; Fischbach and Walsh, 2006). 
    Extra optional or alternative domains can be seen within some modules which introduce 
changes or modifications to the amino acid that has been incorporated. For example, an 
epimerisation (E) domain which catalyzes racemisation (L and D equilibration) of the Cα of 
the amino acid, a reaction which occurs either before or after the formation of the peptide 
bond. This domain is normally located after the PCP domain of the C terminus of some 
modules. Since in several NRPSs the cyclisation (Cy) domain substitutes for the 
condensation (C) domain (Konz and Marahiel, 1999; Lautru and Challis, 2004), the Cy 
domain catalyses both condensation and intramolecular heterocyclisation of serine, cysteine 
or threonine residues to make the corresponding thiazoline or oxazaline ring. The N-
methylation (transfer of CH3 group from S-adenosylmethionine (SAM) to the nitrogen of the 
amine) is an extra reaction catalyzed by methyltransferase (MT) domain which is found in 
NRPSs with C-A-MT-T modules (Challis and Naismith, 2004).   
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Figure 1.10 Typical representation of non-ribosomal peptide biosynthesis (NRPSs). (a) 
Modules and domains included in NRPS. (b) Biosynthetic processes represented by the 
scheme. (Source: Challis and Naismith, 2004). 
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     The final step is release of the assembled peptide from the NRPS into the solution from 
the termination module of the NRPS, which is mostly accomplished by a thioesterase domain 
(TE) which belongs to the α,β-hydrolase fold family and is found at the C-terminus of the last 
module which can be hydrolytic or cyclising (Keating et al., 2001; Kohli and Walsh, 2003). 
However, in myxochelin biosynthesis, a reductase catalysed thioester reduction yields an 
aldehyde as an alternative TE-independent manner of chain release (Lautru and Challis, 
2004; Gaitatzis et al., 2001).      
    A study on the congocidine biosynthetic gene cluster from Streptomyces ambofaciens 
revealed an unusual organisation of NRPS genes which do not encode large multimodular 
enzymes. Only four NRPS genes code for discrete modules or domains. A typical NRPS 
module (A-PCP-C) is encoded by cgc18, while two genes (cgc2 and cgc16) encode two 
stand-alone C domains, and only cgc19 codes for a stand-alone PCP domain (Juguet et al., 
2009). Similarly, one typical NRPS module (Cy-A-T), a free-standing C domain, and two 
thioesterases in addition to other genes responsible for holomycin production, were identified 
in Steptomyces clavuligerus (Huang et al., 2011). Furthermore, the same single NRPS 
module is encoded by holA in the pyrothine (holomycin) part of thiomarinol, the hybrid 
(PKS-NRPS) antibiotic produced by Pseudoalteromonas spp SANK 73390, whose logical 
interpretation suggests that this NRPS (HolA) may act as an iterative NRPS for the formation 
of the cysteinyl-cysteine dipeptide (Fukuda et al., 2011).     
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1.6 Mupirocin  
1.6.1 Structure and indication (uses) 
    Mupirocin is a polyketide antibiotic produced as a mixture of pseudomonic acids by a soil 
bacteria Pseudomonas fluorescens NCIMB 10586. Pseudomonic acids (Figure 1.11) consists 
of a C17 unit, monic acid, esterified to a C9 saturated fatty acid, 9-hydroxynonanoic acid (9-
HN) via an α,β-unsaturated ester linkage, and pseudomonic acid A is the major component, 
which accounts for about 90% of the mixture (Fuller et al., 1971; Chain and Mellows, 1974; 
Chain and Mellows, 1977). Pseudomonic acid A is responsible for most of the antibacterial 
activity (Fuller et al., 1971). Attack of the 7-hydroxyl group on the carbons 10,11 (the 
epoxide) outside the pH range of 4-9 irreversibly change and results in the production of two 
cyclic ethers (Clayton et al., 1979), represented by compounds 1 and 2 in Figure 1.11. 
Pseudomonic acid B constitutes about 8% of the total mupirocin, and has an additional 
hydroxyl group at the position C8 (Chain and Mellows, 1977). The remaining 2% consist of 
two minor metabolites, pseudomonic acids C and D, respectively. Pseudomonic acid C has a 
low polarity and a double bond in the place of the epoxide group between C10 and C11, also it 
is more stable than pseudomonic acid A under mild acidic conditions (Clayton et al., 1980)., 
while pseudomonic acid D has unsaturated fatty acid moiety with an alkene group at C4′-C5′ 
(O’Hanlon et al., 1983).   
    Mupirocin (marketed as Bactroban) has been clinically used in the UK since 1985 
(Cookson, 1990). The main use of mupirocin is to control infections by Staphylococcus 
aureus, especially methicillin resistant S. aureus (MRSA), and some other Gram positive 
bacteria, such as Streptococcus pyogenes and Strep. pneumonia, as well as some Gram 
negative bacteria (Haemophilus influenzae, Neisseria gonorrhoeae), while other antibiotics 
showed ineffectivness (Shiozawa et al., 1995; Szell et al., 2002). Because of its low toxicity 
to human and animals, it is used for the treatment of various kinds of skin, ear and nose 
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infections (Szell et al., 2002). Mupirocin is unstable in vivo, because of the hydrolytic 
inactivation of the ester-bond between MA and 9-HN, and therefore, many attempts have 
been made to improve and develop derivatives with more stability, that can be useful 
systemically (Sutherland et al., 1985; Kim et al., 2003). 
 
 
   
 
Figure 1.11 Chemical structure of mupirocin (pseudomonic acids (PAs) represented by 
PA-A, B, C and D). Compounds 1 and 2 are derivatives of PA-A produced under acidic or 
basic conditions (adapted from Thomas, et al., 2010). 
 
1.6.2 Mechanism of mupirocin inhibition 
    Mupirocin, and more specifically pseudomonic acid A binds reversibly to the catalytic 
centre of bacterial isoleucyl-tRNA synthetase (IleRS) (Figure 1.12), and this inhibition results 
in the depletion of the charged tRNA which eventually blocks both protein synthesis and the 
growth in the pathogenic bacteria (Hughes and Mellows, 1978a, b, 1980). Structural 
elucidation of mupirocin by Chain and Mellows, (1977), revealed that the tail portion 
containing the 14-methyl terminus closely resembles the isoleucyl moiety of the isoleucyl-
adenylate reaction intermediate (Ile-AMS) (Nakama et al., 2001; Silvian et al., 1999). 
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Mupirocin acts by inhibiting IleRS as a bifunctional entity, reacting with and inhibiting both 
the isoleucine and the ATP binding (Yanagisawa et al., 1994). X-ray crystal structures of 
IleRS bound with either mupirocin or Ile-AMS separately confirmed the previous observation 
(Nakama et al., 2001; Hurdle et al., 2004). Mupirocin and the intermediate Ile-AMS binds to 
the same regions of the isoleucyl-tRNA synthetase. Because of the same carbon skeleton of 
the epoxide-containing side chain of PA-A and the hydrophobic side chain of the L-
isoleucine, mupirocin binds to the same hydrophobic pocket of the IleRS that the L-
isoleucine binds to normally (Hughes and Mellows, 1978b; Hurdle et al., 2004). Mupirocin 
interacts with this isoleucine-specific binding pocket, which consist of Pro-46, Trp-518, and 
Trp-558 via Van der Waals interactions. The pyran ring and the region around C1-C3 fit into 
the ATP-binding pocket of IleRS, which is similar to what Ile-AMS binds (Nakama et al., 
2001; Hurdle et al., 2004). Since the models described above show that mupirocin (PA) binds 
in a similar fashion as Ile-AMS binding to the IleRS, it is predicted that mupirocin binds to 
the same architecture that is essential for the binding of both the L-isoleucine and the ATP 
(Brown et al., 2000; Hurdle et al., 2004) mimicking the effect of ribose and adenine.  
    Although all the inhibitory effects occur through the MA part of pseudomonic acid 
revealed by the X-ray models, the effect of the 9-HN has also been discussed. Brown et al., 
(2000) showed that the 9-HN fits into the hydrophobic pocket of the IleRS where valine 588 
is, and an interaction between the carboxylic end of mupirocin (9-HN) and the amide of 
valine through a hydrogen bond is important for stabilising mupirocin within the structure of 
IleRS.  
 
36 
 
                                   
 
Figure 1.12 Mechanistic model of mupirocin binding to its target enzyme, isoleucyl-
tRNA synthetase, from Staphylococcus aureus. Two separate active sites are present within 
the Isoleucyl-tRNA synthetase (IleRS); synthetic site, responsible for the synthesis of tRNA
Ile
 
through an Ile–AMS intermediate, and the editing site for editing of the tRNAIle. Synthetic 
site, is the binding site of mupirocin, which results in mimicking the influence of ribose and 
adenine. Structure of mupirocin is shown with carbons in grey and oxygens in red (source: 
Thomas et al., 2010).  
 
1.6.3 Mechanisms of resistance to mupirocin  
    Although mupirocin shows excellent selectivity for the bacterial isoleucyl-tRNA 
synthetase, resistance generally emerges shortly after it enters clinical use. Pseudomonas 
fluorescens NCIMB 10586, the mupirocin producer is resistant to the antibiotic due to the 
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presence of an IleRS enzyme with lower affinity for mupirocin rather than that of Escherichia 
coli B, and an outer cell membrane preventing re-entry of the antibiotic to the cell (Hughes et 
al., 1980). Analysis revealed that the mupirocin producer has two distinct IleRS (IleRS-R1 
and IleRS-R2) encoded by two separate ileS genes, whose products share only 29.6% 
identical residues, indicating that they are distinct and differ in their recent origin. 
Pseudomonas fluorescens is able to grow and survive in a medium containing in excess of 
1000 µg/ml of mupirocin, and E. coli showed the same result when expressing both of the 
ileS genes. In addition, ileS encoding IleRS-R2 is the more important gene for the survival of 
the producer (Yanagisawa and Kawakami, 2003). Within the biosynthetic gene cluster, mupM 
encodes MupM (IleRS-R2), which is a eukaryotic like IleRS and confer resistance to 
mupirocin (El-Sayed et al., 2003), while the other is located elsewhere in the chromosome.  
    The majority of Gram negative bacteria are relatively resistant to mupirocin, which is 
possibly due to poor permeability or impermeability of the outer membrane, or through an 
inability to reach the specific intracellular target, that binds isoleucyl-tRNA (Capobinco et 
al., 1989). Depending on the level of resistance, the mupirocin-resistant strains are classified 
into groups; those which exert low-level resistance (resistance to 8-256 µg/ml of mupirocin), 
which is related to mutation in the host enzyme (IleRS), while the second group shows high-
level of mupirocin resistance (resistance to > 512 µg/ml of mupirocin) resulting from an 
increase in the copy number, which is due to introduction of exogenous enzymes (Kim et al., 
2003; Antonio et al., 2002; Yanagisawa and Kawakami, 2003; Hudgson et al., 1994). The 
appearance of Staphylococcus aureus with low level mupirocin resistance due to mutation in 
a single amino acid (V588F, V631F and G593V) residue within the sequence of IleRS 
(Hurdle et al., 2004; Antonio et al., 2002; Farmer et al., 1992) showed that the residues 
which alter the enzyme and confer resistance to mupirocin are located near the KMSKS 
conserved motif (Antonio et al., 2002). High level resistance is due to the presence of IleRS 
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which has similarities to eukaryotic IleRS proteins, and may have been acquired through 
horizontal gene transfer (Yanagisawa and Kawakami, 2003; Hudgson et al., 1994; 
Rangaswamy et al., 2002). For high level resistance, bacteria like Staphylococcus aureus 
aquire the mupA gene which is often plasmid borne and encodes a eukaryotic like IleRS, 
which confers high level of resistance (Cookson, 1998; Hudgson et al., 1994).  
 
1.6.4 The mupirocin biosynthetic (mup) gene cluster and pathway  
    Transposon mutagenesis of Pseudomonas fluorescens NCIMB 10586 and subsequent 
chromosomal mapping of the sites of the mutations, identified a ˃ 60 kb region involved in 
the biosynthesis of mupirocin (Whatling et al., 1995). The entire region of chromosomal 
DNA was analysed by sequencing in both directions and showed that the mup cluster 
occupied over 74 kb, and consists of thirty five open reading frames (ORFs), including six 
large ORFs (mmpA-F) containing domains similar to multifunctional proteins of type  
polyketide synthase and fatty acid synthase systems, and 29 genes (mupA-X and macpA-E), in 
which (mupB, mupD, mupG, and mupS) are similar to type II systems (El-Sayed et al., 2003). 
Therefore, it is thought that mupirocin is synthesized through a combination of type I and 
type II PKS system. All the genes included in the biosynthesis of mupirocin with their 
respective function are shown in Figure 1.13 and Table 1.1, respectively. The order of the 
PKS genes involved in the biosynthesis of mupirocin is not colinear with the proposed 
biosynthetic pathway (Figure 1.14). mmpD and mmpA encode two large multifunctional 
proteins (MmpD and MmpA) which together encode the first four and the last two modules 
of elongation steps, respectively, in addition to a single transfer/non-elongating module. They 
consist of suitable required domains; ketosynthase (KS), acyl carrier protein (ACP), 
ketoreductase (KR), dehydratase (DH) and methyl transferase (MT) as well, that are 
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collectively responsible for the biosynthesis of the MA (PKS backbone) part of mupirocin. 
mmpC encodes MmpC, which consist of two acyltransferse (AT) domains and a putative 
enoyl reductase (ER) domain (El-Sayed et al., 2003; Gurney and Thomas, 2011). AT 
domains are predicted to function in loading the biosynthetic modules with the starter and the 
extender units for chain initiation and elongation (El-Sayed et al., 2003). However, AT2, but 
not AT1, exhibited malonyl transferase activity which functions in loading all the ACPs with 
malonyl units (Gurney, PhD thesis, University of Birmingham, 2013). Since in Pederin, 
PedC, a member of AT2 group does not display detectable AT activity, but rather was 
confirmed to act as a proofreading enzyme by removing the stalled acyl units from blocked 
modules, but not malonyl-ACP, it is proposed to rename this enzyme as acyl hydrolase (AH) 
(Jensen et al., 2012). This suggests that AT1 in mupirocin might works as acyl hydrolase as 
well. MmpB is encoded by mmpB, which consists of a single KS, KR, DH domains, and a 
triple ACP domain, which is believed to be responsible for the biosynthesis of the fatty acid 
(9-HN) side chain of mupirocin, as well as a thioesterase (TE) domain, located at the end of 
the cluster, suggested to work as a hydrolase in the final step of the pathway for the release of 
mupirocin. It is also obvious that the mup cluster lacks a loading domain for the attachment 
of an activated starter unit to the first KS in the system (El-Sayed et al., 2003). 
 
 
Figure 1.13 Organization of the mupirocin biosynthesis (mup) genes cluster (source: El-
Sayed et al., 2003).  
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 Table 1.1 Enzymatic functions encoded by orfs of the mupirocin biosynthesis cluster 
(source: Thomas et al., 2010).   
            
macp, mupirocin acyl carrier protein gene; mmp, mupirocin multifunctional polypeptide 
gene. 
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1.6.4.1 Pathway for monic acid assembly 
    The monic acid moiety of mupirocin consists of a C17 heptaketide intermediate, which is 
synthesised by six rounds of chain extension (Claisen condensation). The catalytic reactions 
are carried out on the multifunctional proteins MmpD and MmpA, respectively. The activated 
starter unit (acetyl-coenzyme A intermediate) is transferred by AT2 of MmpC acting in trans 
to the 4´-phosphopantetheine arm of ACP-D1 of the first module of MmpD, which is then 
transferred to the thiol group of the active site cysteine of the KS-D1. Then loading of the 
extender unit (normally malonate or methyl malonate) by the action of AT2 to the unbound 
ACP-D1, which then followed by decarboxylative condensation catalysed by the KS-D1. The 
nascent PK chain then undergoes ketoreduction by KR-D1 but not dehydration, since the 
dehydration domain in this module is predicted to be non-functional because of genetic 
alteration in its active site, and the presence of the hydroxyl group at the β-position of C-13 in 
the structure of the intermediate after module 1 is considered as an indicator. The growing 
chain is then transferred to the three successive modules within MmpD where chain-
extension occurs catalysed by ACP/KS-D2, D3 and D4, respectively, to give a C12 
pentaketide intermediate. The β-keto group of the PK chain intermediate within each module 
(round of chain-extension) undergoes reduction to different levels depending on the activity 
of the reductive domains present in each module (El-Sayed et al., 2003). The 
methyltransferase (MT) domains in module 1 and 3, are responsible for the addition of the 
two methyl groups (C-16 and C17), which are present in the final structure of mupirocin, and 
incorporated from S-adenosylmethionine (SAM) (Feline et al., 1977). The polyketide chain 
(C12 pentaketide) which is produced by four cycles of condensation (Figure 1.14) is then 
transferred to the first module of MmpA. The ketosynthase (KS-A1) of the first module 
(module 5 in the pathway) of MmpA is unusual, since one of the two histidine residues in the 
active site is changed, so it is more likely to function in the transfer of the PK chain to the 
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downstream module in line, than to act in elongation. However, experiments with deletion of 
that KS or even active site mutations, abolished production of mupirocin, confirming that it is 
essential for the biosynthetic pathway. The chain intermediate undergoes two further rounds 
of condensation on MmpA to give the C17 heptaketide precursor to monic acid (El-Sayed et 
al., 2003).   
 
Figure 1.14 Biosynthetic genes of mupirocin, and a scheme representing the proposed 
pathway for its production. a. Genetic organization of the mup cluster and the proposed 
system of regulation of mupirocin expression. b. Schematic representation of the proposed 
pathway for biosynthesis of mupirocin. Six modules of MmpD and MmpA are responsible 
for biosynthesis of the monic acid (MA) backbone via condensation of extender units with 
further modifications. 3-hydroxypropionate is proposed as a starter unit for biosynthesis of 9-
HN through iterative condensations, ketoreduction and dehydration catalysed by MmpB. 
Successive elongations from the MA that is already esterified to 3-HP (pathway 1); or, 
separate synthesis accompanied by esterification (pathway 2), are two possible pathways for 
the addition of 9-HN to the MA (PKS) backbone (source: Thomas et al., 2010).    
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1.6.4.2 Pathway for biosynthesis of 9-Hydroxynonanoic acid (9-HN)  
    The mupirocin biosynthetic pathway currently thought to be most likely is presented in 
Figure 1.14. This shows the involvement of MmpD and MmpA, respectively, in the 
biosynthetic pathway of the MA moiety described in the previous section, so it is reasonable 
to predict that MmpB is responsible for the biosynthesis of the 9-HN part. Feeding 
experiments suggests that 3-hydroxypropionate is the most acceptable starter for the 
biosynthesis of 9-HN (El-Sayed et al., 2003). It is proposed that mAcpD (an ACP), MupS (a 
putative reductase) and MupQ (similar to acyl-CoA ligases) work together in the biosynthesis 
of 3-hydroxypropionate (Figure 1.15). This suggestion is built on sequence homology and 
mutational analysis. One of the homologies is the polyketide difficidin (Chen et al., 2006): as 
part of the synthase gene cluster it shows genes encoding for proteins related to the 
previously mentioned mupirocin genes, since the probable starter of that system is derived for 
3-hydroxypropionate (Thomas et al., 2010). MmpB provides essential domains required for 
the biosynthesis of the fatty acid (9-HN), through iterative use of the domains and 
condensation using three malonate molecules. The triplicate ACP domains (ACP/Ba, Bb and 
Bc) within MmpB could be a good indicator of its capability to incorporate three malonate 
molecules though three successive elongation steps. The ATs of the MmpC acting in trans 
are the possible candidates for loading MmpB with the extender malonate molecules. Since 
there is no enoylreductase (ER) domain in MmpB, the putative enoylreductase (MupE) most 
possibly works in trans to provide that function to give fully saturated 9-HN (El-Sayed et al., 
2003). However, inactivating MupE shows the production of compounds (PAs derivatives) 
with 6´-7´ enoyl bond, but not derivatives with completely unsaturated fatty acids. Further 
experimental results revealed the involvement of MupD with MupE in the enoyl bond 
reduction (Hothersall et al., 2007; Macioszek, PhD thesis, University of Birmingham, 2009). 
Within MmpC, a third domain downstream of the ATs, is predicated to work like an ER 
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which might participate in the essential reductive steps during the biosynthesis of 9-HN. The 
only thioesterase (TE) domain in the whole mupirocin system is located at the end of MmpB, 
which is responsible for the release of final product (El-Sayed et al., 2003). Until now there 
are two possible suggestions related to the release of mupirocin as a final product. The first, is 
that both the MA moiety and the 9-HN are synthesised separately, then esterifed together to 
give the complete structure of mupirocin. The second suggestion is that the 9-HN elongated 
through using a C3 starter unit (3-HP) esterifed with the MA (Figure 1.14) (Murphy et al., 
2011).                   
 
Figure 1.15 Proposed mechanism of biosynthesis of 9-hydroxynonanoic acid from 3-
hydroxypropionate. Synthesis of 9-HN from 3-HP starter unit is proposed to be catalysed by 
multifunctional proteins MmpB and MmpC along with MupE, MupD, and other reductive 
activity acting in trans (Piel, 2010 based on data of El-Sayed et al., 2003; Cooper et al., 
2005ab; Hothersall et al., 2007; Wu et al., 2007 and 2008). 
  
1.6.5 Post-PKS tailoring 
    Immediately after the production of the polyketide synthase derived core, there are further 
modifications of the backbone by tailoring enzymes. Therefore, determining the role of every 
gene that encodes different proteins within the biosynthetic mup cluster may provide 
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significant information about the biosynthesis pathway (Cooper et al., 2005a). In-frame 
deletion of mupO, mupU, mupV, and macpE abolished the production of PA-A, but lead to a 
significant increase in the production of PA-B (Cooper et al., 2005a). This result suggests the 
role of these proteins in the key reduction steps which thus control the flux of the PK 
intermediates down this channel. It was expected previously that PA-B is not simply 
produced by hydroxylation of PA-A, but rather it appear to be either an intermediate or may 
be a shunt product. However, recent observation in Bristol indicates that PA-B is a precursor 
of PA-A (Gao et al., unpublished data). For more details see also Chapter 5. Another two 
mupirocin analogues, mupirocin C and mupirocin F, are released by strains of P. fluorescens 
with deletions in mupC and mupF, respectively. Based on the structure of those two 
compounds, MupC is proposed to reduce the C8, C9 double bond, while MupF should be 
responsible for catalysing the reduction of the C-7 ketone. Further double deletions of mupC 
with either of  mupO, mupU, mupV, or macpE lead to the production of PA-B, indicating that 
the role of MupC and MupF comes after the role of MupO, MupU, MupV, and mAcpE, 
respectively. Therefore, for the biosynthesis of PA-A, MupU is proposed to mediate the 
transfer of the intermediate to mAcpE, and then MupO (cytochrome P450) would activate the 
molecule through catalyzing the oxidation of the C-7 hydroxyl to the ketone, and dehydration 
by MupV to give dienoyl-ketone (C-8,9 olefin). This would then undergo reduction by 
MupC, accompanied by C-7 ketone reduction catalyzed by MupF, which would then be 
converted to PA-A (Hothersall et al., 2007). A novel metabolite designated mupirocin W, 
lacking the tetrahydropyran ring (THP) produced, but having the attached 9-HN as a result of 
mupW and mupT deletion, points to their role in the oxidative activation of the 16-methyl 
group, essential for the formation of THP (Figure 1.16). It also indicates that the 16-
hydroxylation and the following THP formation happens as the last stage in the biosynthesis 
of PA-A, since the other proposed late stages of modifications including 5-hydroxylation, 
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10,11 epoxidation and esterification with the 9-HN moiety were not affected   (Cooper et al., 
2005b). 
 
Figure 1.16 Formation of the pyran ring of the monic acid. The postulated roles of the key 
tailoring enzymes that are identified as responsible for the formation of the tetrahydropyran 
ring of the monic acid moiety and determining the condition of oxidation around the ring. 
Production of pseudomonic acid (PA) A but not pseudomonic acid B was abolished when 
mupO, mupU, mupV and the mupirocin acyl carrier protein E genes (macpE) were knocked 
out (∆) either singly or in combinations, indicating that PA-A is not acting as a precursor to 
PA-B. Mupirocin C is the product of mupC knockout, while mupirocin F is the product of 
mupF knockout (source: Thomas et al., 2010).    
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    Hexaketide mupirocin H, a novel metabolite produced as a result of mutating mupH, an 
HMG-CoA synthase (HCS), which encodes for β-hydroxy-β-methyl-glutaryl CoA, as a first 
member of PAs family with truncation in the PKS backbone (MA) (Figure 1.17). It appears 
that mupH is part of a cassette which consists of five genes: macpC, mupG, H, J and K, 
respectively whose functions are presented in Table 1.1. These act at module A3 and 
functions in the incorporation of acetate at C-3 to generate C-15 methyl group. The proposed 
mechanism starts with the transfer of malonate to mAcpC (also known as mAcp14) by the aid 
of MmpC, decarboxylation of the acetate derived from malonate catalyzed by MupG to make 
acetyl-MacpC. Condensation of the β-ketothiolester moiety of the PK chain with the acetyl-
mAcpC catalysed by MupH makes the glutaryl thiolester. A glutaconate intermediate would 
then be generated by dehydration catalyzed by MupJ and this undergoes decarboxylation by 
MupK to produce the β-methylthioester in the MA precursor (Wu et al., 2008; Hothersall et 
al., 2007). Further analysis through mutating any of the previous components reveals the 
same phenotype, in which the truncated hexaketide mupirocin H and the tetraketide mupiric 
acid were the two major isolable metabolites. In addition, mutating some of the other genes 
including mupB, mupL, mmpB, and mmpF, and of particular interest mupQ, mupS and macpD 
(proposed to be involved in the biosynthesis of 3-HP) showed production of mupirocin H and 
mupiric acid and with the same level as has been produced by the mupH cassette mutations. 
Therefore, a ‘leaky hosepipe’ mechanism was proposed, which considers the predominant 
release of those metabolites as a result of the presence of spontaneous cleavage mechanisms 
or ‘labile points’ in the pathway. Those labile points take place at significant levels whenever 
there are mutations that block the biosynthetic pathway either in proximity or far from those 
points (Wu et al., 2008).  
    Repeated ACPs, duplicate ACPs in module 3 of MmpA (ACPs-A3a, and -A3b) and 
triplicates in MmpB (ACPs-Ba, -Bb and –Bc, respectively) within the biosynthetic pathway 
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have been studied functionally. Those ACP domains examined using different ways of 
mutations. Single deletion of the ACPs of MmpA, result in the reduction of mupirocin 
production to about 60% compare to the wild type, and those ACPs were proposed to work in 
parallel (Rahman et al., 2005). Strains with single or double deletion of the acyl carrier 
proteins included in MmpB are still able to produce mupirocin, but with a lower efficiency 
compared to the wild type strain, while deletion of all the three ACPs blocks mupirocin 
production. Thus, the ACPs function by increasing the flow through the biosynthetic pathway 
as if they work in parallel. However, inactivating the ACPs-Bb and -Bc with point mutation 
reduced the production, in contrast to point mutation with ACP-Ba, which blocks the 
pathway completely, indicating that not all ACPs of MmpB work in parallel (Rahman et al., 
2005). 
 
Figure 1.17. Proposed mechanism for biosynthesis of mupirocin H (Wu et al., 2008).  
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1.6.6 Regulation of mupirocin biosynthesis pathway 
    The mupirocin biosynthesis cluster of Pseudomonas fluorescens NCIMB 10586 was 
revealed to be regulated through an AHL (acyl-homoserine lactone) dependent quorum 
sensing (QS) system. Quroum sensing (QS) is defined as a mechanism that enables the 
bacteria to control the expression of specific target genes when responding to a critical 
concentration of signal molecules, which represents a way of sensing the cell density of a 
bacterial population. For example, QS in bacteria regulates gene expression of virulence 
factors, sporulation, biofilm formation, swarming, biosynthesis of antibiotic and 
bioluminescence. Although a critical concentration of AHL-signal molecules is essential for 
the majority of the genes that are AHL-quorum regulated in Gram-negative bacteria, it may 
be not enough (sufficient) for their expression. One possible explanation is that the bacterial 
growth phase could play a significant and valuable role in preventing the expression of genes 
at early stages of the growth even if the concentrations of AHLs are at a quorum regulated 
level. Numerous regulatory controls were identified to be present and act by ensuring the 
timely expression of QS-controlled genes (qsc), in accordance with both the concentration of 
AHL and metabolic status of the bacterial cell. However, there are some degrading enzymes 
that target the AHL molecules themselves, thus affecting both the total concentration of the 
available AHL and hence QS response (Venturi, 2006). Marine symbiotic bacteria Vibrio 
fischeri and the related free-living Vibrio harveyi are the first studied, which showed QS 
while studying the expression of bioluminescence which is density-dependent (Nealson et al., 
1970; Nealson and Hastings, 1979). Those two species produce and respond to the signalling 
molecules in the form of N-acyl-homoserine lactones (AHL) as autoinducers (Eberhard et al., 
1981; Cao and Meighen, 1989). AHL QS is simply based on the molecular system which is 
mediated by two specific proteins of the LuxI-LuxR families (Fuqua et al., 2001; Whitehead 
et al., 2001). Synthesis of AHL is the responsibility of LuxI protein which is one of the major 
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cytoplasmic enzymes. AHL then accumulates intra- and extra-cellularly in proportion to the 
cell density. When the AHL reaches the QS concentration, it interacts directly and 
sufficiently strongly with LuxR-type proteins to form LuxR-AHL complexes which can then 
bind at specific promoter DNA sequence termed as lux-boxes of QS regulated genes, and 
subsequently affecting their expression (Venturi, 2006). Within the mupirocin gene cluster, 
mupR and mupI genes were shown to encode proteins with great similarity to LuxR/LuxI of 
Vibrio fischeri and LasR/LasI of P. aeruginosa (Gambello and Aglewski, 1991).  In frame 
deletion of mupI and mupR separately abolished mupirocin production, indicating that they 
plays an essential role in the biosynthesis. MupI was identified as an AHL synthase that 
activates mupR, the transcriptional activator. Inactivation of the mup cluster at different 
points by using catechol 2,3-dioxygenase (xylE) as a reporter gene, abolished production of 
AHL, but this could be overcome by the addition of 3-oxo-C10 N-acyl homoserine lactone 
exogenously, demonstrating that mup cluster is regulated via a quorum signal  (El-Sayed et 
al., 2001). N-(3-oxodecanoyl) was identified as the AHL signal produced by mupI 
(Hothersall et al., 2011).  
    Similar to the ‘Lux boxes’ regulatory region that is bound by LuxR, the entire regulatory 
region that is controlled by MupR was identified. Potential regulatory regions are located 
upstream of the mupA promoter (El-Sayed et al., 2001), and between the divergence of mupF 
and macpC. Therefore, it is predicted that transcription of the mup cluster may include one 
very long transcript with more additional internal start points (Hothersall et al., 2011). 
Deletion of the mupX gene reduces the production of mupirocin by 40%, without blocking 
the overall biosynthesis of mupirocin, and is predicted to function as amidase/hydrolase. 
Therefore, this gene may not produce enzymes involve directly in the biosynthetic pathway, 
but may be needed for the optimum expression of the other genes within the cluster (Cooper 
et al., 2005a). The role of mupX gene, encoding for amidase/hydrolase was suggested to 
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regulate the expression of the biosynthetic genes cluster indirectly via two ways. The first one 
is by degrading the AHL (cleaving the amide bond) so as to keep the level in balance within 
the system, and the second is by degrading the minor AHL signals that are produced by the 
mupirocin producer, which act as inhibitors of MupR (Hothersall et al., 2011). Strikingly, 
expression of mupR (which encodes the positive transcriptional regulator, MupR) appears to 
act as a rate-limiting step during mupirocin production, as its overexpression in-trans both in 
the wild type P. fluorescens NCIMB 10586, 10586∆mupC and 10586∆mupF, increased the 
production of mupirocin, mupirocin C and F, and the minor shunt products, mupirocin H and 
mupiric acid, respectively up to 17 fold (Hothersall et al., 2011).    
 
 
1.7 Thiomarinol (PKS-NRPS hybrid) 
1.7.1 Structure and mode of action 
    Thiomarinol, a hybrid of two independent antibiotics; a pseudomonic acid analogue (PKS 
moiety) and a pyrrothine (NRPS part), isolated from a marine bacterium Alteromonas rava 
SANK 73390, with antimicrobial activity against both Gram positive and Gram negative 
bacteria stronger than either separately (Shiozawa et al., 1993). Pseudomonic acid C is most 
similar to thiomarinol, especially with regard to the stereochemistry of the six-membered 
ether ring in the monic acid moiety (Shiozawa and Takahashi, 1994). However, thiomarinol 
is different from pseudomonic acids (Figure 1.18) by the presence of 8-hydroxyoctanoic acid 
instead of 9-hydroxynonanoic acid, which is combined with the chromophore part (holothin) 
(Shiozawa et al., 1995). Pyrrothine is among a group of antibiotics produced by Streptomyces 
clavuligerus (Kenig and Reading, 1979), such as holothin, pyrrothine (N-methylholothin), 
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holomycin (acetylholothin), thiolutin (acetylpyrrothine), and others (Korzybski et al., 1978), 
that have a yellowish chromophore containing a disulfide bond. Pyrrothine antibiotics 
showed a broad spectrum activity, in which they differ depending upon the length of their 
acyl side chain (Korzybski et al., 1978; Mcinerney et al., 1991). The pyrrothine part is 
attached through an amide linkage to the 8-hydroxyoctanoic acid moiety of marinolic acid 
(pseudomonic acid like analogue) of thiomarinol (Fukuda et al., 2011).   
    Thiomarinol includes a series of related molecules with the different forms being 
designated A-to-G (Shiozawa et al., 1997; 1993; 1995; Shiozawa and Takahashi, 1994). The 
pigmented thiomarinol (thiomarinol A) producer appeared to be Pseudoalteromonas, which 
was previously classified incorrectly as Alteromonas rava (Abraham, 2004; Anderson et al., 
1974; Ballester et al., 1977; Barja et al., 1989). Comparison of the molecular architecture  of 
thiomarinol compounds relative to thiomarinol A (TMA), revealed that TMB possess an 
additional two oxygen atoms with the chromophore part (holothin), and TMC is considered 
as its monodeoxy derivative (4-deoxythiomarinol A) (Shiozawa et al., 1995). Also, the 
structure of TMD was deduced as 14-homothiomarinol A, TME as having two more 
methylenes in the acylchromophore part than thiomarinol A, TMF as ketothiomarinol A, and 
TMG which has the same molecular formula and the same acylchromophore as TMC 
(Shiozawa et al., 1997).    
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Figure 1.18. Chemical structure of thiomarinols A-G and the related pseudomonic acids A 
and C (source: Rahman et al., 2010).  
 
    Among all thiomarinol derivatives, TMA, TMB and TME were shown to have a similar 
potency with pronounced activity against Gram positive bacteria including MRSA, and 
slightly less activity with TMC, while TMG is reported to be the weakest one (Shiozawa et 
al., 1997). Specific inhibition of bacterial isoleucyl–tRNA synthetase is the mode of action of 
pseudomonic acids (Hughes and Mellows, 1980), and the inhibition is stronger by 
thiomarinols A, B and D, as they have a similar homoisoleucine type structure as 
pseudomonic acid A, whereas no inhibition of leucyl-tRNA, valyl-tRNA, and phenylalanyl-
tRNA synthetases was observed by thiomarinol (Shiozawa et al., 1997). However, although it 
is obvious that the pyrrothine part improves the inhibitory activity of thiomarinol (Fukuda et 
al., 2011), it is not yet known whether the pyrrothine part imparts any additional mechanism 
of antibacterial activity (Murphy et al., 2011). Moreover, the broad spectrum as well as the 
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strong in vitro antimicrobial activity exhibited by thiomarinol, raises the possibility that 
inhibition of RNA synthesis may be its other target (Shiozawa et al., 1993). This fact raises 
the possibility of an increase in the uptake of thiomarinol since the bacterial outer membrane 
is thought to work as a barrier that protects Gram-negative bacteria (Fukuda et al., 2011).   
 
1.7.2 The genetic organization of the thiomarinol biosynthesis (tml) cluster 
    Sequencing of the whole genome of Pseudolteromonas spp SANK 73390 (thiomarinol 
producer) performed to identify the biosynthetic genes of thiomarinol (tml). Results leads to 
the identification of approximately 97 kb of DNA contained all the genes required for 
thiomarinol biosynthesis (Figure 1.19). This was shown to consist of a trans-AT PKS 
including essential biosynthetic genes and associated reductive enzymes with great similarity 
to the mupirocin (mup) cluster, connected with the NRPS part comprising a set of accessory 
enzymes exhibiting considerable similarity to that which has been shown to control the 
biosynthesis of holomycin in Streptomyces clavuligerus (Huang et al., 2011). These 
observations emerged while investigating the 273 contigs from a whole genome sequencing 
project, in which part of one of them was found to encode many genes with great similarity to 
those in the mup cluster. Amplification of thiomarinol KS sequences using degenerate 
primers lead to the identification of a number of PKS genes, including the largest gene 
(tmpD), with similarity to mmpD in the mup cluster. Using suicide mutagenesis, the KS of the 
tmpD gene was mutated, and the mutants showed a reduction in the antibacterial activity. 
LCMS analysis confirmed that the mutants had lost the ability to produce thiomarinol, while 
they were still able to produce pyrrothine (Fukuda et al., 2011).   
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Figure 1.19. The thiomarinol biosynthesis (tml) gene cluster located on a plasmid 
pTML1 (source: Fukuda et al., 2011).   
 
    Subsequent productive analysis of the contig evidentally showed that it constitutes a 
circular plasmid which was named pTML1. The following evidence confirmed that it is a 
circular plasmid. One orf was identified based on the annotation of the contig, which was 
predicted to encode for a protein (Rep), that initiates DNA replication (Fukuda et al., 2011), 
and whose most similar sequence match is the Rep protein encoded by the megaplasmid-like 
chromosome II of Pseudomonas haloplanktis TAC125 (CR945247: 635,328 bp) (Medigue et 
al., 2005). Also two other adjacent orfs were identified as encoding partitioning proteins 
ParA/ParB equivalent to the plasmid partitioning proteins from the same source. In addition, 
experimental data confirmed that this contig is a circle, since the incomplete ends of the 
contig, were similar to the front and back of a single gene (the oxido-reductase gene that have 
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been designated as holA), compatible with the possibility that they should make a circle by 
joining the ends together (Fukuda et al., 2011). The suicide plasmid pAKE604: tmpD carries 
the sacB gene which encodes levansucrase that confers sucrose sensitivity in Gram-negative 
bacteria and so the tmpD knockout was used to verify whether pTML1 and thiomarinol 
production could be lost. A mutant with white colonies which lost the yellow pigment 
(indicating the loss of the pyrrothine moiety of thiomarinol) was obtained and the whole 
element was confirmed by using multiple PCR reactions across different DNA segments from 
the annotated contig including the rep-par region which confirmed that pTML1 has been lost. 
Therefore, since SANK 73390 could still survive, it is deduced that this contig is a plasmid 
rather than a chromosome (as a chromosome by definition carries at least one essential gene 
and cannot be displaced without the loss of the viability) (Fukuda et al., 2011).  
  
1.7.3 Thiomarinol biosynthesis pathway 
    The final sequence of pTML1 is 97600 bp with a G+C content of 43.2%, which is slightly 
higher than the G+C content (40.6%) of the summed contigs representing chromosomal 
DNA. This is in contrast with the G+C content of the mupirocin biosynthetic cluster of 
Pseudomonas fluorescens which is 56% (El-Sayed et al., 2003). Forty five orfs were 
identified in the final annotation (Figure 1.19), five of which are predicted to have typical 
mobile DNA functions (replication, partitioning, transposition and integration), although 
none of them have been identified which might be involved in either the transfer or 
mobilisation through conjugation. An essentially complete mupirocin gene cluster has been 
identified consisting of twenty seven orfs, which should encode the biosynthesis of the 
moiety termed marinolic acid which is the pseudomonic acid analogue (Figure 1.20) (Fukuda 
et al., 2011). The type  polyketide synthase (PKS) genes (tmpA-tmpD) have a similar order 
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to that of mup cluster (El-Sayed et al., 2003). The minor dissimilarities in the proteins being 
the presence of additional (extra) ACPs, which have been shown generally to increase the 
overall pathway flow (Rahman et al., 2005), in module 3 of TmpD, module 6 in TmpA and in 
TmpB with two extra ACPs, one included in a group of four and one precedes an extra KS 
(creating an extra module in TmpB) (Fukuda et al., 2011). It is predicted that the extra KS-
ACP within TmpB may have a role in the final processing (tailoring steps) to thiomarinol 
production before its release by TE (see also Chapter 5) (Fukuda et al., 2011). There are at 
least five transcriptional units (tmlT to tmlN, tmlM to tacpB, tmlA to tmlF, tmlY to tmlP and 
tacpB to holH) within thiomarinol genes cluster. These are differentiated by the difference in 
the direction of transcription and their interruption by the plasmid backbone functions of 
replication/partitioning and transposition functions (Fukuda et al., 2011).  
 
 
Figure 1.20 Schematic representation of the predicted biosynthesis pathway of 
thiomarinol explaining the critical roles of both TmpD (modules 1 to 4) and TmpA 
(modules 5 and 6), respectively for monic acid, TmpB for the fatty acid (8-
hydroxyoctanoic acid) side chain and HolA (NRPS) for pyrrothine (source: Fukuda et al., 
2011).      
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    Although the PKS and the associated parts of biosynthetic genes of mupirocin and 
thiomarinol are conserved, a high degree of divergence with regard to the sequence of the 
predicted products of the identified orfs was observed. The amino acid sequence alignments 
revealed sequence similarities ranging from approximately 40% to 65%, although the 
functionally constrained regions showed a higher degree of identity. These bioinformatics 
data in accordance with the predicted products raised questions about the possibility of 
functional cross-complementation between the two pathways, which requires more 
experimental evidence (see also Chapter 3) (Fukuda et al., 2011).   
    Fukuda et al., 2011 described seven orfs (designated as holA to holH) in the annotated 
sequence of the thiomarinol cluster which showed valuable similarity to the non-ribosomal 
peptide synthase (NRPS) genes cluster from the holomycin producer Streptomyces 
clavuligerus (Okamura et al., 1977; Huang et al., 2011), and Photorabdus assymbiotica 
(Wilkinson et al., 2009) that generate related compounds (Bode, 2009). Briefly the orfs are 
designated as follows: holA (NRPS), holB (oxidoreductase), holC (thiolesterase), holD 
(dehydrogenase), holE (acyltransferase), holF and holG as oxygenase and decarboxylase, 
respectively. However, the role of holH is not known, which is currently under investigation. 
The most important part is holA (the NRPS) which encodes for a single adenylation (A), 
thiolation (peptidyl carrier protein, PCP or T), and cyclisation/condensation (C) domains, 
which is hypothesized to function as a dimer for adding and joining the two cysteine 
molecules for the formation of a cysteinyl-cysteine dipeptide (Fukuda et al., 2011).  
    An internal segment of holA was used to generate a mutation within the pyrrothine genes 
to confirm their identity. HPLC and further LCMS analysis performed for the detection of the 
product released by holA (NRPS) and the tmpD (PKS) mutants in comparison to the wild 
type thiomarinol producer. Thiomarinol A (640 Dalton) was produced both in the whole cells 
and the supernatant of the wild type. Marinolic acid (486 Da) was produced by the strain with 
59 
 
holA (NRPS) mutation (lost the yellow pigment of pyrrothine), while only the yellow 
pigmented pyrrothine was produced by the tmpD (PKS) mutant. These observations indicate 
that it is possible for both marinolic acid and pyrrothine to be made independently. tmlU 
encodes TmlU, a protein that shows similarity to SimL in Streptomyces antibioticus that is 
responsible for the creation of the amide bond during simocyclinone biosynthesis pathway 
(Luft  et al., 2005; Pacholec et al., 2005), and NovL in Streptomyces spheroids having the 
same function in the biosynthesis of novobiocin (Steffensky et al., 2000). A mutant strain 
with in-frame deletion in tmlU shows the ability to produce both marinolic acid and 
pyrrothines but lost thiomarinol production, implicating TmlU in linking the two parts of 
thiomarinol together (Fukuda et al., 2011). 
    Further analysis confirmed the two antibiotics in the biosynthetic pathway of thiomarinol 
and provided strong evidence for the possibility of performing mutasynthesis and creating 
new families of hybrids. This consisted of restoring thiomarinol production via co-
fermentation of both the ∆tmpD and ∆holA strains, and feeding ∆tmpD with marinolic acid. 
Two novel pyrrothine amides (Figure 1.21) created while feeding ∆tmpD with pseudomonic 
acid A (Fukuda et al., 2011). Further feeding experiments showed that alternative substrates 
including pseudomonic acids could give alternative metabolites which made by P. 
fluorescens or amines, such as anhydroornithine could be incorporated by the two mutants 
(∆tmpD and ∆holA respectively) (Murphy et al., 2011). 
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Figure 1.21. Structure of the hybrids (mupirocin-pyrrothine amide) created by joining 
pseudomonic acid A with pyrrothine via an amide bond (source: Fukuda et al., 2011). 
 
 
1.7.4 Resistance to thiomarinol  
    Since thiomarinol has not been commercialised yet, this section will discuss the potency of 
thiomarinol and the gene responsible for conferring self-resistance to the thiomarinol 
producer. A mutant strain of SANK 73390 which was confirmed as having lost the pTML1 
plasmid shows sensitivity to thiomarinol, indicating that pTML1 is essential for resistance 
and tmlM was found to be responsible for the putative isoleucyl tRNA synthetase (Fukuda et 
al., 2011), similarly to the mupM gene in mupirocin producer that acts by preventing the 
suicide (El-Sayed et al., 2003; Yanagisawa and Kawakami, 2003). Therefore, tmlM may 
confer resistance to the marinolic acid part, while no gene is identified to confer resistance to 
the pyrrothine part. In-trans expression of both mupM and tmlM separately in E. coli 
performed under the control of tac promoter showed that mupM confers partial resistance to 
thiomarinol (MIC=1 µg/ml), in contrast to tmlM which gives higher level of resistance (MIC 
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≥16 µg/ml) (Fukuda et al., 2011). This observation suggests that isoleucyl-tRNA synthetase 
is the sole target of thiomarinol. Investigation of the activity of thiomarinol against 
methicillin resistant Staphylococcus aureus (MRSA) was carried out by plate bioassay and 
minimum inhibitory concentration (MIC) which showed that the growth of MRSA without 
and with the plasmid-borne mupA gene (encoding an IleRS which confers high level of 
resistance to mupirocin) was inhibited by thiomarinol. The same context described above was 
used for cloning and expression of this mupA gene (not the mupA gene from mupirocin 
biosynthetic cluster) in E. coli and the data showed that it also confers on E. coli resistance to 
mupirocin (MIC=50 µg/ml), but gives partial resistance (MIC=2 to 4 µg/ml) to thiomarinol, 
which was slightly higher than that for the mupM gene. However, the growth of E. coli was 
clearly inhibited at concentrations of thiomarinol that were not completely inhibitory to 
bacterial strains carrying SANK 73390 specific ileS gene (tmlM). Therefore, this means that 
both mupM and mupA (encodes mupirocin resistant ileS) are only able to confer partial 
resistance to thiomarinol, while for complete resistance it is essential for the strain to carry an 
altered ileS gene (tmlM) (Fukuda et al., 2011).  
    The antimicrobial activity of the novel compounds including mupirocin pyrrothine amides 
created by mutasynthesis (Murphy et al., 2011) were examined in comparison to thiomarinol, 
via using E. coli and S. aureus (MRSA) as indicator strains. Results indicated that the growth 
of both E. coli and S. aureus (more sensitive MIC≤30 ng/ml) inhibited by thiomarinol and the 
novel mupirocin pyrrothine amides (Fukuda et al., 2011). However, thiomarinol showed 
slightly more activity (MIC= 16-32 µg/ml) against MRSA carrying the mupA gene than the 
pyrrothine amides (MIC= 8 µg/ml). Marinolic acid showed less activity than mupirocin 
against S. aureus, which confirmed that the pyrrothine part is responsible for the increased 
potency of thiomarinol (Fukuda et al., 2011).          
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1.7.5 Modification enzymes 
    Considering tailoring enzymes of thiomarinol biosynthetic pathway, works are currently 
underway to characterise them. However, because there is great similarity between 
thiomarinol (especially marinolic acid part) and mupirocin, the function of several genes with 
their encoded enzymes could be deduced based on comparison with their analogues in 
mupirocin system.   
    Since sequence alignment of TmlA showed identity to MupA (in mupirocin), in addition to 
OmnC and PedJ proteins from the biosynthetic pathway of onnamide and pederin, 
respectively, and as they are proposed to have a role in the addition of hydroxyl groups at C7 
(Piel, 2002; Piel et al., 2004), same function proposed to TmlA as well (Fukuda et al., 2011). 
Moreover, the conserved position of tmlA/mupA directly upstream of tmpA/mmpA in both 
mupirocin and thiomarinol cluster, suggests the responsibility of tmpA/mmpA in the C6 
hydroxylation (Fukuda et al., 2011) of the MA. This possibly happens at the time of its 
attachment to the non-elongating module positioned at the beginning of TmpA/MmpA (El-
Sayed et al., 2003).   
    In thiomarinol, it is not known which gene encodes for the second hydratase (homologue 
of MupK in mupirocin) (Fukuda et al., 2011), which is responsible for decarboxylation, the 
last step in the pathway of HMG-CoA synthase (HCS) cassette which is responsible for the 
addition of C15 methyl group (Wu et al., 2007). However, since the N-terminus of TmpE 
showed identity with MupK, it is expected that TmpE might have the ability to provide this 
function (Fukuda et al., 2011). The lack of MupK analogue in thiomarinol is predicted to be 
as a result of gene fusion, since in the mup cluster both mupK and mmpE are located one after 
the other, so, a simple fusion could end up with such possible arrangement seen in tml cluster. 
This explains the possibility of the HCS cassette working where TmpE is positioned (Fukuda 
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et al., 2011). The idea which is supported by the hypothesis that the HCS cassette in 
kalamanticin/batumin cluster functions at the positions (Mattheus et al., 2010) which showed 
some degree of similarity to that of TmpE in the thiomarinol cluster with regard to the protein 
fusion, which could be taken as evidence (Fukuda et al., 2011).  
    In the mup cluster, macpE, is one of the genes located away from the multifunctional 
enzymes (Cooper et al., 2005a), which does not have an equivalent in the thiomarinol 
biosynthetic cluster. During the biosynthesis of mupirocin, MupU is proposed to play an 
essential role in the transfer of the intermediates to mAcpE, which undergoes further 
processing through MupO, V, C, and F for the production of pseudomonic acid A as a final 
product (Hothersall et al., 2007). However, the presence of an extra KS-B2 and ACP-B2 in 
TmpB which is absent in MmpB, while TmlU which has weak similarity to MupU but must 
have a different or additional role to that of MupU (see also Chapter 3), suggests that all the 
final processing steps for thiomarinol biosynthesis might possibly takes place on TmpB 
before its release by the TmpB thioesterase (TE). This suggestion minimizes the possibility 
that leakiness results from bottlenecks (see section 1.6.4.3) in the biosynthetic pathway, the 
reason which might explain why thiomarinol G (PA-B equivalent with C9 hydroxylation), is 
hardly detectable (released in a tiny amount) (Fukuda et al., 2011).    
    Considering the pyrrothine part of thiomarinol, work is currently underway to investigate 
the role of holH in the biosynthesis of thiomarinol via an in-frame deletion, in addition to 
other genes as well.  
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1.7.6 Regulation of thiomarinol biosythesis    
    The sequence analysis of the thiomarinol genes cluster revealed inverted repeats in the 
divergent promoter regions, which have been identified as putative operator sequences 
through which the genes of thiomarinol (pTML1 plasmid) are regulated. These inverted 
repeats are located in the regions between the following divergent transcriptional units; tmlM 
to tacpB/tmlA to tmlF and tmlY to tmlP/tacpA to holA (Figure 1.19) units, respectively. 
However, there are no clear cut evidences of candidates to function like regulatory proteins in 
the plasmid, and neither of the inverted repeats showed identity or any similarity to the Lux 
box that are found in the mup cluster, which is regulated through QS regulation. Therefore, it 
is expected that for the regulation of the plasmid, including thiomarinol biosynthetic genes 
cluster, it might require some chromosomal genes. This could explain why the plasmid faces 
problems if it were to transfer to an heterologous host which is different from the orginial 
host by not being able to support the plasmid with the essential requirement that it functions 
in plasmid regulation and thiomarinol production (see also Chapter 6). The fact that no 
evidence is available for the conjugation transfer function on the plasmid makes it more 
complicated, although there is evidence that thiomarinol biosynthetic genes cluster appear 
likely to be regulated so as to give expression at late exponential or early stationary phase of 
the growth of the producer Pseudoalteromonas spp SANK 73390 (see also Chapter 2).   
 
1.8 This project: context and objectives 
    This study includes several subprojects investigating the two closely related antibiotics, 
mupirocin and thiomarinol, both active against MRSA and the former in clinical use. The 
mup cluster has been sequenced, and putative enzymes encoded by most of the genes have 
been identified. This has enabled the specifc role of various enzymes in the biosynthesis of 
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mupirocin to be determined (Whatling et al., 1995; El-Sayed et al., 2001; El-Sayed et al., 
2003). In particular and relevant to this study further analysis revealed the successive roles of 
MupO, MupU, MupV and mAcpE in processing the intermediates for the synthesis of 
pseudomonic acid A (major compound), and the significant role of MupW and MupT in 
pyran ring formation. MupX (Cooper et al., 2005a, b) has also been identified to have an 
interesting role with MupI and MupR (rate-limiting step) in the regulation of mupirocin 
biosynthesis (Hothersall et al., 2011). Chapter 2 of this thesis focuses on control of gene 
expression by the thiomarinol producer Pseudoalteromonas spp. SANK 73390. This was 
carried out through studying the growth curve, and determining the timing of thiomarinol 
production relative to the growth while optimizing the conditions for the growth of the 
producer, production and extraction of thiomarinol. This data indicates that the thiomarinol 
gene cluster appears to be regulated so as to give expression in late exponential or early 
stationary phase. For increased production of thiomarinol industrially we need to understand 
how the biosynthetic gene cluster is controlled and how expression of the genes is regulated. 
Therefore, Chapter 3 focuses on determining the role of the gene which encodes a critical 
function in the pathway and which should be strategic for this purpose. Based on the 
observation that inactivation of tmlU prevented thiomarinol production (Fukuda et al., 2011), 
it was hypothesised that this gene controls the production of thiomarinol by catalysing the 
amide bond formation that brings together the two components of this antibiotic-marinolic 
acid and pyrrothine. We hoped that further studying tmlU should therefore test this 
hypothesis as well as allowing the possibility of creating novel hybrid antibiotics between 
analogues of pyrrothine (part of thiomarinol) and mupirocin that could be joined by the 
enzyme encoded by tmlU. Therefore, the first step was by over-expression of tmlU in the 
mutant NCIMB10586∆mupU (cross-complementation), then in the wild type P. fluorescens 
NCIMB 10586 and other mutants described in Chapter 3. The presence of extra KS and ACP 
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in TmpB of thiomarinol biosynthetic cluster and the absence of a mAcpE homologue which 
is responsible for accepting the polyketide intermediate from MupU where it is processed by 
MupO, V, C, and F in the mupirocin system (Hothersall et al., 2011) raises the possibility of 
the involvement of TmpB in the last tailoring steps of thiomarinol biosynthesis (Fukuda et 
al., 2011). Therefore, the aim of thiomarinol subproject in Chapter 4 was to investigate the 
role of this extra non-elongating (KS-B2/ACP-B2) module of TmpB in the removal of the C8-
hydroxyl group, through construction of gene –knockout, which would provide information 
about the structure of the late-stage intermediate in the biosynthetic steps in the pathway. 
    In mupirocin, the proposed mechanism of intermediate transfer by MupU to mAcpE, and 
further processing by additional tailoring enzymes (MupO, MupV, MupC, and MupF) for the 
production of PA-A (Hothersall et al., 2007), prompted Macioszek to attempt to shut down 
PA-B production in favour of PA-A via in-trans expression of these genes together in P. 
fluorescens NCIMB 10586 (Macioszek, PhD thesis, University of Birmingham, 2009). One 
of the aims of this study was to continue that work by different strategies. The first one was 
by increasing the expression of mupU (transferring the intermediates) via genetic 
manipulation to insert a new promoter upstream mupU, and the second was by the fusion of 
mupU and macpE so that they would be expressed and translated into a single functional 
polypeptide. Since the last one was also successful, and as MupU/mAcpE is expected to work 
before the thioesterase (TE) of MmpB, the fused mupU-macpE inserted into two different 
positions within mupirocin cluster of strain with mupU and macpE knocked out, constructed 
during this study, described in Chapter 5.  
    Knowing the regulatory system and how the expression of thiomarinol biosynthetic genes 
cluster is regulated, may reveal ways to increase the production of this antibiotic industrially. 
Since thiomarinol biosynthetic genes cluster in Pseudoalteromonas spp. SANK 73390 is 
located on plasmid pTML1 (Fukuda et al., 2011), and data in Chapter 2 showed that the 
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thiomarinol gene cluster appears to be regulated so as to give expression in late exponential 
or early stationary phase, it would not make sense for genes to be on a plasmid and able to 
move between bacteria if they could not carry their regulatory system with them. Therefore, it 
was proposed to transfer pTML1 to a new host to see if the genes are expressed and can be 
regulated in the same way, or whether it needs one or more chromosomal genes from 
Pseudoalteromonas spp. SANK 73390. For this purpose, attempts to transfer pTML1 plasmid 
out of SANK 73390 were carried out in Chapter 6 using different strategies including the use 
of different vectors constructed with different specificites, such as RK2 vector, R6K replicon, 
and a vector which depends on an E. coli strain with chromosomally integrated pir gene for 
the replication.  
    Overall, the aim of these investigations was to cover more aspects of the critical steps that 
control thiomarinol biosynthesis, and to give better understanding about various enzymes in 
the synthesis of mupirocin and thiomarinol which have functional and specific roles in 
switching on the system to a specific compound. Also to make a link between those two 
antibiotics, which would serve in two most useful and powerful ways, the first one is to 
provide more valuable understanding about synthesis context of every part (i.e fatty acid side 
chain), and second to generate more powerful tools for creating a new hybrid with higher 
potency.    
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CHAPTER 2 
 OPTIMAL CONDITIONS FOR THIOMARINOL 
EXTRACTION AND DETECTION FROM THE 
PRODUCER Pseudoalteromonas STRAIN SANK 73390 
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2.1 Introduction:-  
    Thiomarinol, the naturally hybrid antibiotic of pseudomonic acid (PKS part) and 
holomycin (NRPS part) has occuring much attention in recent years due to its antibacterial 
activity against both Gram-positive and Gram-negative stronger than either of the two 
separate antibiotics (Shiozawa et al., 1993), which offers important pharmaceutical and 
medicinal benefits. Thiomarinol is produced by Gram-negative marine bacterium 
Pseudoalteromonas spp SANK 73390. Holomycin belongs to the group of pyrrothine 
antibiotics with a yellowish chromophore containing a disulphide bond (Korzybski et al., 
1978), and so the holomycin component means that thiomarinol has a yellowish colour. It has 
been hypothesised that only pigmented species of the genus Pseudoalteromonas, such as the 
thiomarinol producer, are able to produce natural products (Egan et al., 2002), and they seem 
to have more restricted growth requirements, such as the need for a special amino acids 
(Bowman, 2007). Pseudoalteromonas spp SANK 73390 grows at temperatures between 4
o
C 
to 32
o
C, with optimum growth temperature falling between 17
o
C to 26
o
C. However, 
temperatures not falling within this range are also applicable for strains adapted to grow at 
lower/higher temperatures. Furthermore, growth at temperatures ranging between 20
o
C to 
26
o
C, and maintaining the pH of the culture medium between pH 5 to pH 8 is preferable for 
the production of thiomarinol B and/or C but without stopping the growth of the 
microorganism or having any irreversible influence on the quality of the final product 
(Takahashi et al., 1995).  
    Acetone and ethyl acetate were used for the isolation and extraction of thiomarinol from 
broth cultures of SANK 73390 which was then concentrated in vacuo in order to give the 
final yellowish oily substance (Shiozawa et al., 1993). Moreover, extraction of thiomarinol B 
and/or C has been performed according to their physico-chemical properties and by using 
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water-immiscible organic solvents, for example ethyl acetate or ethylene chloride under 
either neutral or acidic conditions, then purified and applied on preparative HPLC, using a 
normal or reverse phase column (Senshu-Park, ODS, H4251, 10 x 250 mm) and 40% 
acetonitrile at a flow rate of 5 ml/minutes (Takahashi et al., 1995).   
    The present study illustrates several different attempts searching for the best way of 
sampling, extracting and then profiling production of thiomarinol from the producer micro-
organism marine Pseudoalteromonas spp SANK 73390. Different protocols were 
implemented to monitor thiomarinol with regard to both the quality and the quantity of 
production. 
 
 
2.2 Materials and Methods:- 
2.2.1 Bacterial strains 
     Marine bacterium Pseudoalteromonas spp SANK 73390 was used as the wild type 
thiomarinol producer. Bacillus subtilis 1604 was used as the test organism in the bioassay to 
detect the antibacterial activity of thiomarinol. 
 
2.2.2 Growth and culture conditions 
     Pseudoalteromonas spp SANK 73390 was grown at 23
o
C in M-broth consisting of 
peptone (5.0 g/l), yeast extract (1.00 g/l), ferric citrate (0.10 g/l), sodium chloride (19.45 g/l), 
magnesium chloride (5.9 g/l), magnesium sulfate (3.24 g/l, calcium chloride (1.80 g/l), 
potassium chloride (0.55 g/l), sodium bicarbonate (0.16 g/l), potassium bromide (0.08 g/l), 
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strontium chloride (0.034 g/l), boric acid (0.022 g/l), sodium silicate (0.004 g/l), sodium 
fluoride (0.0024 g/l), ammonium nitrate (0.0016 g/l), and disodium phosphate (0.008 g/l), and 
M-agar (M-broth, except magnesium chloride with (8.8 g/l), sodium sulfate (3.24 g/l) instead 
of magnesium sulfate, and (15.0 g/l) agar). Bacillus subtilis 1604 was grown at 37
o
C in L-
broth medium consisting of yeast extract (10 g/l), tryptone (5 g/l), NaCL (10 g/l), and 
Glucose (1 g/l). All medium was sterilised by autoclaving (121
o
C at a pressure of 15 pounds 
per square inch for 15 min). 
 
2.2.3 Determination of the growth curve of Pseudoalteromonas spp SANK 
73390 
     Seed cultures of Pseudoalteromonas spp SANK 73390 were prepared by inoculating 25 
ml marine broth in 250 ml Erlenmeyer flask (Takahashi et al., 1995) with a single colony 
from the young culture of SANK 73390, followed by overnight incubation at 23
o
C with 
shaking at 200 rpm. Triplicates of three separate 500 ml flasks each containing 100 ml marine 
broth were inoculated with the freshly prepared seed culture as follows respectively; 1 ml 
washed bacterial cells (100X), 1 ml (100X) and 2 ml (50X) without washing. The process of 
washing involves spinning down the culture, discarding the supernatant, and then re-
suspending in 1 ml of fresh marine broth. Cultures were incubated at 23
o
C with shaking at 
200 rpm for up to 12 h, 21 h and 48 h separately at different times, and 1 ml samples were 
taken either every 3 h or every h for determining the optical density at 600 nm from time 
zero.      
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2.2.4 Optimal conditions for thiomarinol extraction 
    Samples of 800 µl or 2 ml from the broth cultures of SANK 73390 strain were used for the 
extraction of thiomarinol. To stabilise thiomarinol compounds the pH of the samples was 
adjusted to pH 6.0 (acidic condition). An equal volume (800 µl or 2 ml) of acetone was added 
to each sample and mixed well for 5 minutes using a vortex mixer, and then left in the fridge 
for at least 1 h to allow complete decomposition of bacterial cell wall. Evaporation of acetone 
was then carried out using a speed vacuum pump for 1 h, followed by the addition of an equal 
volume of ethyl acetate and mixed well for at least 5 min. At this stage the mixture of 
thiomarinol, ethyl acetate, and cell debris left for enough time (at least 30-60 min) to ensure 
that the whole mixture separated into two phases. The yellow compound (thiomarinol) moved 
to the upper solvent (ethyl acetate) phase, while cell debris settled in the bottom (water) 
phase. The upper phase of ethyl acetate and thiomarinol was transferred to a new 2 ml 
microfuge tube, while the bottom phase was poured off.  The ethyl acetate was dried out 
completely by speed vac. pump to obtain dried thiomarinol.  The dried out samples were then 
dissolved in either 80 µl or 200 µl of methanol in the case of preparing antibiotic discs or 
dimethyl sulfoxide (DMSO) for HPLC analysis.   
 
2.2.5 Sample analysis by HPLC 
    HPLC analysis was performed to detect the presence of thiomarinol in samples prepared in 
the previous section from cultures of Pseudoalteromonas spp SANK 73390. Two solvents 
were used; solvent A (HPLC grade water); and solvent B (HPLC grade acetonitrile), and both 
were supplemented with 0.01% formic acid to adjust the pH of the mobile phase. Both 
solvents were degassed using an aspirator in order to completely release all the bubbles from 
the solvents before use. HPLC was performed using Uni-point LC system software, reverse 
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phase C18 column (15 cm x 4.6 mm), UV detector was used at a sensitivity of 0.002 
absorbance units at 385 nm. 10 µl, 20 µl or 100 µl of each sample was injected into the 
HPLC machine. Thiomarinol and other intermediates were eluted using a mobile phase 
gradient (40% or 35%) of acetonitrile, and H₂O (60% or 65%) at a flow rate of 1 ml min⁻¹.  
 
2.2.6 Paper disc assay for thiomarinol production 
    Cultures of the indicator strain were prepared by inoculating 5 ml of L-broth with Bacillus 
subtilis 1604 and incubated overnight at 37
o
C with shaking at 200 rpm. The bottom agar 
media was prepared the next day by pouring 15 ml of L-agar into a plastic petridish and left 
for 1 h to solidify. Then the upper soft-agar media was prepared by pouring 20 ml of melted 
L-agar and 20 ml of pre-warmed L-broth into a Falcon tube and mixed well. To this was 
added 0.4 ml of the indicator broth and the Falcon tube inverted to ensure complete mixing. 
10 ml of the soft-agar mixture was poured onto the bottom agar media and left on the bench 
for at least 30 min to solidify. While waiting for the upper soft-agar to solidify with the 
bottom one, paper discs from the extracted samples of thiomarinol were prepared by first 
marking the paper discs with a pencil. The discs were placed on an aluminium surface and 40 
µl of the samples in methanol dissolved were added onto the paper discs slowly and left for 
10 min to dry out. Antibiotic discs were then placed onto the prepared antibacterial indicator 
plate and incubated overnight at 37
o
C. The size of the clearance zone around the antibiotic 
discs was then taken as an estimate of the antibacterial activity of thiomarinol present in the 
antibiotic discs. 
          
                
74 
 
2.3 Results 
2.3.1 The importance of washing bacterial inocula for cultures to profile 
antibiotic production 
     Preliminary studies on production of thiomarinol indicated that even 100-fold diluted 
cultures of SANK73390 gave a significant level of antibacterial activity by plate bioassay 
indicating either production of thiomarinol in low density cultures or significant carryover of 
antibiotic from the stationary phase cultures. It was therefore decided that bacteria from 
stationary phase cultures should be washed to remove existing antibiotic before inoculation of 
the fresh, dilute culture. Since bacterial cultures are not ready instantly to be used from agar 
plates, they need to be ensured that they are growing very well and are presented as young 
and fully active before using them for investigation. This could be done be transferring the 
cultures several times into another media (broth is preferable), which leads to increase in cell 
number and increase in cell population mass, in addition to ensuring the uniformity. 
Researchers normally follow bacterial growth as populations instead of following the growth 
of individual cells, and this is due to that the characteristics of individual cells usually is 
preferable to be studied in the context of populations of cells. Therefore, cultures with and 
without washing and with different densities of inoculation were investigated (section 2.2.3). 
From the growth curves with washed inocula diluted 100x, unwashed inocula diluted 100x 
and 50x (Figure 2.1 A, B and C) incubated for 48 h, 21 h and 12 h, respectively, it can be 
seen that the logarithmic phase occurred between 3-9 h of incubation followed by a stationary 
phase until the end of the incubation period (48 hr). Washing the bacterial cell inocula prior 
of the inoculation had no negative effect on the growth profile. When the growth curved of 
washed cells was repeated in triplicate it can be seen that the growth profile is highly 
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reproducible (Figure 2.2). Also it is of significance that the growth curves were repeated 
several times and the cell densities measured either every hour or every 3 h intervals.  
 
 
 
Figure 2.1 Growth curve of Pseudoalteromonas spp. SANK 73390. Growth checked every 
3 hrs over 48 hour (a), over 21 hr (b) and every hour for 12 hr (c). Blue line (washed pellet 
100X); Pink line (Unwashed inoculum 100X); and Yellow line (Unwashed inoculum 50X). 
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(Figure 2.1 continued) 
 
 
 
 
Figure 2.2 Growth curve of Pseudoalteromonas sp. SANK 73390 using washed bacterial 
pellet as inocula with triplicate cultures. 
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2.3.2 Efficient solvent for concentrating thiomarinol, sample volume and 
optimal concentration of acetonitrile for thiomarinol detection    
    The extracted samples were primarily dissolved in 40 µl or 80 µl of methanol, and 10 µl or 
20 µl subjected to HPLC analysis for 1 h or 25 min using 40% acetonitrile and formic acid 
(0.01%), with H₂O 60% and formic acid (0.01%), at a flow rate of 1 ml min⁻¹. HPLC 
chromatograms showed that the thiomarinol peak could not be separated from the other 
unknown peaks due to the hydrophobic property of thiomarinol. Also, it is expected that the 
unknown peaks might possibly belong to some other materials that had been adsorbed and 
detected by the HPLC. However, when the extracted samples were dissolved in 200 µl of 
DMSO, and 100 µl used for HPLC analysis for 25 min with solvent concentrations 35% 
acetonitrile and formic acid (0.01%), with H₂O 65% and formic acid (0.01%), at a flow rate 
of 1 ml min⁻¹, typical and separated thiomarinol peak was observed as a result of change in 
the retention time.   
 
2.3.3 Disc bioassay does not correlate completely with the amount of 
thiomarinol produced in comparison with that of HPLC analysis 
    Paper disc bioassay were performed to investigate the presence of antibiotic (thiomarinol) 
in the extracts obtained from using cultures with and without washing and with different 
densities of inoculation  over 48 h of incubation at 23
o
C with shaking at 200 rpm. The results 
of bioassay (Figure 2.3) did show the presence of thiomarinol in the paper discs prepared 
from extracts after 9 h incubation and onward from cultures with unwashed inoculation. 
However, there was also a sign of slight inhibition zones even with paper discs prepared from 
extracts at time zero and after 3, and 6 h of incubation, but there was not enough to give a 
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clear zone of inhibition, remaining cloudy and rather indeterminate. However, the presence of 
thiomarinol in paper discs prepared from extracts of culture with washed inoculation after 12 
h and up to 48 h incubation could be determined, and there was no observable sign of 
antibiotic around paper discs prepared from samples extracted at other times (0, 3, 6, and 9 h) 
of incubation. The size of the clearance zone around the antibiotic discs was then taken as an 
estimate of the amount of thiomarinol present in the antibiotic discs. 
     Although the profile of thiomarinol production with incubation time up to 48 h using the 
disc bioassay showed reasonable similarity to the amount of thiomarinol determined with that 
of HPLC analysis, it did not correlate completely.     
 
 
   
Figure 2.3 Disc bioassay activity of thiomarinol produced by SANK 73390. 
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2.3.4 Addition of HCl improved thiomarinol extraction 
    In order to investigate the effect of acidic condition on thiomarinol extraction, samples in 
triplicates with two different volumes (800 µl and 2 ml) were used for the extraction of 
thiomarinol. Samples were then separated into two groups. HCl was added to the first group 
to adjust the pH to the acidic condition, while the second group was left without HCl 
addition. Thiomarinol was extracted following the procedure described in section 2.2.4, and 
the extracted samples were then subjected to HPLC analysis (section 2.2.5). HPLC 
chromatograms significantly showed the importance of pH adjustment of the samples for 
thiomarinol extraction, as the yield increased two fold compared to the samples without pH 
adjustment (Table 2.1 and Figure 2.4). In addition, the yield was significantly higher in 
samples of 2 ml than 0.8 ml. This result indicates the role of pH adjustment of samples to the 
acidic condition in improving the yield of thiomarinol which might be due to the role of HCl 
(acidic pH) in stabilising thiomarinol compounds while using acetone in combination with 
ethyl acetate for thiomarinol extraction. 
 
      Table 2.1 Effect of pH adjustment on the yield of thiomarinol. 
 
 
    
Sample description 
 
Concentration µg/ml 
 
Sample volume 
 
 
800 µl 
 
 
2 ml 
 
+ HCl 
 
4.85 ± 0.44 µg/ml 
 
 
4.91 ± 0.59 µg/ml 
 
-HCl 
 
1.66 ± 0.29 µg/ml 
 
 
1.63 ± 0.09 µg/ml 
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Figure 2.4 HPLC chromatogram at 385 nm of thiomarinol from Pseudoalteromonas spp 
SANK 73390 showing the effect of HCl addition on thiomarinol extraction in different 
volumes of samples. 
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2.3.5 In-efficiency of ethyl acetate alone to extract thiomarinol attached to 
the bacterial cells unless used with acetone 
    Samples of 800 µl and 2 ml were used for extraction of thiomarinol by using ethyl acetate 
alone. Extraction was carried out separately in total sample, supernatant and bacterial cell 
pellet. The pellet was re-suspended in fresh marine broth (same volume of the total sample), 
and then HCl was added to each part separately to adjust the pH to acidic conditions. Then 
thiomarinol extraction was carried out using ethyl acetate as well as ethyl acetate with 
acetone (section 2.2.4). The amount of thiomarinol extracted using ethyl acetate alone from 
each part of the broth culture of SANK 73390 was measured separately by HPLC 
chromatogram (Table 2.2 and Figure 2.5). These data showed that some thiomarinol remains 
attached to the pellet when using ethyl acetate alone for the extraction. However, when 
acetone was used with ethyl acetate for the extraction, all thiomarinol could be determined, 
illustrating the critical role of acetone in decomposing the bacterial cell pellet so that 
extraction detected as much thiomarinol as possible, although the difference is not highly 
significant which mostly due to changes while the baseline of the peaks was adjusted. (Table 
2.3 and Figure 2.6). 
Table 2.2 Extraction of thiomarinol using ethyl acetate alone.  
 
 
Sample description 
Concentration µg/ml  
Sample volume 
 
800 µl 
 
2 ml 
 
 
Total culture 
 
 
7.59 
 
7.82 
 
Bacterial cells pellet 
 
 
1.01 
 
0.61 
 
Supernatant 
 
 
4.10 
 
4.98 
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Figure 2.5 HPLC analysis at 385 nm of thiomarinol extracted from Pseudoalteromonas 
spp SANK 73390 in different volumes (0.8 ml and 2 ml) and using solely ethyl acetate. 
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Table 2.3 Effect of using acetone in combination with ethyl acetate for thiomarinol 
extraction. 
 
 
Sample volume 
 
Concentration µg/ml  
 
 
Acetone + ethyl 
acetate 
 
 
Ethyl acetate 
 
800 µl 
 
 
5.95 ± 0.12 µg/ml 
 
5.86 ± 1.17  µg/ml 
  
 
 
 
 
                                                          
Figure 2.6 HPLC analysis at 385 nm of thiomarinol extracted from Pseudoalteromonas 
spp SANK 73390 in 0.8 ml of culture samples using ethyl acetate alone and in 
combination with acetone.  
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2.3.6 Best sample volume for extraction of thiomarinol at early stages of the 
growth (0, 6, 12 and 18) h. 
    Since we had demonstrated that acetone with ethyl acetate improved thiomarinol 
extraction, therefore, we wanted to determine whether 800 µl or 2 ml was better for sampling 
from the broth cultures of SANK 73390 at early stages of the growth (0, 6, 12, and 18 h).  
Samples of 800 µl and 2 ml were used from cultures at the growth times specified, and 
thiomarinol extracted by adjusting samples pH to acidic condition and following the acetone-
ethyl acetate protocol. HPLC chromatograms revealed the usefulness of both 800 µl and 2 ml 
for sampling at early stages since both showed no detectable thiomarinol in the samples 
collected after 6 h of the growth of SANK 73390, while thiomarinol was observed in the 
samples of both volumes after 12 h (Table 2.4 and Figure 2.7).    
 
Table 2.4 Best sample volume for thiomarinol extraction. 
 
 
 
 
 
 
                                           
                                                                                         
 
 
 
 
 
Sampling time (hr.) 
 
Concentration µg/ml  
 
Sample volume 
 
800 µl 
 
2 ml 
 
0 
 
No tml 
 
No tml 
 
6 
 
No tml 
 
No tml 
 
12 
 
2.05 
 
1.92 ± 0.08 µg/ml 
 
18 
 
6.32 
 
      6.38 ± 0.84 µg/ml 
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Figure 2.7 HPLC analysis at 385 nm of thiomarinol extracted from 0.8 ml and 2 ml of 
samples of Pseudoalteromonas spp SANK 73390 at early stages of the growth using ethyl 
acetate and acetone.  
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2.3.7 Time course of thiomarinol production 
    For the purpose of analysing the production profile of thiomarinol by HPLC over a long 
period of the growth incubation time, triplicate cultures with washed inocula of SANK 73390 
were incubated for 48 h at 23
o
C with shaking at 200 rpm. Sampling commenced from 0 time 
up to 48 hr of incubation. 2 ml samples were taken out from broth cultures every 3 h up to 30 
h, followed by sampling every 6 h. The acetone-ethyl acetate protocol was followed for the 
extraction of thiomarinol (Materials and Methods section 2.2.4). The extracted thiomarinol 
dissolved in 200 µl DMSO and 100 µl used for HPLC analysis for 25 min with solvent 
concentrations 35% acetonitrile and formic acid (0.01%), with H₂O 65% and formic acid 
(0.01%), at a flow rate of 1 ml min⁻¹. HPLC chromatograms (Figure 2.8) showed a typical 
peak of thiomarinol in samples of 12 h and following samples, but not in the samples before 
12 h of incubation (0, 3, 6 and 9 h). To identify precisely the starting point of thiomarinol 
production, all the steps mentioned from culturing to HPLC analysis were repeated twice 
with duplicates, first for samples at 7, 8, 9 and 10 h of incubation, and then for samples at 9, 
10, 11 and 12 h of incubation. The HPLC analysis confirmed that thiomarinol production 
started after 9 h of incubation. Then the concentration of thiomarinol in all the samples with 
thiomarinol peak was estimated and the concentration plotted against the incubation time 
(Figure 2.9). Results indicated that production of thiomarinol increased quickly after the 
starting point (9 h) until 12 h, then increased slightly to reach a maximum production at 18 h 
within the first 24 h of incubation. Production of thiomarinol then fluctuated and decreased at 
27 h but then dramatically increased to 36 h as the maximum point of thiomarinol production, 
followed by a slight reduction until the last point of incubation (48 h).     
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Figure 2.8 Time course of thiomarinol production from Pseudoalteromonas spp SANK 
73390 analysed by HPLC at 385 nm on 2 ml samples at different times of the growth up 
to 48 h using triplicate cultures, and using acetone-ethyl acetate for the extraction.  
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(Figure 2.9 continued) 
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(Figure 2.9 continued) 
 
 
 
 
Figure 2.9 Time course production of thiomarinol. 
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2.4 Discussion 
    Thiomarinol has a strong and broad spectrum antibacterial activity, and more specifically 
against MRSA. Thus over the last decade there has been research into the production and 
extraction of thiomarinol for use as a new interesting antibiotic. However, these studies did 
not address the critical role of HCl, particularly in improving the extraction process or a 
specific role of each solvent in the protocol. In addition, there is no indication about the 
timing of thiomarinol expression. In this study the onset and maximum point of thiomarinol 
production has been determined relative to the growth phases of the producer 
Pseudoalteromonas spp SANK 73390, while optimising the parameters of metabolite 
extraction and HPLC analysis. 
    Typically, secondary metabolites and more specifically antibiotics are expected to be 
produced during stationary phase, indicating a strong association between growth and 
antibiotic production. We therefore initially determined the growth phases of 
Pseudoalteromonas spp SANK 73390 to help us determine at which time point we might 
expect to start detecting thiomarinol production. We found that under our standard conditions 
the logarithmic phase occurred between 3-9 h of the growth time, followed by a stationary 
phase which lasts for the rest of the incubation time. Although the pH of the culture broth of 
SANK 73390 was adjusted to acidic pH with HCl by Shiozawa et al., (1993) during the 
isolation of thiomarinol, they have not stated clearly the reason, or the usefulness of the 
adjustment. It might have been used to stop the fermentation, or to start the extraction, since 
it is preferable to extract the thiomarinol (i.e thiomarinol B and/ or C) that are existing in the 
filtrate or in the supernatant with water-immiscible organic solvent including ethyl acetate 
under neutral or acidic conditions (Takahashi et al., 1995). However, HPLC analysis showed 
a significant improvement in thiomarinol extraction after adjusting pH of the samples to the 
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acidic condition, which might be due to the role of acidic condition in stabilising thiomarinol 
compounds. We have also showed the inability of ethyl acetate alone to extract all the 
thiomarinol present in the culture, since our data confirmed that some thiomarinol is still 
trapped intracellularly or attached to the bacterial pellet after extraction. Therefore, to 
overcome this problem, acetone was used in combination with ethyl acetate for the purpose 
of releasing and extracting the trapped thiomarinol as well.  As a consequence, there was a 
small increase in the yield of thiomarinol. These findings extend those of Shiozawa et al., 
(1993), and are in good agreement with those of Takahashi et al., (1995), that aqueous 
acetone or methanol with a concentration of 50-90% may purify intracellular thiomarinol B 
and/or C. More recently acetone was effectively used for the extraction of antifungal 
metabolite KB425796-A from the fermentation broth of Paenibacillus sp. 530603 (Kai et al., 
2013).  
    Compounds elute at different time points when analysed by HPLC according to their 
chemical properties such as whether hydrophilic or hydrophobic, and the condition of both of 
the mobile phase and the stationary phase (column). Detection of thiomarinol using 40% 
acetonitrile was not successful to separate thiomarinol peak from other unknown compound 
peaks. Therefore, and since thiomarinol appears to be hydrophobic, when the concentration 
of acetonitrile was changed in the mobile phase to 35%, thiomarinol peak was eluted and 
separated from the other unknown peaks. Moreover, we found that 100 µl of samples as a 
sufficient amount to be analysed accurately by HPLC, which gave a typical thiomarinol peak. 
The dried extracts were first dissolved in methanol, since as a crystal solvent methanol forms 
two hydrogen bonds to thiomarinol (especially TH-B) while recrystallizing with methanol-
H2O solution, which play a pronounced role in stabilizing the crystal structure of the 
antibiotic (Shiozawa et al., 1995). However, as methanol evaporates quickly, and so 
consequently affected the sample volumes in uncapped tubes prepared for HPLC analysis, 
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DMSO was used as alternative solvent. When the best method of extraction was established, 
it appeared that culture samples of 800 µl is sufficient for the extraction and quantification of 
thiomarinol even at early stages of the growth. We monitored the amount of thiomarinol 
produced by batch culture of Pseudoalteromonas spp SANK 73390 over 48 hours using 
HPLC. Thiomarinol production was detected from the 9
th
 hour of incubation and was 
maximal from 18 to 36 hours and it then dropped after the 36 hour. These observations tend 
to be in agreement with Takahashi et al., (1995), that the amount of thiomarinol reaches 
maximum level after 19 hour of incubation and onward when they monitored production of 
thiomarinol B and C. However, they did not specify the initial point of the production. If we 
compare the timely expression of thiomarinol relative to the growth of the producer, we can 
see that SANK 73390 grew firstly up to the formation of a considerable amount of growth 
(population density), and then followed by the formation of thiomarinol. Therefore, these 
results are consistent with those observed by Pirt and Righelato, (1967), and Lurie et al., 
(1975), as they reported the observation of two phases during the propagation of antibiotic 
producers. The ideal characteristic of the first phase (trophophase) is the rapid growth of the 
producer to reach a population density (biomass production), while a slow growth and 
maximal productivity of the antibiotics is the characteristic of the second phase (idiophase). 
However, although the amount of thiomarinol produced by disc bioassay did show some 
degree of similarity with that of HPLC analysis they were not correlated completely.  
    Generally, it could be concluded that this work has demonstrated that 3 to 9 h is the time of 
the logarithmic phase of Pseudoalteromonas spp SANK 73390, and that 9 h (late exponential 
phase) is the initial point of thiomarinol production, which is an important indicator of the 
regulated expression of thiomarinol gene cluster. Therefore, future work should include 
follow-up work designed to quantify level of gene expression by using the available 
techniques such as dot/slot blotting or possibly by Northern blotting. We have also shown 
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that acidic conditions and using acetone with ethyl acetate improves thiomarinol extraction, 
while dissolving the extracted thiomarinol in methanol for disc bioassay is preferable. 
Injection of 100 µl of the extracted thiomarinol into HPLC is better and using a solvent 
gradient of 35% acetonitrile and 65% water separates a typical peak of thiomarinol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
 
 
 
 
 
CHAPTER THREE 
INVESTIGATING THE INHIBITORY EFFECT OF 
THE THIOMARINOL AMIDE SYNTHETASE, TmlU, 
ON 9HN ELONGATION IN MUPIROCIN SYNTHESIS 
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3.1 Introduction 
    Much research in recent years has focused on the growing family of ATP-dependent amide 
synthetases involved in antibiotic biosynthesis, due to their potentially useful role in 
combinatorial biosynthesis of new analogues. One of the best–known group of antibiotics are 
the aminocoumarins (Figure 3.1), produced by several different Streptomyces strains, which 
include novobiocin, clorobiocin and coumermycin A1 as three classical aminocoumarins, in 
addition to the structurally more complex simocyclinones and rubradirins (Heide, 2009). The 
amino group of the 3-amino-4,7-dihydroxyaminocoumarin moiety of all aminocoumarin 
antibiotics is combined with an acyl moiety via an amide bond (Figure 3.1). Biochemical 
investigations revealed the catalytic enzymes responsible for the formation of this amide 
bond in the novobiocin, clorobiocin, coumermycin and simocyclinone biosynthesis clusters 
which are named NovL (Steffensky et al., 2000), CloL (Galm et al., 2004), CouL (Schmutz 
et al., 2003; Caren et al., 2004), and SimL (Luft et al., 2005; Pacholec et al., 2005), 
respectively. Although there is just one amide synthetase gene (couL) in the biosynthetic gene 
cluster of coumermycin A1 as revealed by sequence analysis (Wang et al., 2000), two 
aminocoumarin moieties have been determined to be connected to the acyl component 3-
methyl-pyrrole-2,4-dicarboxylic acid via amide bonds (Schmutz et al., 2003). 
    In the thiomarinol biosynthetic cluster, tmlU has been identified as encoding a putative 
amide synthetase required for the attachment of the pyrrothine moiety to an 8-
hydroxyoctanoic acid side chain in the mupirocin-like component, designated marinolic acid 
on the basis of its similarity with the more generic name of mupirocin, pseudomonic acid 
(Figure 3.2) (Fukuda et al., 2011). It was named TmlU on the basis of weak amino acid 
similarity to MupU, the acyl CoA synthase in the mup cluster proposed to be responsible for 
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loading an intermediate in the pathway, PA-B, to mAcpE, where it is further processed by 
MupO, V, C and F for the production of PA-A (Hothersall  et al., 2007).  
 
Figure 3.1 Structures of the aminocoumarin antibiotics clorobiocin, novobiocin, 
coumermycin A1, simocyclinone D8 and rubradirin (adapted from Heide, 2009).  
              
Figure 3.2 Chemical structures of: (a) pseudomonic acid A (mupirocin), and (b) 
thiomarinol A. Holomycin is the amide N-acetylpyrrothine. In addition to thiomarinol, 
producer bacteria generate a variety of fatty acyl pyrrothine analogues (adapted from 
Fukuda et al., 2011). 
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    Incorporation of synthetic analogues of the acyl moieties into mutants of aminocoumarin 
antibiotic producers, defective in production of the acyl component, depends upon their 
acceptance by the producers amide synthetases, CloL, NovL, and CouL, respectively (Galm 
et al., 2004). The yields from such experiments with the clorobiocin system through feeding 
synthetic analogue of different acyl moieties in vivo has been confirmed to depend directly 
upon the in vitro conversion rates of the acyl moieties by the amide synthetase, as well as 
substrate specificity of the amide synthetase (Galm et al., 2004;  Luft et al., 2005). Two novel 
pyrrothine amides (Figure 3.3) have been gained through feeding pseudomonic acid A to the 
∆ tmpD mutant of thiomarinol producer Pseuoalteromonas sp SANK 73390 (Fukuda et al., 
2011). The possibility of creation of new families of hybrid antibiotics increased after 
successful incorporation of a range of alternative substrates such as different pseudomonic 
acid derivatives produced by Pseudomonas fluorescens or amines, such as anhydroornithine 
and anhydrolysine into mutants defective in tmpD and holA respectively (Murphy et al., 
2011). However, although it is obvious that TmlU is responsible for the formation of the 
amide bond between marinolic acid and pyrrothine, and we know very little about its 
substrate specificity (Murphy et al., 2011), little attention has been paid to the possibility of it 
having additional roles.  
   
Figure 3.3 Mupirocin pyrrothine amide, a new hybrid created consisting of 
pseudomonic acid A joined with pyrrothine via an amide bond (source: Fukuda et al., 
2011). 
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    The purpose of this study is to characterise the controlling role of TmlU in linking 
marinolic acid and pyrrothine, and to determine whether TmlU can complement 
NCIMB10586∆mupU. Truncated products released when TmlU was expressed in trans in the 
NCIMB10586 WT and different mutants including NCIMB10586∆mupU indicated that 
TmlU cannot complement NCIMB10586∆mupU, and significantly interferes with normal 
mupirocin biosynthesis.  
 
3.2 Materials and methods 
3.2.1 Bacterial strains and plasmids 
    Competent DH5α, an Escherichia coli strain was used for plasmid transformation and 
propagation. Young culture of Pseudomonas fluorescens NCIMB10586 was used as a 
standard wild type mupirocin-producing bacterium. E. coli strain S17-1 was used to mobilise 
expression vectors into NCIMB10586 WT and mutant strains by bacterial conjugation. The 
mupirocin-sensitive organism Bacillus subtilis 1064 was used in biological assays to detect 
the antibacterial activity of mupirocin. Bacterial strains and plasmids used in this study are 
listed in Table 3.1, and 3.3, respectively.  
  
3.2.2 Growth media and culture conditions 
     L-broth consisting of yeast extract (10 g/l), tryptone (5 g/l), NaCl (10 g/l), and glucose (1 
g/l) or L-agar (L-broth with 15 g/l agar) supplemented with either 100 µg/ml ampicillin or 15 
µg/ml tetracycline (Table 3.2) was used as culture media for the growth of NCIMB10586 WT 
and mutants with or without the presence of vectors. Same media used for the growth of 
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Escherichia coli strains, either supplemented with 15 µg/ml tetracycline or without. All 
medium was sterilised by autoclaving (121
o
C for 15 min under pressure of 15 bar) before 
adding antibiotics or IPTG. Pseudomonas fluorescens strains were grown at 30
o
C, while 
Escherichia coli strains were grown at 37
o
C.  
 
Table 3.1 Bacterial strains used during this study. 
 
Bacterial strain 
 
 
Genotype 
 
Reference 
 
Escherichia coli 
DH5α 
F
ˉ
 Ф80dlacZ∆M15, recA1, endA1, gyrA86, thi-1, 
HsdR17(r kˉ, m k+), supE44, relA1, deoR, ∆(lacZYA- 
ArgF)U169 
 
Hanahan, 
1983 
Pseudomonas 
fluorescens 
NCIMB10586 
 
Wild type (WT) mupirocin producer 
 
Whatling et 
al., 1995 
Escherichia coli 
S17-1 
RecA pro hsdR RP4-2-Tc::Mu-km::Tn7 Simon et 
al., 1983 
 
Bacillus subtilis 
1604 
 
TrpC2 
Moir  et al., 
1979 
NCIMB10586 
∆mupU 
P. fluorescens with deletion of mupU gene Cooper et al., 
2005a 
NCIMB10586 
∆mupX 
P. fluorescens with deletion of mupX gene Cooper et al., 
2005a 
NCIMB10586 
∆TE 
P. fluorescens with deletion of TE gene El-Sayed et 
al, 2003 
NCIMB10586 
∆ACP5 (ACP-Ba) 
(mmpB) 
P. fluorescens with ACP5 (mmpB) deletion  Rahman et al., 
2005 
NCIMB10586 
∆ACP6 (ACP-Bb) 
(mmpB) 
P. fluorescens with ACP6 (mmpB) deletion Rahman et al., 
2005 
NCIMB10586 
∆ACP7 (ACP-Bc) 
(mmpB) 
P. fluorescens with ACP7 (mmpB) deletion Rahman et al., 
2005 
NCIMB10586 
ACP5 (ACP-Ba) pm 
(mmpB) 
P.fluorescens with ACP5 active site mutation (Serine 
to Alanine) 
Rahman et al., 
2005 
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NCIMB10586 
ACP6 (ACP-Bb) pm 
(mmpB) 
P.fluorescens with ACP6 active site mutation (Serine 
to Alanine) 
Rahman et al., 
2005 
NCIMB10586 
ACP7 (ACP-Bc) pm 
(mmpB) 
P.fluorescens with ACP7 active site mutation (Serine 
to Alanine) 
Rahman et al., 
2005 
NCIMB10586 
∆ACP5/6 (mmpB) 
P. fluorescens with ACP5/6  (mmpB) deletion  Rahman et al., 
2005 
NCIMB10586 
∆ACP6/7 (mmpB) 
P. fluorescens with ACP6/7  (mmpB) deletion Rahman et al., 
2005 
NCIMB10586 
∆ACP5/7 
(mmpB) 
P. fluorescens with ACP5/7  (mmpB) deletion Rahman et al., 
2005 
   
Table 3.2 Antibiotics used in this study. 
 
Antibiotic 
 
 
Stock solution (mg/ml) 
 
Working solution (µg/ml) 
Ampicillin 100 100 
Tetracycline hydrochloride 15 15 
 
Table 3.3 Plasmids used and constructed during MupU and TmlU protein study. 
plasmid Size 
(Kb) 
Genotype Description Reference 
pET28a 5.3 Kan
R
, His-Tag,T7p,lacI Novagen 
pET28a-tmlU 7.2 1.9 kb EcoRI-SalI fragment containing tmlU 
Cloned into pET28a 
Fukuda et 
al., 2011 
pJH10 13.76  IncQ replicon, multiple cloning site  
  (EcoRI-SacI), Tet
R
 
EL-Sayed et 
al., 2001 
pJH10-Xho1-
linker 
13.76  IncQ replicon, multiple cloning site  
  (EcoRI, NheI, XhoI, KpnI, ClaI, XbaI, SacI), 
Tet
R 
with Xho1-linker 
Hothersall et 
al., 2007 
pSCCU 15.36 1.6 kb EcoRI-SacI fragment containing mupU 
Cloned into pJH10 
Cooper et al., 
2005a 
pAMH1 15.72 1.96 kb EcoRI-SalI fragment containing tmlU 
Cloned into pJH10-Xho1-linker  
This study 
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3.2.3 Isolation of plasmid DNA 
3.2.3.1 Large scale production of high quality DNA (maxi-prep) 
    The method for the plasmid DNA preparation below is essentially the large scale 
preparation of plasmid DNA according to the alkaline-SDS method of Birnboim and Doly, 
(1979) with modifications described by Smith and Thomas, (1983). 
    Usually 400 ml L-broth supplemented with appropriate antibiotics for plasmid selection 
was used for growing overnight culture of bacteria carrying plasmids. This O/N culture was 
then transferred to two 200 ml pots, balanced equally. The culture was spun down at 10,000 g 
for 10 minutes at 4
o
C. The supernatant was then discarded and the bacterial pellet re-
suspended in 25 ml of ice-cold lysis buffer (solution 1), starting from the first pot then 
transferred to the other pot to re-suspend the whole pellet and mix them together. 50 ml of 
freshly prepared NaOH-SDS mix (solution 2) was added to the re-suspended bacterial pellet, 
and the pot was inverted several times to ensure the complete lysis of the bacterial cells. The 
pot was then incubated on ice for 5 minutes, followed by the addition of 37.5 ml of 3 M 
sodium acetate, pH 5.0 (solution 3) and carefully mixing the contents by inverting the pot for 
5 times, then placed back on ice for 5 more minutes. To pellet proteins and cell debris, the pot 
was centrifuged at 10,000 g for 15 minutes at 4
o
C. Either a pot of another preparation which 
was balanced with sterile distilled water, or a pot with just sterile distilled water used for 
keeping the rotor balance during centrifugation. To remove any remaining cell debris, 
supernatant was filtered through Whatman 1 mm paper, and the cell free filtrate collected in 
another clean centrifuge pot containing 100 ml isopropanol. At this stage it is possible to 
store the pots at -20
o
C. 
    The pots were then centrifuged at 14,000 g for 10-15 minutes at 4
o
C to precipitate plasmid 
DNA. The supernatant discarded and the pellet dried by leaving the pots for at least 15-30 
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minutes to ensure that all the isopropanol dried out completely, which is essential for the next 
step. DNA pellet was then dissolved in 3 ml of 1X TNE buffer, pH 8.0. Volume of DNA 
solution measured accurately, and then caesium chloride added in a ratio of 4.75 gm: 4.5 ml 
plasmid DNA in clean universal bottle. The salt dissolved by gently shaking the bottle, then 
the volume made up to 4.5 ml with 1X TNE buffer. Further mixing to ensure that the salt 
dissolved, and then 0.5 ml Ethidium Bromide solution (10 mg/ ml) was added. After mixing, 
the solution transferred to two Beckman ultracentrifuge tubes, balanced, then filled up to the 
frosted line using 1X TNE buffer. The tubes were sealed using the cap heating machine, and 
then centrifuged at 100,000 rpm for overnight at 20
o
C using a Beckman TL 100 
ultracentrifuge.  
    After overnight centrifugation, the plasmid DNA bands in the Beckman tubes visualised 
with UV light, and by using a syringe with a wide bore the extracted plasmid DNA was 
collected and transferred to a clean tube, followed by the addition of an equal volume of 
CsCl/H2O saturated isopropanol with gentle mixing to remove Ethidium Bromide. The top 
pink layer of Ethidium Bromide was removed by Pasteur pipette, and this step repeated until 
no more pink layer collected at the top of the DNA solution indicating that the Ethidium 
bromide had virtually all been removed. 400 µl of the plasmid DNA solution was placed into 
1.5 ml microfuge tube, and to this 500 µl of distilled water, 100 µl of 3M sodium acetate, and 
530 of µl isopropanol were added sequentially. The tube was mixed well, and then 
centrifuged at 10,000 rpm for 10 minutes at room temperature. The supernatant was poured 
off, and the pellet re-dissolved in 200 µl of 1X TNE. To this, 25 µl of 3M sodium acetate, 
and 500 µl of ethanol were added, followed by centrifugation at 10,000 rpm for 10 minutes at 
room temperature to pellet the precipitate. The pellet was then dried well and re-dissolved in 
100 µl of 1/10
th
 TNE. 
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3.2.3.2 Bioneer kit for isolation of plasmid DNA 
    Plasmid DNA with high purity isolated using AccuPrep plasmid extraction kit (Bioneer), 
and the protocol described in the manual was followed accurately. To collect bacteria cell 
pellet 5 ml of overnight culture of bacteria spun down for 3 minutes at 14,000 g. The 
supernatant was poured off and the pellet re-suspended in 250 µl of re-suspension buffer by 
vortex mixing to ensure that the pellet completely re-suspended. 250 µl of the lysis buffer 
was added to the bacterial cells suspension and mixed by inverting the tube gently for 5 
times, followed by incubation at room temperature for 5 minutes. To this, 350 µl of 
neutralising solution was added, and then centrifuged at 14,000 g for 10 minutes at 4
o
C. 
Supernatant transferred to the assembled filter column with collection tube and spun down at 
14,000 g for 1 minute at room temperature. The flow-through discarded, and 500 µl of 
nuclease inhibitor was then added to the top of the filter and spun at 14,000 g for 1 minute at 
room temperature after incubation for 5 minutes at room temperature. Again the flow-through 
was poured off. The filter was then washed with 700 µl of wash buffer and centrifuged at 
14,000 g for 1 minute at room temperature, followed by discarding the flow-through. 
Centrifugation was repeated one more time to ensure that the ethanol on the filter had 
completely dried off. Then the filter was transferred to a sterilised micro-centrifuge tube, and 
50-100 µl of elution buffer was added generally 50 µl was used to obtain concentrated DNA. 
The tube was incubated for 1 minute at room temperature, and plasmid DNA was eluted by 
centrifugation at 14,000 g for 1 minute at 4
o
C.  Plasmid DNA was then stored at -20
o
C. 
 3.2.4 Manipulation of plasmid DNA 
3.2.4.1 Restriction digestion analysis    
     Plasmid DNA was digested using specific and suitable restriction enzymes purchased 
from New England Biolabs (NEB), MBI Fermentas, or Invitrogen. Usually, total digestion 
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reactions were carried out either in 20 µl or 40 µl with incubation for 2 h at 37oC. 10X Bovine 
Serum Albumin (BSA) prepared as a stock for the digestion reaction, was kept at -20
o
C. 
Optimum reaction mixture contained a desired amount of DNA (up to 1 µg), 1/10 volume of 
10x restriction enzyme buffer, 1-10 units of restriction enzyme and distilled water to adjust 
the reaction volume. However, 1/10 volume of 10x BSA was added to the reaction whenever 
it was recommended for typical enzyme function. In case of double digestions where the two 
enzymes required the same buffer, enzymes were added simultaneously.  
 
3.2.4.2 Agarose gel electrophoresis 
     Plasmid DNA, PCR, and restriction enzyme digestion were analysed using agarose gel 
electrophoresis.  1.0-1.5% agarose was mixed with 1x TAE buffer (40 mM Tris-acetate and 1 
mM EDTA pH 8) and 0.2 µg/µl ethidium bromide for gels preparation. DNA samples were 
mixed in 1x DNA loading dye (6x stock solution contains 15% ficoll, 0.25% bromophenol 
blue and 0.25% xylene cyanol). Prepared samples were run against 5 µl 1 kb ladder (NEB of 
Fermentas). Gels were typically run at 100-140 V in 1x TAE buffer. 
 
3.2.4.3 Purification of DNA from agarose gels 
    A sterilised scalpel was used for the excision of DNA fragments out of the gel, and 
purified using the Gel Band Purification Kit (GE Healthcare). 300 mg in a single batch is the 
maximum allowed weight of gel slice that could be purified using this method in a single 
tube. 300 µl of Capture Buffer (GE Healthcare) was added to the 300 mg gel slice. After 
closing the lid, the tube was mixed by vortex mixing and incubated at 55
o
C in a water bath 
while mixing the tube every 3 minutes until the agarose was completely dissolved (15-30 
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min). When the agarose was dissolved the sample was centrifuged briefly to collect the whole 
sample, then it was transferred to the column assembled with the collection tube and 
incubated for 1 min at room temperature followed by centrifugation at room temperature for 
30 s at 12,000 g. The flow through was discarded and followed by washing the column with 
500 µl of wash buffer, then centrifugation at room temperature for 30 s at 12,000 g. The 
column was transferred into a sterilised 1.5 ml tube and 15-20 µl of elution buffer was 
applied to the top of the column, followed by incubation for 1 min at room temperature, and 
then centrifuged at room temperature for 1 min at 12,000 g to recover the purified DNA. This 
last step was repeated twice to ensure the DNA was eluted completely, and to make the total 
volume as 30-40 µl.   
 
3.2.4.4 Ligation 
    The enzyme T4 DNA ligase, purchased from Invitrogen was used for performing the 
ligations, which carried out usually in a total of 20 µl reaction mixture. The amount of DNA 
of both the insert and the vector was measured in 1 µl of each using nanodrop, and then 
mixed together in a ratio of approximately 3:1, respectively to make up no more than 100 ng 
of DNA in total. The required quantities of both of the vector and insert DNA were calculated 
using the following formula: 
 
         
                                   
                   
    
        
        
                   
  
The ligation reaction was usually incubated overnight at 4
o
C. 
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3.2.5 Preparation of competent cells 
    Competent cells of E. coli strain DH5α, S17-1 or GM2163 were prepared using the 
calcium chloride method (Cohen et al., 1972). 1 ml of the overnight (starter) cultures 
incubated at 37
o
C, 200 rpm was used for the inoculation of 100 ml of LB, and then incubated 
at 37
o
C, 200 rpm until to mid-log phase (OD600~0.4-0.6). The young cultures were then 
harvested by centrifugation for 7 minutes at 5000 g and at 4
o
C. Supernatant was discarded 
and the cells were re-suspended in ice-cold 100 mM CaCl2 and incubated on ice for 30-45 
minutes. Bacterial cells were pelleted again using the same parameters as before, and re-
suspended in 5 ml of 100 mM CaCl2. Fresh competent cells were ready at this stage and 
could be stored at 4
o
C if used within two weeks. However, cells were re-suspended in 5 ml of 
100 mM CaCl2 with 20% glycerol solution for longer storage. Liquid nitrogen was used for 
freezing 100 µl of competent cells in a sterilised microfuge tubes and stored at -80
o
C. 
 
3.2.6 Transformation of bacteria 
     For bacterial transformation, plasmid DNA (300-200 ng) or 10 µl of ligation mixture were 
added to 100 µl of competent cells and placed on ice for 30-60 min. The cells were then heat-
shocked at 42
o
C for 2 min using a water bath. After incubation, 0.5 ml of fresh LBB was 
added and the cells were incubated at 37
o
C for at least 1 hr with gentle mixing every 10 min. 
After incubation, 200 µl and 50 µl of the cell suspension were spread on two selective agar 
plates separately, and incubated overnight at 37
o
C.  
3.2.7 Transfer of plasmid DNA by conjugation 
     E. coli S17-1 was used for mobilising plasmids (for example pJH10 with the insert) into 
P. fluorescens via bacterial conjugation. 1 ml of overnight culture of each strain (donor and 
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recipients) was mixed in a sterile universal bottle. The mixture was then filtered using a 
sterile filter, and the filter transferred on to L-agar without any antibiotic selection to support 
the conjugation, followed by overnight incubation of the plate at 30
o
C. The filter was then 
removed from the plate, and transferred into 1 ml of saline solution (0.85%) and vortex 
mixed to re-suspend the cells. Serial dilutions 10
-1
, 10
-2
, 10
-3
, 10
-4
 and 10
-5 
of bacterial 
suspension were prepared using saline solution. Then 100 µl of the dilutions was spread on 
M9 minimal media supplemented with tetracycline or another appropriate antibiotic and then 
incubated at 30
o
C for 2-3 days. A single colony was then picked up and streaked again on the 
same media mentioned before and incubated at 30
o
C for 24 h to obtain pure cultures with 
isolated colonies. Single colonies from the pure culture were then streaked on L-agar plates 
supplemented with tetracycline and ampicillin.  
 
3.2.8 Bioassay for mupirocin production 
    Single colonies of trans-conjugant, mutants and wild type strains were inoculated into 5 ml 
LB containing appropriate antibiotics. The cultures were incubated overnight at 30
o
C with 
shaking at 200 rpm. The OD600 of each culture was measured and the cultures were then 
diluted to the OD600 of the lowest reading using fresh LBB so that each patch started at the 
same density. 10 µl of each culture was spotted onto L-agar plates without IPTG as well as 
with 0.5 mM IPTG. The plates were incubated overnight at room temperature. Overnight 
cultures of Bacillus subtilis 1064 (sensitive organism) were grown in L-broth without any 
antibiotic selection at 37
o
C with shaking at 200 rpm. The plates with spot culture were 
overlaid with a mixture of 100 ml L-agar (molten and cooled to 45
o
C) with 4 ml of Bacillus 
subtilis 1064 culture and 0.5 ml of 2, 3, 5-triphenyltetrazolium chloride (5% TTC) and left on 
the bench for about 1 hr, then incubated overnight at 37
o
C. TTC is used as a reagent that is 
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reduced to give a red precipitate in the presence of bacterial cells. Therefore, the area in 
which the B. subtilis 1064 were growing turned red and where the bacteria had been killed by 
antibiotic production were seen as a clear zone. The size of the clearance zone around the 
spot culture was taken as an estimate of the amount of mupirocin produced. 
            
3.2.9 Culture preparation for HPLC 
     In order to obtain the seed culture of trans-conjugant strains, mutants, and the wild type P. 
fluorescens NCIMB10586, a single bacterial colony was inoculated into 25 ml of LB with 
appropriate antibiotic (tetracycline or ampicillin) in a 250 sterile conical flask, and incubated 
overnight at 25
o
C, 200 rpm. 1.25% ml (5%) of the seed culture was then used to inoculate 25 
ml of fresh MPM (Mupirocin Production Media: Yeast extract, 2.3 g/l; NaHPO4, 2.6 g/l; 
KH2PO4, 2.4 g/l; (NH4)2SO4, 5 g/l). 550 µl of 40% glucose was added as supplementary 
material to each 200 ml MPM after autoclaving, and 0.5 mM IPTG was added to the 
production media in case of induction. The new culture was then shaken overnight at 22
o
C, 
200 rpm, for 40 hours. 1 ml of each culture was spun down by centrifugation at 15,000 g for 
10 minutes. Before injection into the HPLC, the supernatant was filtered through 0.2 µm 
filter (Pall-Gelman, labs). 
    It should be noted that a new production media (SSM) was used for ACPS mutants 
expressing tmlU in trans and the following experiments, which prepared as follows:- 
(Soya flour 25 g/l; spray dried corn liquor 2.5 g/l; (NH4)2SO4 5.0 g/l, MgSO4.7H2O 0.5 g/l; 
Na2HPO4 1.0 g/l; KH2PO4 1.5 g/l; KCL 1.0 g/l; CaCO3 6.25 g/l) with pH adjusted to 7.5, then 
10 ml of separately autoclaved 40% glucose was added to each 200 ml of the media before 
using.  
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 3.2.10 Sample analysis by HPLC 
    HPLC analysis was performed to detect antibiotic production by wild type, mutant, and 
trans-conjugant strains of NCIMB10586. Two solvents were used; solvent A (HPLC grade 
water); and solvent B (HPLC grade acetonitrile), and both were supplemented with 0.01% 
formic acid to adjust the pH of the mobile phase. Both solvents were degassed using an 
aspirator in order to completely release all the bubbles from the solvents before using. HPLC 
was performed using Uni-point LC system software, reverse phase C18 column (15 cm x 4.6 
mm), UV detector was used at a sensitivity of 0.002 absorbance units at 233 nm. 100 µl of 
filtered supernatant of each sample was injected into the HPLC machine. Mupirocin and 
other intermediates were eluted using a solvent gradient (5—70%) of water/acetonitrile over 
1 hr at 1 ml/min flow rate.  
 
3.2.11 Sample analysis by ES-MS and NMR 
          Samples were subjected to ES-MS analysis followed by NMR in the School of 
Chemistry-University of Bristol by Dr Zhongshu Song. 
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3.3 Results 
3.3.1 Putting tmlU under the control of tac-promoter 
    For the purpose of in trans expression of tmlU using a broad host range vector pJH10, the 
tmlU expression plasmid was constructed. The tmlU gene was cut out on an EcoRI-SalI 
fragment from pET28a tmlU and inserted into the expression vector pJH10-XhoI linker, 
digested with EcoRI-XhoI enzyme. This yielded an expression plasmid designated pAMH1 as 
shown in Figure 3.4. However, pSCCU is a pJH10 vector for in trans expressing of mupU, 
that was constructed previously (Table 3.3).  
 
 
 
 Figure 3.4 pJH10 based plasmids containing mupU and tmlU genes.       
                                                                                                                                                                                                                                                          
  3.3.2 Bioassay to check the effect of TmlU and MupU 
     Although there is only weak similarity between TmlU, the putative amide synthetase in 
thiomarinol cluster, and MupU, the acyl CoA synthase in mupirocin system, we wanted to 
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investigate whether the in trans over-expression of both mupU, and tmlU, each separately, 
could complement NCIMB10586∆mupU strain. According to our hypothesis over-expression 
of tmlU in trans might complement NCIMB10586∆mupU, which could be of significance for 
mutasynthesis experiments through feeding other compounds, mostly analogues of pyrrothine 
to NCIMB 10586 WT. The presence of TmlU might allow join to mupirocin to produce new 
hybrids. Also, it might give extra details about the role of TmlU in joining marinolic acid 
with the pyrrothine in thiomarinol system. Therefore, to test the formulated hypothesis, both 
mupU, and tmlU were over-expressed in trans separately, in NCIMB10586∆mupU strain, 
using pSCCU plasmid (encoding mupU), and pAMH1 plasmid (encoding tmlU), respectively. 
On bioassay plates (Figure 3.5 and 3.6), it was observed that pSCCU plasmid provided in 
trans did complement NCIMB10586∆mupU, and the strain exhibited mupirocin production 
like the wild type with production being increased slightly with IPTG induction. However, 
over-expression of tmlU from pAMH1 not only did not complement the 
NCIMB10586∆mupU strain, but also blocked the normal biosynthesis of mupirocin. This 
demonstrates that TmlU is different from MupU and has a different functionality. 
     In order to determine specifically where TmlU is interacting in mupirocin cluster, we 
predicted that TmlU will block the biosynthesis in the NCIMB10586 WT as well, through 
modifying PA-A. In addition, since one of the predicted activities of MupX is to hydrolyse 
amides, perhaps it can counteract the action of TmlU. Therefore, putting TmlU into 
NCIMB10586 ∆mupX strain might not need to be induced so much to inactivate mupirocin, 
because the enzyme that works in the opposite direction will not be there. Therefore, to test 
this hypothesis, TmlU was over-expressed in trans from pAMH1 plasmid in both of the 
NCIMB10586 WT, and NCIMB10586∆mupX strains, respectively. The results from bioassay 
(Figures 3.5 and 3.6) showed a similar effect with over-expression of tmlU in the 
NCIMB10586 WT, and NCIMB10586∆mupX strains, through affecting the production of 
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mupirocin. The effect was stronger with IPTG induction and this blocked the normal 
biosynthesis of mupirocin. This indicates that TmlU interference with mupirocin biosynthesis 
is not affected by the presence or the absence of MupX, and that MupX is not affecting the 
normal function of TmlU as an amide synthetase.  
     Furthermore, and to further explore what TmlU is doing to the mupirocin cluster, we 
proposed that TmlU may either compete or interact with thioesterase (TE) to promote the 
release of pseudomonic acids (PAs). Therefore, by using pAMH1 plasmid, over-expression 
of tmlU in NCIMB10586∆TE strain was carried out. On bioassay plates (Figure 3.5 and 3.6) 
no observable difference could be seen in  NCIMB10586∆TE with and without the presence 
of TmlU, even when the expression was induced with IPTG, indicating that TmlU is not 
working like an abnormal thiolesterase or hydrolase. It should also be mentioned that in all 
the previous bioassay data presented, both NCIMB10586 WT, and WT with empty pJH10 
vector provided in trans, were taken as controls.  
 
 
 
 
 
 
 
 
 
113 
 
                                             WT + pJH10                 WT                 W.T. + pAMH1   
                                          
        ∆mupU + pSCCU     ∆mupU + pJH10          ∆mupU               ∆mupU + pAMH1  
     
                                         ∆mupX + pJH10            ∆mupX                 ∆mupX + pAMH1 
                                            
                                          ∆TE + pJH10                   ∆TE                   ∆TE + pAMH1 
                                     
 
Figure 3.5 Complementation analysis of the NCIMB10586∆mupU with pSCCU (pJH10-
mupU) and pAMH1 (pJH10-tmlU) plasmids in trans; and the effect of in trans 
expression of pAMH1 plasmid in the NCIMB10586 WT, NCIMB10586∆mupX and 
NCIMB10586∆TE. The zone of clearance around the central spot culture is taken as an 
estimate of antibacterial activity. 
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Figure 3.6 Quantitative bioassay of the NCIMB10586 WT, NCIMB10586∆mupX and 
NCIMB10586∆TE mutants expressing TmlU protein from pAMH1 plasmid, and 
NCIMB10586∆mupU expressing MupU protein from pSCCU plasmid, also triplicates 
were used for each case.  
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3.3.3 HPLC analysis of pseudomonic acids produced by WT NCIMB10586, 
NCIMB10586∆mupU, NCIMB10586∆mupX and NCIMB10586∆TE expressing tmlU in 
trans; PA-A and PA-B production by NCIMB10586∆mupU expressing mupU in trans  
    HPLC analysis was used for investigating pseudomonic acids produced by 
NCIMB10586∆mupU, over-expressing both pSCCU plasmid (encoding mupU), and pAMH1 
plasmid (encoding tmlU), separately, and also NCIMB10586 WT, NCIMB10586∆mupX, and 
NCIMB10586∆TE expressing pAMH1 plasmid (encoding tmlU) only. As controls, both 
NCIMB10586 WT and WT with empty pJH10 vector provided in trans were used. HPLC 
analysis showed that over-expression of mupU from pSCCU did complement 
NCIMB10586∆mupU, and the strain restored mupirocin production (PA-A and PA-B) like 
the wild type strain even without IPTG induction. However, over-expression of tmlU from 
pAMH1 modified most of PA-B in NCIMB10586∆mupU to a new compound that was eluted 
earlier (with retention time between 13 to 14 min) than the normal pseudomonic acid 
compounds, rather than complementing it. Moreover, over-expression of tmlU both in the 
NCIMB10586 WT and NCIMB10586∆mupX modified most of the PA-A to the same 
compound that had been observed in NCIMB10586∆mupU strain with tmlU, but without any 
observable effect on NCIMB10586∆TE.  
     More precisely, there was still release of some PA-B in the case of tmlU expression in 
NCIMB10586∆mupU, and release of less PA-A when tmlU was expressed in both of the 
NCIMB10586 WT and NCIMB10586∆mupX without induction, but when expression was 
induced with 0.5 mM IPTG, all remaining PA-B and PA-A was modified to the new 
compound as well (Figure 3.7 and 3.8).  
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Figure 3.7 HPLC chromatograms of NCIMB10586 WT with pAMH1 plasmid, and 
NCIMB10586∆mupU first with pSCCU plasmid and second with pAMH1 plasmid 
expressed in trans. WT and WT+pJH10 strains are controls. 
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Figure 3.8 HPLC chromatograms of IPTG induced NCIMB10586∆mupX and 
NCIMB10586∆TE strains with pAMH1 plasmid expressed in trans. WT and 
WT+pJH10 strains are controls.  
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3.3.4 ES-MS analysis of pseudomonic acids produced by NCIMB10586 WT, 
NCIMB10586∆mupU, NCIMB10586∆mupX, and NCIMB10586∆TE expressing tmlU in 
trans, and PA-A and PA-B production by NCIMB10586∆mupU strain expressing mupU 
in trans  
    HPLC analysis of NCIMB10586 WT, NCIMB10586∆mupU, NCIMB10586∆mupX, and 
NCIMB10586∆TE expressing tmlU in trans, was followed by ES-MS analysis and NMR to 
confirm and to provide extra evidence about the changes in PAS production from the effect of 
TmlU. As a control NCIMB10586 WT showed the production of both PA-A and PA-B, 
respectively, and NCIMB10586 WT with empty vector (pJH10) did not have any negative 
effect on PAS production. Production of mupirocin (PA-A and PA-B) was confirmed in the 
NCIMB10586∆mupU when mupU was expressed in trans. However, conversion of PA-B to 
truncated C5 and C7 version of PA-B was observed when tmlU was over-expressed in trans, 
although all PA-B was converted to C5 PA-B with IPTG induction (Figure 3.9a).  
    Conversion of the C9 version of PA-A to C5 and C7 version was observed when tmlU was 
over-expressed in trans both in the NCIMB10586 WT and NCIMB10586∆mupX, and the 
effect was stronger with induction, which results in the conversion of all PA-A to only C5 
(PA-A and PA-B), respectively. Surprisingly, we could see the release of a smaller amount of 
C5 PA-A and B when tmlU was over-expressed in NCIMB10586∆TE, although release of a 
very tiny amount of C9 PA-A was observed in NCIMB10586∆TE, with and without tmlU 
(3.9b).  
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Figure 3.9a Detection of various pseudomonic acids produced by NCIMB10586 WT and 
NCIMB10586∆mupU strains expressing pAMH1 plasmid in trans, with the sole 
expression of pSCCU plasmid in NCIMB10586∆mupU with induction using 
Electrospray Ionisation (ES-MS). WT and WT+pJH10 strains are taken as controls. 
NCIMB10586∆mupU complementation with pSCCU restored PA-A production. However, 
pAMH1 plasmid expressing tmlU in NCIMB10586∆mupU strain produced C5 PA-B only, 
while NCIMB10586 WT produced equal amounts of C5 PA-A and B; tmlU in 
NCIMB10586∆mupU did not produce C5 PA-A at all (data from Bristol).     
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Figure 3.9b Detection of various pseudomonic acids produced by NCIMB10586 WT, 
NCIMB10586∆mupX and NCIMB10586∆TE strains, expressing pAMH1 plasmid in 
trans (B-F) using Electrospray Ionisation (ES-MS). WT and WT+pJH10 strains are 
taken as controls (A and G). pAMH1 plasmid expressing tmlU in NCIMB10586 WT, 
NCIMB10586∆mupX and NCIMB10586∆TE strains produced C5 PA-B at the same ratio; 
tmlU in the WT produced equal amount of C5 PA-A and B; tmlU expression in  
NCIMB10586∆mupX produced half amount of C5 PA-A (data from Bristol).        
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3.3.5 Effect of TmlU on tandem ACPs of MmpB 
    The data described above showed that TmlU interferes with mupirocin biosynthesis, and 
more specifically with the biosynthesis of 9HN (9-Hydroxynonanoic acid), which is predicted 
by El-Sayed et al., (2003), to be the product of MmpB (with tandem ACPS 5 (Ba), 6 (Bb), 
and 7 (Bc)) on the basis that it is the most like candidate for an iterative fatty acid synthase 
working via three condensation using malonate as extender unit. The results showed that 
TmlU blocks the 2
nd
 (C5-C7) and the 3
rd
 (C7-C9) round of condensation, but not the 1
st
 one 
(C3-C5). Although MmpB can function with just one ACP (Rahman et al., 2005) it is possible 
that there may be differential involvement in successive condensations so it seemed 
reasonable to determine the effect of over-expressing tmlU in NCIMB10586 with mutations 
in ACPS of MmpB. 
 
3.3.5.1 TmlU and ACPS (5 (Ba), 6 (Bb), and 7 (Bc)) point mutation 
    tmlU was expressed in NCIMB10586 with point mutations (pm) in single ACPs(5, 6, or 7), 
where the active site serine was mutated to alanine. The purpose of this experiment was to 
see whether TmlU is targeting the active site of ACPs for its interference or not. Bioassay 
performed to confirm that expression of tmlU from pAMH1 plasmid by tac promoter is 
functional. Bioassay did not show any detectable clearance zone of inhibition around the 
culture spot of ACP5 pm with in trans expression of tmlU, neither with nor without 
induction, which means it was quite similar to ACP5 pm itself which produces no 
biologically active compounds as previously observed by Ayesha Rahman (Rahman et al., 
2005). By contrast, there was still a significant clearance zone of antibacterial activity around 
culture spot of both strains of ACP6 and ACP7 point mutation with tmlU expression in trans, 
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without induction, but that activity disappeared when induced with 0.5 mM IPTG (Figure 
3.10 and 3.11). Indicating that TmlU was likely to interfering with 9-HN elongation in these 
mutants as well.  
                               WT + pJH10                   WT                   WT + pAMH1  
                       
                        ACP5 pm + pJH10           ACP5 pm          ACP5 pm + pAMH1 
                     
                       ACP6 pm + pJH10            ACP6 pm            ACP6 pm + pAMH1 
                     
                       ACP7 pm + pJH10             ACP7 pm             ACP7 pm + pAMH1 
                    
Figure 3.10 Bioassay to show the expression of tmlU, and its influence on strains of 
NCIMB10586 with active site mutation in one of the ACPs (ACP5, ACP6, or ACP7) of 
MmpB, separately. W.T, W.T with pAMH1 plasmid, and W.T with pJH10 vector were 
taken as controls.  
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Figure 3.11 Quantitative bioassay of NCIMB10586 strains with active site mutation in 
one of the ACPs (ACP5, ACP6, or ACP7) of MmpB, separately, expressing tmlU from 
pAMH1 plasmid. NCIMB 10586 WT, NCIMB10586 WT with pAMH1 plasmid, and 
NCIMB10586 WT with pJH10 vector were taken as controls. Triplicates were used.   
     HPLC analysis was performed to give clear evidence about the product released after tmlU 
expression in trans from pAMH1 plasmid in NCIMB10586 strains with a point mutation in 
one of the ACPS (5, 6, or 7). NCIMB10586 WT with pAMH1 (in trans expression of tmlU), 
and NCIMB10586 WT with pJH10 vector used as controls. There was no detectable 
compound in strain with ACP5 pm when tmlU was expressed in trans. This result was the 
same as the mutant strain (ACP5 pm) even without in trans expression of any gene. In 
contrast, a compound eluted earlier in strains of either ACP6 or ACP7 pm with tmlU 
expression in trans, and this appears to be the same compound that has been detected and 
analysed in the WT with in trans expression of tmlU (Figure 3.12). That compound was 
identified in previous experiments as a shorter pseudomonic acid, the C5 version of either PA-
B or PA-B or both. This result may rule out the possibility that TmlU interacts with the 
phosphopantetheinylated version of the active site of the MmpB ACPS.   
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Figure 3.12 HPLC chromatograms of IPTG induced NCIMB10586 strains with ACPS 
(either 5, 6, or 7) active site mutations, with pAMH1 plasmid expressed in trans. 
NCIMB10586 WT and WT+pJH10 strains are controls.  
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3.3.5.2 TmlU effect in NCIMB10586 strains with ACPS (5, 6, or 7) single 
deletions  
    Expression of tmlU in NCIMB10586 strains with single deletions in one of the ACPS of 
MmpB carried out using the expression vector pAMH1. The purpose of this experiment was 
to see whether we are able to link the tmlU effect to one of those ACPS. Bioassay was 
performed using Bacillus subtilis 1064 as sensitive bacteria, and plates of both LA and LA 
supplemented with 0.5 mM IPTG. Clearance zone around the spot of the culture was 
measured from the disc diameter as zone of antibacterial activity, and all the calculations 
made to work out the final result using WT once as 100 %. Data from this quantitative 
bioassay showed a stronger effect of TmU on the biosynthesis of mupirocin in 
NCIMB10586∆ACP7, than on NCIMB10586∆ACP5 without induction. Moreover, this 
effect was much stronger when tmlU expression was induced with 0.5 mM IPTG that blocks 
biosynthesis of mupirocin. However, this effect was less on NCIMB10586∆ACP6 even with 
induction (Figure 3.13 and 3.14).      
    In order to be more confident about any particular compound that is being released as a 
result of tmlU expression in NCIMB10586 strains with single deletion in one of the ACPS (5, 
6, or 7) of MmpB, HPLC analysis performed. NCIMB10586 WT, and NCIMB10586 WT 
with pJH10 vector used as controls. The HPLC chromatograms showed that TmlU blocks 
mupirocin biosynthesis and again causes the formation of the new compound, which has a 
retention time between 13 to 14 min which is the same compound as observed previously 
with tmlU expression in NCIMB10586 WT, and strains with active site mutation in ACP6 
and ACP7. However, a small peak of PA-A was observed in the strain with the ACP6  
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                       WT + pJH10                  WT                   WT + pAMH1  
                 
                       ∆ACP5 + pJH10           ∆ACP5              ∆ACP5 + pAMH1 
                    
                  ∆ACP6 + pJH10           ∆ACP6             ∆ACP6 + pAMH1 
                 
                    ∆ACP7 + pJH10           ∆ACP7              ∆ACP7 + pAMH1 
                
 
Figure 3.13 Bioassay to show the expression of tmlU, and its influence on NCIMB10586 
strains with deletion in one of the ACPS (ACP5, ACP6, or ACP7) of MmpB, separately. 
NCIMB10586 WT, WT with pAMH1 plasmid, and WT with pJH10 vector were taken 
as controls.  
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Figure 3.14 Quantitative bioassay of NCIMB10586 strains with deletion in one of the 
ACPs (ACP5, ACP6, or ACP7) of MmpB, separately, expressing tmlU from pAMH1 
plasmid. NCIMB10586 WT, WT with pAMH1 plasmid, and WT with pJH10 vector 
were taken as controls. 5 replicates were used for each case.  
 
deletion, in addition to the new compound that has been seen in strains with deletion in other 
ACPS (Figure 3.15). The observation that deletion of ACP6 appears to reduce the sensitivity 
to the negative effects of tmlU expression is very significant since it provides the first direct 
evidence that MmpB is involved in 9HN production. It suggests that normal ACP 
configuration is needed for sensitivity and the fact that NCIMB10586∆ACP6 is still sensitive 
to tmlU expression may indicate that tmlU interacts with all the ACPS in the tandem ACP of 
MmpB.  
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Figure 3.15 HPLC chromatograms of IPTG induced NCIMB10586 strains with single 
deletion in one of the ACPS (5, 6, or 7) of MmpB with pAMH1 plasmid expressed in 
trans. NCIMB10586 WT and WT+pJH10 strains are controls.  
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3.3.5.3 TmlU and ACPS (5, 6, or 7) double deletion 
     As the results of tmlU expression in NCIMB10586 strains with single deletion in ACPS (5, 
6, or 7) suggested that TmlU may interact with the ACPS, and to obtain more specific details 
about that interaction, tmlU was expressed in NCIMB10586 strains with double deletions of 
those ACPS. Quantitative bioassay showed that the effect of tmlU was very similar, in which 
there was a very small inhibition zone with all the three double deletions of ACPS when tmlU 
is being expressed, in a way that is negligible, since NCIMB10586 WT showed the same 
zone, and it confirms that TmlU is interacting with all those ACPS (Figure 3.16 and 3.17). As 
expected, there was no observable negative effect of pJH10 vector on any of those strains 
with double deletion of ACPS.  
     HPLC analysis was carried out to confirm the data obtained by bioassay, and to make sure 
whether the same compound is being released by tmlU expression in those strains with 
double ACPS deletion. NCIMB10586 WT and WT with pJH10 vector were used as controls. 
The HPLC chromatograms showed the release of the same compound that has been seen with 
previous experiments about TmlU interaction. This compound eluted earlier than the standard 
mupirocin and with a different level in each strain with double ACPS deletion (Figure 3.18). 
Although of presence of a very small peak that looks to be PA-A (based on retention time) in 
NCIMB10586∆ACP6/7 and NCIMB10586∆ACP5/7 with tmlU expression, and a very less 
clear one with NCIMB10586∆ACP5/6, however, since it is totally different from the one that 
has been detected in NCIMB10586∆ACP6 with tmlU, it could not be consider as PA-A. This 
exclude the possibility of the release of even a tiny amount of PA-A, since there is only one 
ACP in NCIMB10586 strains with double ACPS deletion which tmlU interact with.   
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                       WT + pJH10              WT                 WT + pAMH1                  
                     
                   ∆ACP5/6 + pJH10      ∆ACP5/6        ∆ACP5/6 + pAMH1 
                    
                 ∆ACP6/7 + pJH10      ∆ACP6/7        ∆ACP6/7 + pAMH1 
                    
                    ∆ACP5/7 + pJH10      ∆ACP5/7        ∆ACP5/7 + pAMH1 
                   
 
Figure 3.16 Bioassay to show the expression of tmlU, and its influence on NCIMB10586 
strains with double deletion of the ACPS (ACP5, ACP6, or ACP7) of MmpB, separately. 
NCIMB10586 WT, WT with pAMH1 plasmid, and WT with pJH10 vector were taken 
as controls.  
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Figure 3.17 Quantitative bioassay of NCIMB10586 strains with double deletion of the 
ACPS (ACP5, ACP6, or ACP7) of MmpB, separately, expressing tmlU from pAMH1 
plasmid. NCIMB10586 WT, WT with pAMH1 plasmid, and WT with pJH10 vector 
were taken as controls, also triplicates samples were used. 
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Figure 3.18 HPLC chromatograms of IPTG induced NCIMB10586 strains with double 
deletion of the ACPS (5, 6, or 7), with pAMH1 plasmid expressed in trans. NCIMB10586 
WT and WT+pJH10 strains are controls.  
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3.4 Discussion   
    Prior work has documented that amide synthetase implicated in additional role to the 
ligase activity during the biosynthesis of antibiotics. In aminocoumarins as an example, 
reports indicated that, although CouL from coumermycin A1 is active in the form of a 
monomer, it is able of catalysing two adenylation and two acyl transfer reactions, results in 
the formation of two amide bonds (Schmutz et al., 2003). Recent investigations from 
rubradirin biosynthesis revealed more than one gene responsible for the aminocoumarin acyl 
ligases, and that RubC1 is a bi-functional enzyme that might catalyse both the activation of 
tyrosine as well as the aminocoumarin acyl ligation (Boll et al., 2011). However, these 
studies have just focused on the role of amide ligases within the family of amincoumarin 
antibiotics rather than being expanded to other antibiotics with similar ligases. In this study 
the putative amide synthetase TmlU from the biosynthesis pathway of thiomarinol was tested 
for the possibility of complementing the defect in MupU from mupirocin biosynthetic 
pathway, the most related antibiotic to thiomarinol. We also wished to investigate any 
additional interesting role that TmlU might have which may open a strategic way to the 
development of novel compounds with improved characteristics. 
    The results indicated that TmlU cannot complement NCIMB10586∆mupU, and the effect 
was stronger when induced with IPTG which prevented any observable biological activity, 
and this means that TmlU cannot promote the movement of the intermediate from MmpB to 
mAcpE assuming that the scheme proposed for the role of MupU and mAcpE in mupirocin 
biosynthesis (Hothersall et al., 2007) is correct. Most striking was the fact that not only did 
TmlU not complement MupU, but it even seemed to reduce the antibacterial activity 
remaining in the NCIMB10586∆mupU, and this effect of TmlU was seen when expressed in 
trans in the NCIMB10586 WT and NCIMB10586∆mupX as well. However, data from both 
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HPLC analysis and LC-MS followed by NMR experiment showed that TmlU promotes 
premature release of intermediates, which were confirmed to be homologues of PA-A and 
PA-B with truncated C5 and C7 side chains, while only the C5 version instead of the C9 side 
chain was observed as a major product in the case of IPTG induction (Figure 3.19). These 
indicate that the increased level of TmlU allows it to compete better with the normal 
processes happening on MmpB, and that essentially most of the intermediates are released 
after the first or the second round of condensation with a corresponding reduction in the 
release of specific PA-A with C9 side chain. This indicates that in the NCIMB10586 WT, 
TmlU at low levels blocks elongation but does not block the conversion to PA-A. These 
findings tend to be in a good agreement with those of Hothersall et al., (2011), in which they 
observed related metabolites to pseudomonic acid A released in trace quantities while up-
regulating NCIMB10586 WT via in trans expression of mupR, the transcriptional activator. 
Moreover, these results are consistent with Murphy’s suggestion that both in mupirocin and 
thiomarinols the saturated acyl side chains does not essentially have to be produced by the 
ligation of the fully assembled (C9 or C8, respectively) hydroxy acids but are more likely to 
be built up by successive elongations from the PKS-derived product (Murphy et al., 2011).   
    It was hypothesised that TmlU might compete with TE to capture the activated thiolester 
intermediate in order to create an amide, but release it if there is no appropriate amino-donor, 
or probably it associates with TE and blocks its normal function. Therefore, to test the 
formulated hypothesis, tmlU was expressed in trans in the NCIMB10586∆TE, and both 
bioassay and the HPLC data did not show the release of any product with biological activity 
neither with nor without IPTG induction. However, LC-MS results revealed the release of 
low amounts of truncated C5 PA-A and PA-B with a very faint amount of C9 PA-A. This 
result might indicate that TmlU could release some intermediates but with a less efficiency 
than in the presence of TE, in addition to affecting the elongation processes. However, in the 
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rifamycin biosynthesis cluster, the amide synthase encoded by rifF gene was found to 
function as a chain terminator by displacing the thioester linkage of the assembled polyketide 
chain, which means it is substituting for the function of TE (August et al., 1998). Comparable 
to the current findings, Yu et al., (1999), showed the release and accumulation of a series of 
linear polyketides from rifamycin B mutants, even when rifF gene was inactivated which 
results in the disruption of rifamycin B synthesis. Additionally, repositioning of the TE 
domain within eryPKS downstream of DEBS1 resulted in the production of a triketide 
lactone rather than the normal 14-member macrolide (Cortes et al., 1995). More surprisingly, 
polyketides of virtually all the elongation stages have been produced by Bacillaene (bae), the 
trans-AT PKS, in mutants with an inactivated TE domain (Moldenhauer et al., 2007, 2010). 
With the exception in rifamycin (Yu et al., 1999), this phenomenon has not been observed in 
cis-AT PKS and suggests the existence of a proofreading mechanism that releases the stalled 
acyl intermediates (unites) from the enzyme, which has not been characterised yet (Jensen et 
al., 2012). Later on, the same group proved in Pederin, that PedC, a member of AT2 group 
does not display detectable AT activity (loading ACPS with malonyl units), but rather acts as 
a proofreading enzyme by removing the stalled acyl units from blocked modules. Therefore, 
they proposed to rename this enzyme as acyl hydrolase (AH) than PedC or AT2, and 
suggested that to enhance polyketide yields, addition of enzymes in this group (AHS) to tran-
AT PKS pathways lacking these enzymes could have a meaningful result. Concomitantly, in 
the mupirocin system, AT2 was found to be responsible for loading ACPS with malonyl 
extender units while not AT1 (Gurney, PhD thesis, University of Birmingham, 2013), which 
might work as a proofreading function in the system, and presumably, might explain the 
reason why we are getting the release of a tiny amount of C9 PA-A in mutant with TE 
deletion, as well as the release of stalled oligoketides (C5 PA-A and PA-B) when TmlU is 
present.       
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Figure 3.19 Chemical structure of shorter pseudomonic acids (C5 and C7) version of PA-
A and PA-B, compare to normal pseudomonic acid (mupirocin) with C9 fatty acid side 
chain. 
    Consequently, and as predicted by El-Sayed et al., (2003), that MmpB (with tandem ACPS 
5, 6, and 7) is more likely to be responsible for the biosynthesis of 9HN (9-Hydroxynonanoic 
acid) by three condensations using malonate molecule, and our results showed that TmlU 
blocks the 2
nd
 (C5-C7) and the 3
rd
 (C7-C9) round of condensation, but not the 1
st
 one (C3-C5). 
Therefore, this might indicate that the 2
nd
 and the 3
rd
 round of condensation are more likely 
happening on MmpB, while the 1
st
 condensation (C3-C5) might happen outside MmpB on 
another protein within the mupirocin system since at low levels of TmlU only the 3
rd
 (C7-C9) 
round of condensation is blocked, followed by the 2
nd
 (C5-C7) round when the levels of TmlU 
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increased, but without affecting the 1
st
 (the C5 version) condensation. Moreover, Rahman et 
al., (2005) showed that inactivating the ACP5 (ACP-Ba) domain by Ser-to-Ala mutation at 
the acyl binding site, prevents other ACPS (ACPs-Bb and Bc) from access to the machinery, 
suggesting they work in parallel. Therefore, we predicted that TmlU might interact with 
either the 2
nd
 or the 3
rd
 ACPS of MmpB. To evaluate this possibility, tmlU was expressed in 
NCIMB10586 strains with point mutation in the active site of MmpB ACPS. Bioassay data 
revealed blocking the production of biologically active product in all three strains with point 
mutation when TmlU was available at high levels. This result was consistent with the HPLC 
chromatograms, that showed production of truncated shorter pseudomonic acids when tmlU 
expressed in ACP6 (Bb) and ACP7 (Bc) point mutants but not in the strain with ACP5 (Ba) 
point mutation, as already there is no product released from this mutant. This indicates that 
TmlU is not targeting the active site serine residue of the tested ACPS since it is still able to 
block the biosynthetic pathway and modify PA-A. To convince ourselves about the 
possibility of any protein-protein interaction between TmlU and either one or more ACPS of 
MmpB, tmlU expression in NCIMB10586 mutants with both single and double deletion in 
those ACPS was carried out. Plate bioassay revealed blocking of biosynthesis, and there was 
no production of biologically active product of significance in mutants with double ACP 
deletions and even in NCIMB10586 mutants with single deletion of ACP5 (Ba) and ACP7 
(Bc), respectively, when tmlU induced. However, a reasonable amount of antibacterial 
activity was observed in ACP6 (Bb) mutant, even in presence of high levels of TmlU.  
Subsequent HPLC analysis confirmed modification of C9 PA-A to the truncated C5 version in 
all the deletion mutants mentioned, with the exception of production of observable amount of 
C9 PA-A in ACP6 (Bb) mutant in addition to the truncated compound. Therefore, these data 
did not give support to the idea of protein-protein interaction between TmlU and MmpB- 
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ACPS, and at present, we do not have such a model to explain that, the fact that needs more 
experiments (Figure 3.20).  
 
 
Figure 3.20 Primary proposed interaction of TmlU (thiomarinol amide ligase) with 
MmpB of mupirocin biosynthetic pathway. (A), and (B) interference of TmlU with 
mupirocin system with either ACP5 (Ba) or ACP7 (Bc) deletion of MmpB, and partial 
sensitivity with ACP6 (Bb) deletion in (C).    
 
    Recently, Keatinge-Clay describes the control of the flow of polyketide intermediates in 
modular type I PKS through the pathway as one of the biggest mysteries in the enzymology 
of this group of polyketide (Keatinge-Clay, 2012). This review proposed a theory supported 
by accumulating evidence about how ACPS interacts, in which apparently it interact with the 
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KS of the same module through a specific surface, while it interacts with the KS of the 
downstream module using a different surface, and that is either due to surface 
complementarity or geometric restraint imposed by the linker. However, and in order to come 
out with mechanisms that explains precisely the manner that control the flow of intermediates 
during polyketide synthesis, extra experimental data is needed (Kapur et al., 2010; 
Charkoudian et al., 2011; Kapur et al., 2012). Nevertheless, all cases of intermediate release, 
as a phenomenon involving in trans-AT PKSS, for example, in Bacillaene (Moldenhauer et 
al., 2007), mupirocin (Wu et al., 2008), and rhizoxin (Kusebauch et al., 2009), have been 
reported in systems containing AH-type enzymes within the assembly line (Jensen et al., 
2012). In accordance to this, Piel and co-workers proposed the significance of this 
coincidence due to high selectivity of KSS for the α,β-functionalization of the incoming 
substrates shown by phylogenetic (Irschik et al., 2010; Nguyen et al., 2008; Teta et al., 2010) 
and their other unpublished data. Therefore, they interpret the biosynthetic blocks as a result 
of faulty in β-processing, which in turn prevents further elongation of incorrectly processed 
intermediates. 
    In conclusion, we have presented new data indicating that TmlU, the amide synthetase in 
thiomarinol cluster, is not able to work instead of MupU (the Acyl CoA synthase) in 
mupirocin system, but rather it interferes with the biosynthesis of the 9HN part of mupirocin, 
which MmpB is predicted to be responsible for (El-Sayed et al., 2003). TmlU blocks the 2
nd
 
and the 3
rd
 round of condensation in the synthetic stages of 9HN, but did not block the 1
st
 
round of condensation, without affecting the conversion from PA-B to PA-A. By using 
NCIMB10586 strains with different forms of mutation in the ACPS of MmpB, we have been 
able to show that TmlU is not targeting the active site serine of the ACPS for the interaction 
with mupirocin cluster. In addition, we have obtained some data that indicates that TmlU may 
interacts with all the ACPS (ACP5, ACP6, and ACP7) in the tandem ACP of MmpB, while 
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deletion of ACP6 reduces the sensitivity to the negative effects of tmlU expression. To our 
knowledge, these observations are very significant since it provides the first direct evidence 
that MmpB is involved in 9HN production, and in addition, it provides evidence that the 2
nd
 
(C5-C7) and the 3
rd
 (C7-C9) round of condensation might happen on MmpB, while the 1
st
 (C3-
C5) condensation might happen outside MmpB since this last condensation was not affected 
by TmlU. 
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CHAPTER 4 
INVESTIGATING THE ROLE OF THE SECOND 
MODULE WITHIN TmpB OF THE THIOMARINOL 
BIOSYNTHETIC PATHWAY IN Pseudoalteromonas spp 
SANK 73390 
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4.1 Introduction  
    Modular (type I) polyketide synthases (PKSS) (Donadio et al., 1991), are multifunctional 
enzymes that are involved in the biosynthesis of structurally diverse natural products of 
medicinally important (Brautaset et al., 2003). In a similar fashion to fatty-acid synthases, 
PKSs catalyse the decarboxylative condensation of basic carboxylic acids into the growing 
polyketide chain. However, as PKSS can use of different primer and extender units, they are 
more diverse in their catalytic reactions. Several different domains with distinct catalytic 
functions during the biosynthetic pathway are brought together in a single module which is 
responsible for a single condensation step during PKSS catalysis. Ketosynthase (KS), 
acyltransferase (AT), and acyl carrier protein (ACP) are the minimal domains essential for a 
single condensation. Further additional domains which are responsible for various degrees of 
the reduction state of each β-carbon within the polyketide chain represented by ketoreductase 
(KR), dehydratase (DH), and enoyl reductase (ER) may be present in various combinations 
(Brautaset et al., 2003). The order of functional domains in modular PKSS reflect the series of 
reactions being carried out on the growing polyketide chain so that the most important part of 
the programming of this type of polyketide biosynthesis is essentially organisational 
(Tsukamoto et al., 1996).  
    Based on the structure of PKSS, Staunton and Weissman, (2001) suggested that modules 
prime with a KS domain and end in an ACP, and in order for the polyketide chain to transfer 
and progress between modules, the ACP of one module requires partner KS in the next 
module. Only the linker region located in front of the next module but not its entire KS 
domain makes the modular unit. Also they reported the necessity of downstream linker for 
the first module and the high degree of tolerance exhibited by the second module to the 
protein structure that precedes it. Deletion of one or more specific modules could change the 
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chain length, while swapping one module with a heterologous one derived from another PKS 
(differ by a combination of enzymatic domains) could promote diversity, for example by 
changing the extent of processing of the polyketide chain by that module (Lal et al., 2000).      
    MmpB in the mupirocin biosynthesis cluster is proposed to be responsible for synthesis of 
9-HN (Hothersall et al., 2007; Martin et al., 1989; El-Sayed et al., 2003). MupU is proposed 
to be responsible for the transfer of an intermediate (PA-B with C8-OH) to mAcpE which is 
then further processed by MupO, V, C and F for the production of PA-A (mupirocin) (Cooper 
et al., 2005a; Hothersall et al., 2007). Therefore, it is proposed that PA-B is acting either like 
a precursor or a side product of PA-A (Cooper et al., 2005a). Since there is no C8-OH in the 
structure of thiomarinol, we were interested to know how thiomarinol system get ride of C8-
OH. In contrast to mupirocin system, the absence of mAcpE in the thiomarinol system and 
the presence of an extra KS and ACP (Figure 1.20) in TmpB (that is absent from MmpB in 
mupirocin system) suggest the possibility that this step in processing the intermediate for 
thiomarinol production might happen on TmpB prior to its release by the TE of TmpB 
(Fukuda et al., 2011). This raises the possibility that such an arrangement might lower the 
potential for the release of incomplete products (Fukuda et al., 2011) and could be the reason 
for not observing detectable amounts of thiomarinols, the equivalent to pseudomonic acid B 
which is with C8-OH (Murphy et al, 2011). Therefore, this work aimed to test that hypothesis 
by deleting the KS-B2/ACP-B2 represented as a second module of tmpB to see whether we 
could get an accumulation of molecules with an extra OH at C8. 
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4.2 Materials and methods 
4.2.1 Bacterial strains and plasmids 
    Escherichia coli DH5α was used for plasmid transformation and propagation. 
Pseudoalteromonas spp SANK 73390 was used as the wild-type thiomarinol–producing 
bacterium. E. coli S17-1 was used to mobilise the suicide vector into Pseudoalteromonas spp 
by bacterial conjugation. Bacillus subtilis 1064 (thiomarinol-sensitive organism), was used in 
disc bioassays to detect the antibacterial activity of thiomarinol (Materials and Methods 
2.2.6). DNA isolation and manipulations were described in Chapter 3. Samples preparation 
and HPLC analysis of the extracted thiomarinol was described in Chapter 2. Bacterial strains 
and plasmids used in this study are listed in Table 4.1 and 4.3, respectively.  
 
4.2.2 Growth media and culture conditions 
     Pseudoalteromonas spp SANK 73390 was grown at 23
o
C in marine broth and marine agar 
described in Chapter 2. E. coli strains DH5α and S17-1 were grown at 37oC in L-broth and L-
agar described in Chapter 3 and supplemented with 50 µg/ml kanamycin, while Bacillus 
subtilis 1604 was grown at 37
o
C in L-broth only without any supplement. Antibiotics used 
during this study are listed in Table 4.2. All medium was sterilised by autoclaving (121
o
C at a 
pressure of 15 pounds per square inch for 15 min) before adding antibiotics or sucrose. 
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Table 4.1 Bacterial strains used or constructed during this study. 
 
Bacterial strain 
 
 
Genotype 
 
Reference 
 
 
Escherichia coli 
DH5α 
 
Fˉ Ф80dlacZ∆M15, recA1, endA1, gyrA86, thi-1, 
HsdR17(r kˉ, m k+), supE44, relA1, deoR, ∆(lacZYA- 
ArgF)U169 
 
 
Hanahan, 
1983 and 
1985 
 
 
Pseudoalteromonas 
spp SANK 73390 
 
Wild type (WT) strain which produces thiomarinol 
 
Fukuda et al., 
2011 
 
Escherichia coli 
S17-1 
 
RecA pro hsdR RP4-2-Tc::Mu-km::Tn7 
 
Simon et 
al., 1983 
 
Bacillus subtilis 
1604 
 
TrpC2 
 
Moir et al., 
1979 
 
Pseudoalteromonas 
spp SANK 73390 
∆tmpB 2nd module 
 
 
Pseudoalteromonas spp SANK 73390 with deletion 
of 2
nd
 module (KS-ACP) in tmpB gene 
 
This study 
 
        
  Table 4.2 Antibiotics used in this study. 
 
Antibiotic 
 
Stock solution (mg/ml) 
 
Working concentration 
(µg/ml) 
 
Ampicillin 100 100 
Kanamycin sulphate 50 50 
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Table 4.3 Plasmids used and constructed in this study. 
 
plasmid 
 
Size 
(Kb) 
 
Genotype Description 
 
Reference 
 
pAKE604 
 
 
7.2 
 
Ap
R
, Km
R
, oriT, lacZα, sacB 
 
El-Sayed et 
al., 2001 
 
pGEM-T Easy 
 
 
3.0 
 
Ap
R
, lacZα (PCR cloning vector) 
 
Promega 
 
pAMG1 
 
 
3.672 
 
0.672 kb EcoRI-BamHI fragment containing N-
terminal fragment of 2
nd
 module of tmpB cloned 
into  pGEM-T Easy 
 
This study 
 
pAMG2 
 
 
3.521 
 
0.521 kb BamHI-XbaI fragment containing C-
terminal fragment of 2
nd
 module of tmpB cloned 
into  pGEM-T Easy 
 
This study 
 
pAMKE 
 
8.393 
 
1.193 kb (arm1 672 bp EcoRI-BamHI and arm 2 
521 bp BamHI-XbaI) PCR products for deletion 
of 2
nd
 module of tmpB cloned into EcoRI-XbaI 
of pAKE604. 
 
 
This study 
 
Table 4.4 Primers used in this study. 
 
Gene 
 
Primer 
 
Length 
(bp) 
          
Primer sequence, 5’→3’ 
 
Purpose 
 
Restriction 
sites 
 
 
 
 
tmpB 
 
FmutB1 
 
 
30 
 
CACGAATTCATTGAGATCTCAGCCACGCTG 
 
 
In frame 
Deletion of 
the 
2
nd
 module 
(KS-B2-
ACP-B2) 
of tmpB 
 
EcoRI 
 
RmutB1 
 
 
29 
 
GCCGGATCCCAGATAATCTACCAGCGCCG 
 
BamH1 
 
FmutB2 
 
 
31 
 
GCCGGATCCATTACCGAACGGTTAATAGAGG 
 
BamH1 
 
RmutB2 
 
 
30 
 
CGCTCTAGAGCTTGCGTTAATGGCTCTATC 
 
XbaI 
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4.2.3 Polymerase chain reaction  
     The PCR procedure (Saiki et al., 1985; Saiki et al., 1988) allows the in vitro amplification 
of specific DNA regions by multimillion fold replication using nanogram amounts of a 
specific segment of DNA as a template, and two specific primers complementary to the ends 
of the amplified DNA sequence. 
    Either plasmid or chromosomal DNA was used as a template for PCR prepared using the 
boil preparation technique. Colonies from young bacterial cultures were picked up by a sterile 
200 µl micropipette tip and placed into a sterilised microfuge tube containing 50 µl sterilised 
distilled water and vortex-mixed to make a homogenous suspension. The re-suspended 
bacterial colonies were boiled for 10 min with the microfuge lid closed with a special plastic 
lock to prevent contamination with the boiled water. The cells were pelleted by centrifugation 
at 14,000 g for 5 min and the supernatant (DNA) transferred to another sterile microfuge tube 
and kept in the ice. The dried oligonucleotide primers were purchased from Alta Biosciences, 
University of Birmingham and resuspended using the recommended amount of sterile 
distilled water to make up 100 pmol/ µl concentration (100 µM) with gentle mixing. From 
this, 10 µM stocks were prepared and the rest stored at -20
o
C. The 10 µM was stock used 
whenever PCR reactions were performed using the Bioline Velocity kit for the amplification 
of DNA fragments for cloning since it is provided with proofreading activity. Taq DNA 
polymerase (Invitrogen) was used whenever proofreading was not essential, for example 
when checking for mutations introduced into the DNA. The annealing temperature was set to 
5
o
C less than the melting temperature of the primers, and the extension times were calculated 
based on 15-30 second per each kb of the amplified DNA, which is equal to 0.06s per each 
base pair.  
 
148 
 
4.2.3.1 PCR using Velocity
TM
 DNA polymerase (Bioline) 
    Amplification of the DNA fragments for cloning carried out using Velocity kit (Bioline), 
which includes a highly thermostable proofreading DNA polymerase that provides 50-fold 
higher fidelity than Taq DNA polymerase and results in higher yields of the PCR products. It 
includes 5’-3’ DNA polymerase and 3’-5’ proofreading exonuclease activities as well. In 
addition, it is desirable for amplification of difficult templates and for mutagenesis. A 
standard reaction contained 48 µl of the below mixture: 
 
 
Reagent 
 
 
Volume per 
Reaction (µl) 
5x Hi-Fi Reaction Buffer (contains 10 mM Mg
2+
) 
dNTPs (2.5 mM)  
Forward primer (10 µM) 
Reverse primer (10 µM) 
DMSO 
Water (ddH2O) 
Velocity DNA polymerase  
10 
5 
2 
2 
1.5 
27.0 
0.5 
 
Due to the inherent 3’-5’ exonuclease activity of the Velocity DNA polymerase’s, the 
enzyme was added as last ingredient or just before dispensing and adding DNA so as to 
prevent the primers from the degradation. Amplification of each DNA fragment was carried 
out using four reactions, therefore, the above reaction mixture was prepared according to the 
number of the reactions. 48 µl of the reaction mixture was added to each of the four reactions. 
To three of them 2 µl of prepared DNA was added, while 2 µl of SDW was added to the 
fourth one as a control. PCR reactions carried out using SensoQuest Lab-cycler and the 
programme with the following parameters:       
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Step 1                    Initial denaturation             98
o
C           2 min                      1 cycle 
Step 2a                  Denaturation                       98
o
C            30 s 
Step 2b                  Annealing                            (Tm-5)
o
C    30 s          25-35 cycles 
Step 2c                  Extension                             72
o
C            15-30s /kb 
Step 3                    Extension                             72
o
C            7 min                     1 cycle 
 
Since Velocity generates blunt-ended amplicons which are not suitable for effective 
integration into TA cloning vectors such as pGEM-T Easy vector (Promega), therefore an A’ 
overhang was added to each PCR product (section 4.2.4) to facilitate cloning into sequencing 
vectors. 
 
4.2.3.2 PCR using Taq DNA polymerase (Invitrogen) 
     For checking bacterial isolates for any mutation introduced into the DNA, Taq DNA 
polymerase obtained from Thermus aquaticus was used for performing PCR reactions. The 
following 45 µl ingredients were included in the mixture of PCR reactions: 
 
Reagent 
 
 
Volume per 
Reaction (µl) 
10X PCR Buffer minus Mg  
dNTPs (2.5 Mm)  
Taq DNA polymerase  
50% Glycerol  
Forward primer (100 µM) 
Reverse primer (100 µM) 
50 mM Magnesium Chloride 
SDW 
5 
4 
0.6 
10 
0.3 
0.3 
1.0 
23.8 
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    According to the number of PCR reactions, enough of the above mixture was prepared, and 
then 45 µl was dispensed into each PCR reaction tube. 5 µl of the DNA boil prep from the 
wild type strain (control negative), and from the bacterial isolates to investigate the mutation 
was added to separate reaction tubes, respectively. 1 µl of plasmid DNA, the suicide vector 
that has been used for mutagenesis plus 4 µl of sterile distilled water were added to another 
reaction tube as positive control, while only 5 µl of SDW was added to the last reaction tube 
as a control negative.  
 The SensoQuest Lab-cycler was adjusted to the desired PCR programme suitable for Taq 
DNA polymerase performance was consist of the following parameters:       
Step 1                    Initial denaturation             94
o
C           2 min                      1 cycle 
Step 2a                  Denaturation                       94
o
C            15 s 
Step 2b                  Annealing                            (Tm-5)
o
C    30 s                29 cycles 
Step 2c                  Extension                             72
o
C              * s  
Step 3                    Extension                             72
o
C            7 min                      1 cycle 
 
* Length of the sequence in base pair was taken as an estimate to calculate the extension 
times per seconds 
 
4.2.4 Addition of ‘A’-overhangs to purified PCR products 
     PCR products were run in agarose gel electrophoresis and purified from the gel as 
described in Chapter 3. Since the Velocity DNA polymerase generate PCR products with 
blunt-ended which makes them not ready for ligation into pGEM-T Easy vector which has 
‘T’-overhangs on both 3´-ends. Therefore, an ‘A’-tail must be added to the 3’-ends of the gel 
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purified and eluted PCR products in order to make them suitable for ligation into pGEM-T 
Easy vector. 6 µl of the eluted PCR product was added to a sterile microfuge tube. To this, 1 
µl of 10X buffer without magnesium chloride, 1 µl of 2 mM dATP (which was prepared by 
mixing 2 µl of 100 mM dATP with 98 µl SDW), 1 µl magnesium chloride, and 1 µl Taq 
DNA polymerase were added. The whole contents were mixed gently and then heated at 
70
o
C for 30 minutes using hot block.   
 
4.2.5 Cloning into the pGEM-T Easy vector 
    The prepared PCR products with ‘A’-overhangs added to the 3´-ends were used for cloning 
into pGEM-T Easy vector (Promega). A linearized pGEM-T Easy vector contains a single 3´-
thymidine at both ends, which makes it compatible to the ‘A’- tailed PCR products. In 
addition, the presence of the ‘3’-T overhangs at the insertion site of the vector improves the 
efficiency of the ligation into this vector and prevents it from re-circularization as well. The 
following ligation mixture in a total 12 µl worked efficiently: 
 
Reagent 
 
 
Volume per 
Reaction (µl) 
2x Rapid Ligation Buffer 
pGEM-T Easy vector (50 ng/ µl) 
‘A’-overhangs insert DNA 
T4 DNA Ligase (3 units/ µl) 
6 
1 
4 
1 
 
    The ligation mixture was incubated at 4
o
C overnight. Half of the ligation reaction (5-6 µl) 
was used for the transformation of competent DH5α, and the rest kept at 4oC. 50 µl and 200 
µl of the transformation mixture was plated out onto two separate LB-agar plates 
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supplemented with X-gal (80 μg/ml), IPTG (0.5 mM) and ampicillin (100 μg/ml) and 
incubated overnight at 37
o
C for blue/white colonies selection. 
 
4.2.6 DNA sequencing 
    For sequencing the genes or the PCR products cloned into pGEM-T Easy vector, plasmids 
were isolated from 5 ml overnight cultures as described in Chapter 3 using the AccuPrep 
plasmid extraction kit (Bioneer). 4 µl of eluted plasmid was then mixed with 3 µl of 1.1 µM 
universal forward primer once and 3 µl of 1.1 µM universal reverse primer in the second 
tube, and make up to a final volume of 10 µl with SDW. The whole 10 µl was loaded into 
micro-titration plate in the Functional Genomic Laboratory, University of Birmingham, and 
sequencing performed using the Sanger dideoxy method (Sanger et al., 1977) by using the 
ABI 3700 analyzer.    
 
4.2.7 Sequencing analysis  
    The sequence of the cloned DNA compared to the original (wild type) sequence using the 
programmes provided by the National Centre for Biotechnology Information 
(www.ncbi.nlm.nih.gov), which were also used for translation of ORFs. The New England 
Biolabs (www.tools.neb.com/NEBcutter2/) was used for mapping the restriction sites. The 
Oligonucleotide Properties Calculator (www.basic.northwestern.edu/biotools/oligocalc.html) 
was used for obtaining the reverse complement strand (5´ to 3´) for designing the reverse 
primers.       
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4.2.8 Construction of deletion mutant using suicide vector strategy 
    The strategy used by Rahman et al., (2005) and illustrated in Figure 4.1 was used for the 
construction of mutants with in-frame deletions. The protocol started by designing two 
different sets of primers for the PCR amplification of 672bp and 521bp-flanking regions on 
either side of the gene to be deleted and ligating them. Then the 1.163 kb insert was 
introduced into the suicide vector pAKE604 containing the Amp
R
, Kan
R
,lacZα, sacB as 
selectable markers, E.coli S17-1 was then transformed to mobilize the plasmid into 
Pseudoalteromonas spp SANK 73390. This suicide plasmid pAKE604 constructed in this 
way was transferred from E.coli S17-1 into wild type Pseudoalteromonas spp SANK 73390. 
Later on these two strains were mixed and then filtered via 0.45 μm sterile Millipore filter, 
followed by placing the filter on marine-agar plates without antibiotics, followed by 
overnight incubation at 23
o
C in order for the conjugation to take place. The filter was then 
removed from the plate, and transferred into 1 ml of marine broth and vortex mixed to re-
suspend the cells. Serial dilutions 10
-1
, 10
-2
, 10-3, 10-4 and 10-5 of bacterial suspension were 
prepared using marine broth. 100 µl from each dilution was then spread on marine agar with 
kanamycin for the selection of Pseudoalteromonas spp SANK 73390 with pTML1 integrated 
suicide plasmid, which incubated at 23
o
C for 2-3 days. Typical colonies of SANK 73390 
were then selected and used for the inoculation of marine broth without antibiotic for the 
excision of the suicide vector, incubated overnight at 23
o
C. Then serial dilutions prepared 
from the broth culture, and 100 µl of the dilutions was spread on marine agar containing 
5.5% (w/v) sucrose for the selection of the strains in which the suicide plasmid had been 
excised from pTML1, followed by overnight incubation at 23
o
C for 2-3 days. Selected 
colonies were picked up, and further screening for the sensitivity of those strains to 
kanamycin confirmed that excision of the suicide plasmid was successful. PCR of the wild 
type and the new strains gave quite reliable evidence that mutation occurred.  
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                        Figure 4.1 Strategy for the suicide vector integration and excision. 
pAMKXX is the suicide vector pAKE604, which XX refers to the specificity.  
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4.3 Results 
4.3.1 Deletion of KS-B2 and ACP-B2 from TmpB does not block antibiotic 
production 
     Using the standard suicide vector strategy, in-frame deletion of the second module of 
tmpB in the thiomarinol system was achieved, removing KSB2/ACPB2 which are proposed 
to be non-elongating. Two mutants (different isolates) were confirmed as lacking the 2
nd
 
module. Since it was proposed that this extra KS and ACP might have a role in the removal 
of the C8-OH group from marinolic acid (PKS part) of thiomarinol, strains lacking them 
either might switch on the system totally to compounds retaining C8-OH group (compounds 
like PA-B in mupirocin) or at least might raise the level of such compounds. Disc bioassays 
were performed to check the biological activity of thiomarinol compounds extracted from 
mutants with KS-B2/ACP-B2 deletion using the WT Pseudoalteromonas spp SANK 73390 
as a control. The area of the zone of inhibition was estimated and was taken as an indicator of 
the potency of the compounds produced by the mutants in comparison to those of the wild 
type. Production of thiomarinol by the mutants decreased compare to the WT 
Pseudoalteromonas spp SANK 73390 (Figure 4.2), and a reduction was about 30% less using 
the WT as 100% (Figure 4.3). Since the major compound produced by the WT strain is 
thiomarinol A (TH-A), the most potent thiomarinol compound, this strain should give 100% 
productivity and the biggest zone of inhibition. A smaller zone of inhibition with any mutants 
might be an indicator of the production of less TH-A, but could also indicate that the 
thiomarinol system could have shifted to some extent to a pathway specific for minor 
compounds with lower bacteriocidal activity. The latter effect was what we were proposing 
for the extra KSB2/ACPB2 in the biosynthesis of thiomarinol.    
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Figure 4.2 Disc bioassay of thiomarinol produced by the KS-B2/ACP-B2 mutant using 
thiomarinol produced by the WT Pseudoalteromonas spp SANK 73390 as control. From 
left to right WT: wild type strain, ∆1: ∆KS-B2/ACP-B2 isolate1, and ∆2: ∆KS-B2/ACP-B2 
isolate2. 
 
 
  
Figure 4.3 Quantitative bioassay of Pseudoalteromonas spp SANK 73390 with ∆KS-
B2/ACP-B2 of tmpB in comparison to the WT strain. Triplicate samples were used. 
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4.3.2 HPLC analysis for thiomarinol production 
    Thiomarinol extracted with the standard technique using acetone and ethyl acetate, was 
subjected to HPLC analysis to investigate the effect of the in frame deletion of the KS-
B2/ACP-B2 of tmpB on thiomarinol production. HPLC chromatograms obtained from the WT 
SANK 73390 and the two isolates (mutant) showed a detectable peak of thiomarinol (Figure 
4.4) indicating that the mutants still able to produce thiomarinol but with a much lower yield.  
 
 
 
Figure 4.4 HPLC chromatograms of thiomarinol produced by Pseudoalteromonas spp 
SANK 73390 with ∆KS-B2/ACP-B2 of tmpB using WT strain as control.  
    Quantitative HPLC analysis showed a strong reduction in the production of thiomarinol by 
the mutant (isolates) to about 30% of the amount produced by the WT strain (Figure 4.5 and 
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4.6). This observation clearly indicated the negative effect of KS-B2/ACP-B2 deletion of 
tmpB on the strain productivity. However, the deletion did not block thiomarinol production, 
as effect which might be due to the reduction in the production of thiomarinol A in favour of 
other thiomarinol compounds.       
 
 
Figure 4.5 HPLC analysis of production of thiomarinol by the WT Pseudoalteromonas 
spp SANK 73390 and strains with ∆KS-B2/ACP-B2 of tmpB, and using triplicates.  
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Figure 4.6 Quantitative HPLC analysis of production of thiomarinol by the WT 
Pseudoalteromonas spp SANK 73390 and strains with ∆KS-B2/ACP-B2 of tmpB. 
  
 
4.3.3 Detection of PA-B analogue (TH-H) by LC-MS analysis  
    To analyse the change in the product profile in more detail the extracts were subject to 
LC/MS analysis by our colleagues at the University of Bristol. The results presented in 
Figure 4.7 shows various thiomarinol compounds produced by the WT Pseudoalteromonas 
spp SANK 73390 and the mutants with KS-B2/ACP-B2 deletion from tmpB, and the percent 
productivity of each compound by the mutants relative to the WT ones in Figure 4.8. 
Thiomarinol A, the major compound of the WT is still produced by the mutants but with a 
much lower yield (approx. 35.6%). However, production of other compounds such as 
thiomarinol C was increased significantly in the mutants by more than two-fold. Both the 
wild type and the mutants produced marinolic acid as expected and with a similar yield. 
However, while we predicted a decrease in the production of thiomarinol B by the mutants, a 
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small peak with the same MW as TH-B identified although it has not been confirmed as TH-
B or even related. Nevertheless, the most striking result was a profound increase (about 3-
fold compare to the WT) in the production of a compound with MW 656. This compound has 
been confirmed structurally as a hybrid of TH-A and TH-G (with C8-OH), which is an 
analogue of pseudomonic acid B in the mupirocin system and we call it TH-H. Since we get 
an accumulation of this compound which has an extra OH at C8, therefore, this strongly 
indicates that our hypothesis was correct and that this extra KS-B2/ACP-B2 (2
nd
 module) of 
tmpB is non elongating module where the removal of the C-8 OH occurs.     
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Figure 4.7 Comparison of various thiomarinol compounds produced by the WT strain 
Pseudoalteromonas spp SANK 73390 and isolates with ∆KS-B2/ACP-B2 of tmpB.  
Compounds were analysed using diode array, LC-MS and ELS detection. Compounds from 
left to right; marinolic acid with m/e 486.60; hybrid of thiomarinol A and G (compound with 
C8-OH named as TH-H), the pseudomonic acid B analogue with m/e 656.81; thiomarinol A 
with m/e 640.81; unknown compound (TH-B?) with m/e 640; thiomarinol B with m/e 672.81 
and thiomarinol C with m/e 624.81 (data from Dr. Song in Bristol).   
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Figure 4.8 Quantitative analysis of various thiomarinol compounds produced by isolates 
of SANK 73390 with ∆KS-B2/ACP-B2 of tmpB relative to thiomarinol A and using WT 
ones as 100%. Compounds were analysed using diode array, LC-MS and ELS detection. 
Significant decrease in the yield of both TH-A and TH-B were observed, while profound 
increase in the yield of TH-H (compound with extra OH at C8) and a valuable increase in 
TH-C could be seen by the mutant in comparison to the WT ones (data from Dr. Song in 
Bristol).    
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4.4 Discussion 
    Progressive research on modular polyketides, clearly provides the possibility of modifying 
the structure of complex polyketides by introducing direct changes within PKSS (Katz, 
1997). More specifically, Tsukamoto et al., (1996) confidentially support the idea of 
producing new polyketide products by dealing with the enzymatic domains using diverse 
ways like addition, deletion, swapping, or rearrangements. However, keeping the balance 
between substrate recognition and permissiveness characteristic of any of the included 
enzymatic roles or activities is required for the success of such a strategy. Retaining the most 
essential functions including within the TE as a termination domain, provides evidence that 
the steps of releasing, cyclising and post-PKS modifications of the products does not seem to 
be a major consequence of deleting modules from this PKS  (Kao et al., 1994 and 1995; 
Cortes et al., 1995). TmpB is one of the multifunctional megaproteins in the PKS part of the 
thiomarinol pathway, and is constituted with a 2
nd
 module extra KS-B2/ACP-B2 designated 
as a putative non-elongating KS. The absence of mupirocin mAcpE’s analogue from 
thiomarinol system led to the proposal that it is involved in the last few tailoring steps of 
pseudomonic acid production; namely of conversion of PA-B with OH at C8 to PA-A. This 
implies that the extra module of TmpB could be involved in the equivalent process. 
Therefore, the present study aimed to test the hypothesis of accumulation of thiomarinol 
molecules with extra OH at C8 as a result of deletion of the extra KS-B2/ACP-B2 from tmpB. 
    By suicide mutagenesis, mutants of Pseudoalteromonas spp SANK 73390 with KS-
B2/ACP-B2 deletion from tmpB was obtained and thiomarinol extracted from mutants as well 
as the WT using optimal condition of extraction. Disc bioassay showed inhibition of the 
sensitive bacteria tested by thiomarinol extracted from mutants but with less effectiveness 
than compounds extracted from the WT. HPLC analysis carried out to confirm the amount of 
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thiomarinol produced by the deletion mutants in comparison to the WT ones, showed a 
significant reduction in the production of biologically active thiomarinol (mostly TH-A) by 
the mutant to about 1/3 the amount produced by the WT. This might explain that the module, 
or at least what has been deleted, is important for the biosynthetic pathway since the profile is 
clearly changed.  
    To investigate in more detail the various compounds that had been produced, we analyzed 
the metabolite profile of the ∆KS-B2/ACP-B2 of tmpB mutant by LCMS and found that both 
thiomarinol A and thiomarinol B decreased significantly compare to the WT ones, while 
marinolic acid was produced in the same range. Strikingly, the product retaining an extra OH 
at C8 with MW= 656 dalton has been detected in the mutant with a ratio more than the WT 
by about 3 folds. According to LCMS and fragmentation pattern the structure of this 
compound was elucidated to be a hybrid of TH-A and TH-G (with OH at C8) as an analogue 
of pseudomonic acid B in mupirocin system and we designated it TH-H (Figure 4.9). This 
result provides good evidence that our hypothesis about the possible implication of the extra 
KS and ACP of tmpB in the removal of the extra OH at C8 from thiomarinol structure is 
correct. Moreover, it might indicate that this extra module of tmpB is a non-elongating 
module and that the KS-B2 is working as a transferase rather that to function in a Claisen 
condensation since the deletion mutant did not change the carbon backbone of thiomarinol. In 
that case the ACP-B2 in the 2
nd
 module might function like a tailoring enzyme in thiomarinol 
system. Another exciting result with this mutant is the significant increase in the production 
of thiomarinol C, the compound lacking OH at C4 by approximately two fold than the WT. 
This observation might indicate that somehow ACP-B2 is involved in the removal of OH 
group at C8 while retaining it at C4 (C4-hydroxlyation). The prediction which is consistent 
with Murphy’s suggestion that C4-hydroxylation does not have to happen before or even 
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during the elongation of the polyketide backbone (Murphy et al., 2011), since this deletion 
did not change the polyketide chain (acts in tailoring steps only).     
 
 
Figure 4.9 Predicted chemical structure of thiomarinol compound with molecular 
weight 656.81 with an extra OH group at C8 produced by the mutant ∆KS-B2/ACP-B2 
of tmpB by about three fold more than the WT. 
 
   In summary, it is obvious that deletion of the KS-B2/ACP-B2 of tmpB has a profound effect 
on the biosynthesis pathway of thiomarinol by reducing but not eliminating thiomarinol A 
and thiomarinol B production. It also increased the production of thiomarinol C, the 
compound lacking OH at C4. We have also been able to demonstrate the accumulation of 
thiomarinol molecule with extra OH at C8 in the mutant of ∆KS-B2/ACP-B2 of tmpB. 
Presumably, this might be due to the role of either, both the KS-B2 and ACP-B2, or just the 
ACP-B2 that works like a tailoring enzyme, since we observed that this module is a non 
elongating module and that the KS-B2 function may be as a transferase instead of working in 
chain extension by a Claisen condensation.   
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CHAPTER 5 
MANIPULATION OF mupU AND macpE GENES FOR 
INCREASED PA-A PRODUCTION 
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5.1 Introduction 
    During the past two decades, tailoring enzymes in modular PKSs have been shown to play 
a striking role in the conversion of the core products of PKSs into the active form through 
further modifications. In mupirocin they are represented by mono-functional enzymes. For 
example, epoxidation of C-8,-16 double bond, as an essential step in the formation of the 
tetrahydropyran ring, has been proposed to possibly be due to the catalytic role of both 
MupW and MupT. This process apparently makes C-16 more receptive to assault by C-5 
hydroxyl group. Two further steps that may occur either before or after this, including 
esterification with 9-HN and C-10,-11 epoxidation, result in pseudomonic acid B. Knocking 
out mupW and mupT produced a new metabolite, mupirocin W, that lacks the tetrahydropyran 
ring but still has the fatty acid side chain (9-HN) attached, a fact that confirms the critical role 
of MupW/MupT in the biosynthesis of mupirocin. However, other genes like mupO, mupU, 
mupV, and macpE (Figure 5.1) are necessary for PA-A production but not PA-B (Cooper et 
al., 2005a), and the latest evidence indicates that PA-B is a precursor of PA-A (Gao et al., 
unpublished data). Therefore, it is hypothesised that MupU is responsible for loading mAcpE 
with an intermediate, which in turn is processed by MupO, aided by MupV/C/F for the 
production of PA-A. Also, since mupirocin is produced as a mixture of pseudomonic acids, 
and it is likely that different tailoring enzymes are responsible for the different forms 
(compounds), then manipulation of the level of those tailoring enzymes might change the 
balance of the different forms. 
    The commercial importance of PA-A as the most potent product of the mupirocin cluster 
led Macioszek in 2009 to demonstrate that over-expression of macpE and mupO/U/V/ C/F 
genes could increase the production of both PA-A and PA-B more than two fold. Other 
experiments demonstrated increase in the production of mupirocin and novel metabolites by 
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about 17-fold resulting from in trans expression of mupR, the transcriptional regulator, both 
in the wild type and mutants (Hothersall et al., 2011). Furthermore, tandem acyl carrier 
proteins both in mupirocin and curacin were shown to play a crucial role in promoting the 
enzymatic reactions consecutively, and thus increasing the polyketide production (Rahman et 
al., 2005; Liangcia et al., 2011). 
 
Figure 5.1 Multistep reactions for mupirocin production proposed to explain why in-frame 
deletion of open reading frames mupO, mupU, mupV and macpE abrogate PA-A production 
but not PA-B production, demonstrating that PA-B is either a precursor or, a side product to 
PA-A (Cooper et al., 2005a). 
 
    It is predicted that one of the reasonable explanations for why over expression of macpE 
and mupO, U, V, C, F (essential genes for PA-A production) was not a complete strategy to 
shut down PA-B production, is that the thioesterase associated with MmpB (Figure 5.2a)  
could possibly release PA-B. This means that there may be a need for more flux onward in 
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the mupirocin pathway to transfer an ACP bound intermediate to mAcpE by MupU in order 
to convert it to PA-A (Macioszek et al., unpublished data).                             
      
 
 
 
 
Figure 5.2 Differences in the proposed domain structure responsible for fatty acid 
synthesis in mupirocin and thiomarinol production. A tandem ACP in mupirocin is 
followed by TE, while in thiomarinol there is an extra non elongating module designated by 
the arrows that separate tandem ACP from TE.  
 
    Three valuable strategies were used for the purpose of this study. The first was to construct 
a strain of P. fluorescens NCIMB 10586 with a new promoter upstream mupU (proposed to 
be responsible for the transfer of intermediates to mAcpE), in order to increase the flux of 
intermediates and finally more production of PA-A. The second was to examine whether it is 
possible to increase the flow from PA-B to PA-A by increasing the expression of fused mupU 
(-STC)-macpE, based on the concept that to increase flux we need more ACPs, and the 
enzyme essential to transfer the intermediate onto the ACP. The third was based on the fact 
that in TmpB (Figure 5.2b) of the thiomarinol cluster there is an extra module separating the 
last ACP from the TE domain, which is demonstrated in Chapter 4 of this thesis to have a 
probable role in the removal of C8-OH group, and the release of thiomarinol PA-B analogue 
(TH-G or C and TH-H). This led to an attempt by atomic level surgery to insert fused mupU 
(-STC)–macpE(-STC) into mmpB before TE in order to reduce PA-B, which in turn should 
increase PA-A to the highest level.  
  a.                                     b.   
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5.2 Materials and Methods   
 5.2.1 Bacterial strains and plasmids 
    Bacterial strains used or constructed in this study are listed in Table 5.1. The growth 
conditions and media used with their supplements are described in Chapter 3, and only 
kanamycin (50 µg/ml) as an extra antibiotic was used whenever strains carried pAKE604 
plasmid. DNA isolation and manipulations was described in Chapter 3. Bacterial conjugation 
and DNA transfer via bi-parental mating was described in Chapter 3. Suicide vector strategy 
for in-frame deletion of open reading frames was described in Chapter 4, except that saline 
solution and L-agar were used instead of marine broth and agar, respectively, and the growth 
at 30
o
C, during the excision of the suicide vector. Plasmids used and constructed during the 
present study are listed in Table. 5.2. 
 
Table 5.1 Bacterial strains used and constructed during this study. 
 
Bacterial strain 
 
Genotype 
 
 
Reference 
Escherichia coli 
DH5α 
F
ˉ
 Ф80dlacZ∆M15, recA1, endA1, gyrA86, thi-1, 
HsdR17(r kˉ, m k+), supE44, relA1, deoR, ∆(lacZYA- 
ArgF)U169 
 
Hanahan, 
1983 and 
1985 
Pseudomonas 
fluorescens 
NCIMB10586 
 
Wild type (WT) strain which produces mupirocin 
 
Whatling et 
al., 1995 
Escherichia coli 
S17-1 
recA pro hsdR RP4-2-Tc::Mu-km::Tn7 Simon et al., 
1983 
 
Bacillus subtilis  
1604 
 
trpC2 
 
 
Moir et al., 
1979 
NCIMB10586 
∆macpE 
P.  fluorescens with deletion of macpE gene Cooper et al., 
2005a 
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NCIMB10586 
∆mupU/∆macpE 
 
P. fluorescens with deletion of mupU and macpE 
genes 
 
 
This study 
 
NCIMB10586∆UE 
(UE in mmpB) 
NCIMB10586∆mupU/∆macpE with mupU (-stop 
codon)-Linker (20 aas)-macpE (-stop codon) inserted 
into mmpB (between ACP7 and TE) 
 
 
This study 
 
NCIMB10586∆UE 
(UE after mmpA) 
NCIMB10586∆mupU/∆macpE with mupU (-stop 
codon)-Linker (20 aas)-macpE (-stop codon) inserted 
after ACP4 of mmpA  
  
 
This study 
 
NCIMB10586 
mupUp 
 
P. fluorescens with a new promoter upstream mupU 
 
This study 
 
 
Table 5.2 Plasmids used and constructed in this study. 
plasmid Size 
(kb) 
Genotype Description Reference 
pGEM-T Easy 
 
3.0 
 
Ap
R
, lacZα (PCR cloning vector) 
 
Promega 
 
pAKE604 
 
7.2 
 
Ap
R
, Km
R
, oriT, lacZα, sacB, multiple cloning 
sites (BamHI-EcoRI) 
 
 
EL-Sayed 
et al., 2001 
 
pJH10 
 
13.76 
  
TC
R
; lacI
q
, tacp, IncQ replicon, multiple 
cloning site (EcoRI-SacI) 
 
 
EL-Sayed 
et al., 2003 
 
pJH2 
 
14.482 
 
mupR cloned into pJH10 
 
 
 
Hothersall 
et al., 2011 
 
pAMGUPA1 
 
3.574 
574 bp BamHI-SacII PCR product containing 
arm 1 for putting promoter upstream mupU,  
cloned into pGEM-T Easy vector 
  
 
This study 
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pAMGUPA2 
 
 
3.585 
 
585 bp SacII-EcoRI PCR product containing 
arm 2 for putting promoter upstream mupU,  
cloned into pGEM-T Easy vector 
 
 
 
This study 
 
 
pAMK1 
 
 
8.3 
 
1.15 kb {arm1 (574 bp BamHI-SacII) PCR and 
arm 2 (585 bp SacII-EcoRI)} PCR products 
for putting promoter upstream mupU, cloned 
into BamHI-EcoRI of pAKE604. 
 
 
 
This study 
 
pAMGUA1(deletion) 
 
3.513 
513 bp BamHI-XbaI PCR product containing 
arm 1 for mupU deletion, cloned into pGEM-T 
Easy vector 
 
 
This study 
 
pAMGUA2(deletion) 
 
3.618 
618 bp XbaI-EcoRI PCR product containing 
arm 2 for mupU deletion, cloned into pGEM-T 
Easy vector 
 
 
This study 
 
 
pAMK2 
 
 
8.3 
 
1.13 kb {arm1 (513 bp BamHI-XbaI) PCR and 
arm 2 (618 bp XbaI-EcoRI)} PCR products for 
deletion of mupU, cloned into XbaI-EcoRI of 
pAKE604. 
 
 
 
This study 
 
pAMGU 
 
4.6 
1.6 kb KpnI-MfeI PCR product containing 
mupU (-stop codon) cloned into pGEM-T Easy 
vector  
 
 
This study 
 
pAMGE1 
 
3.26 
 260 bp ClaI-XbaI PCR product containing 
macpE  cloned into pGEM-T Easy vector 
 
 
This study  
 
pAMGE2 
 
3.26 
260 bp ClaI-XbaI PCR product containing 
macpE (-stop codon) cloned into pGEM-T 
Easy vector 
 
 
This study 
 
pAMG(ACP7-mmpB) 
 
3.516 
516 bp BamHI-EcoRI PCR product containing 
ACP7 of mmpB, cloned into pGEM-T Easy 
vector. 
 
 
This study 
 
pAMG(TE-mmpB) 
 
 
3.549 
549 bp XbaI-EcoRI PCR product containing 
TE of mmpB, cloned into pGEM-T Easy 
vector. 
 
 
This study 
 
pAMG(ACP4-mmpA) 
 
3.495 
495 bp BamHI-XbaI PCR product containing 
ACP4 of mmpA, cloned into pGEM-T Easy 
vector. 
 
 
This study 
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pAMG(mupB) 
 
3.490 
 
490 bp XbaI-EcoRI PCR product containing 
mupB, cloned into pGEM-T Easy vector. 
 
 
This study 
 
pAMH1 
 
13.86 
 
96 bp KpnI-NheI-MfeI---20aa---ClaI-NheI-
XbaI, cloned into pJH10 vector   
 
 
This study 
 
 
pAMH2-a 
 
 
15.3 
 
1.6 kb EcoRI, KpnI-MfeI PCR product 
containing mupU (-stop codon), cloned into 
pAMH1 vector with multiple cloning sites 
KpnI-XbaI and 20aa linker 
 
 
 
This study 
 
 
pAMH2-b 
 
 
15.3 
 
1.6 kb EcoRI, KpnI-MfeI PCR product 
containing mupU (-stop codon), cloned into 
pAMH1 vector with multiple cloning sites 
EcoRI, KpnI-XbaI and 20aa 
  
 
 
This study 
 
 
pAMH3 
 
15.6 
260 bp ClaI-XbaI PCR product containing 
macpE,  cloned into pAMH2-a {with mupU  
(-stop codon)  and 20aa} vector 
 
 
This study 
 
pAMH4 
 
15.6 
 
260 bp ClaI-XbaI PCR product containing 
macpE (-stop codon), cloned into pAMH2-b 
{with mupU (-stop codon)  and 20aa} vector 
 
 
This study 
 
 
pAMH5 
 
 
16.1 
 
516 bp BamHI-EcoRI PCR product containing 
ACP7 of mmpB cloned into pAMH4{with 
mupU (-stop codon)--20aa--macpE (-stop 
codon)}vector 
 
 
 
This study 
 
pAMK3 
 
7.75 
 
549 bp XbaI-EcoRI PCR product containing 
TE of mmpB cloned into pAKE604 vector 
 
 
This study 
 
 
pAMK4 
 
 
10.2 
 
2.5 kb BamHI-XbaI fragment containing 
{ACP7 of mmpB, mupU (-stop codon)--20aa- 
macpE (-stop codon)} in pAMH5 cloned into 
pAMK3 vector. 
 
 
 
This study 
 
 
pAMH6 
 
 
16.1 
495 bp BamHI-EcoRI PCR product containing 
ACP4 of mmpA cloned into pAMH4{with 
mupU (-stop codon)--20aa--macpE (-stop 
codon)} vector 
 
 
 
This study 
174 
 
 
pAMK5 
 
7.75 
 
490 bp XbaI-EcoRI PCR product containing 
mupB, cloned into pAKE604 vector. 
 
 
This study 
 
 
pAMK6 
 
 
10.2 
 
2.5 kb BamHI-XbaI fragment containing 
{ACP4 of mmpA, mupU (-stop codon)--20aa- 
macpE (-stop codon)} in pAMH6, cloned into 
pAMK5 vector. 
 
 
 
This study 
 
 
 
Table 5.3 Primers used during this study. 
 
Gene 
 
 
Primer 
 
Primer 
Length 
(bp) 
 
Primer sequence, 5’→3’ 
 
Purpose 
 
 
 
mupU 
FP1mupUPR 27 CGCGGATCCGAGCCACATGTGCCACTG 
 
Putting mupU 
under the control 
of new promoter 
RP1mupUPR 26 CGCCCGCGGTGTCAAGCGAAGCAGGC 
FP2mupUPR 40 GCCCGCGGCAATGTGCGTCTATCATTT 
TTGGTATGGCAAG 
RP2mupUPR 41 GCGAATTCCGTATAGAGGATCAGCGCT 
GGATGATCGCCTGC 
 
 
mupU 
 
FP1mupUDel 24 GGATCCCGTGAGCAGTGAGGTCGT 
 
Deletion of 
mupU 
RP1mupUDel 24 TCTAGAGCACACCTGCGCTAATGC 
FP2mupUDel 24 GCTCTAGACTTCAAGCGGCCTCGC 
RP2mupUDel 24 GCGAATTCCTCCACCTCACCCGAA 
 
 
mupU 
FPmupUConst 
                   ruction 
26 CGGGTACCGGTATGGCAAGGGAATGT  
Construction of 
mupU 
 
RPmupUConst 
                    ruction 
26 CGCAATTGGGCCGGTTCATGGGCCTG 
FPmupUInter 
                      nal 
36 GGATCCGTGCTCCGTTTTTCCTGGTAT 
CGATGAGCT 
 
Internal primers 
for checking of 
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RPmupUInter 
                      nal 
36 GAATTCATGTACCAACCGTCCTCTGTG 
AAGGCGTCG 
mupU sequence 
 
macpE 
 
FPmacpE 
     Construction 
26 CGATCGATCATCCACAGGAGGCGTAG  
 
Construction of 
macpE RPmacpE 
     Construction 
26 CGTCTAGATCACTGCTCACGTTGGGC 
macpE 
(-stop 
codon) 
FPmacpE 
     Construction 
29 CGATCGATCGGCATCCACAGGAGGCG 
TAG 
 
Construction of 
macpE (-stop 
codon) RPmacpE 
     Construction 
29 CGTCTAGACTGCTCACGTTGGGCGAAC 
CA 
 
Fused 
(mupU-
macpE) 
-stop 
codon 
FPACP7-mmpB 27 GGATCCCTGCTCGATGAGTTGGTGGCA  
 
 
Insertion of fused 
mupU-macpE 
into mmpB 
RPACP7-mmpB 27 GAATTCCAATGCCTCCAGGCTGACCAC 
FPTE-mmpB 27 TCTAGAGCCGAGCAGTTGCGCGCCTAT 
RPTE-mmpB 27 GAATTCCTCGAAAGCCACGCTGGCCCC 
 
Fused 
(mupU-
macpE) 
-stop 
codon 
FPACP4-mmpA 27 GGATCCCCCGCCGACGGCATTTATACC Insertion of fused 
mupU-macpE 
after ACP4 of 
mmpA 
 
RPACP4-mmpA 27 GAATTCCTACCGCTGCGCCAACACGTC 
FPACP4-mupB 27 TCTAGACAACCATGACTTTCAATGTCG 
RPACP4-mupB 27 GAATTCGAACCGGAAAGCTTCGTCTTC 
 
 
Any 
Cloned  
Gene(s) 
 
 
pJH10 pre 
EcoRI 
primer
*
 
 
22 CCGACATCATAACGGTTCTGGC  
Sequencing of 
pJH10 for any 
gene cloned into 
MCS EcoRI-SacI 
 
      
      ♦ The restriction sites are shown by red. 
     * Designed by Prof. C.M. Thomas 
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5.2.2 Oligonucleotide annealing 
    Purchased oligonuclotides from Alta Biosciences were dissolved in sterile distilled water 
to make up a concentration of 100 pmol/µl. A special PCR tube was used for mixing equal 
volumes (20µl or 25µl) of the two complementary oligonucleotides. The reaction was carried 
out in PCR machine, which was programmed for 10 min denaturation step at 98
o
C followed 
by ramp cooling to 25
o
C. 
  
       
Table 5.4 Oligonucleotides used in this study. 
Purpose 
Primer sequence, 5’→3’ 
 
Restriction 
sites 
 
 
 
To add 20aa 
Between fused 
mupU-macpE 
CGCTAGCCAATTGGGCGGCGGCAGCGGCGGCGGCAGCGGTAC
CGGCGGCGGCAGCGGCGGCGGCAGCGGCATCGATGCTAGCT 
 
 
 
KpnI 
NheI 
MfeI 
 ClaI 
XbaI 
CTAGAGCTAGCATCGATGCCGCTGCCGCCGCCGCTGCCGCCGC
CGGTACCGCTGCCGCCGCCGCTGCCGCCGCCCAATTGGCTAGC
GGTAC 
 
 
 
 
5.2.3 Construction of insertion mutant using suicide vector strategy 
    The strategy presented in Figure 5.3 illustrate the manner which was followed for the 
insertion of the fused mupU(-STC)-macpE(-STC) into the mup cluster in 
NCIMB10586∆mupU/∆macpE. The procedure started by designing two different sets of 
primers (Table 5.3) for the PCR amplification of two adjacent regions from the mup cluster 
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where the fused mupU/macpE planned to be inserted. These two regions were then ligated on 
either side of the fused mupU(-STC)-macpE(-STC) for the construction of the suicide vector 
pAKE604 (pAMK4 and pAMK6, respectively). E. coli S17-1 was then transformed with the 
suicide vector and the procedure described in Chapter 3 (Materials and Methods section 
3.2.7) was followed to mobilise the plasmid into NCIMB10586∆mupU/∆macpE by 
conjugation. Then the steps described in Chapter 4 (Materials and Methods section 4.2.8) 
were followed for the excision of the suicide vector, with the exception of using saline 
solution and L-agar instead of marine broth and agar, whenever required, in addition to the 
incubation of the plates at 30
o
C.        
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Figure 5.3 Strategy for the insertion of the fused mupU(-STC)---macpE(-STC) into the 
chromosome of P. fluorescens. 
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5.3 Results 
5.3.1 Construction of P. fluorescens strains with promoter upstream of 
mupU encoding the acyl CoA synthase involved in PA-A production 
    MupU is proposed to load PA-B or related substrate onto mAcpE as the first step in 
conversion to PA-A. It may therefore represent a rate limiting step in the production of PA-A 
so increasing the level of MupU relative to the other enzymes of the factory may help to 
reduce PA-B relative to PA-A. Since mupU appears to be far away from the second promoter 
in the mup operon a strategy was devised to create a promoter immediately upstream of 
mupU in order to increase the transcription of mupU and therefore level of MupU. This was 
proposed to reduce PA-B production and increase the production of PA-A, the major 
component and the most active mupirocin compound.   
    An existing SacII site that is flanked by two regions that were looking similar to -35 and -
10 regions respectively, has been used for joining them together after they had been improved 
and the distance between them reduced as well (Figure 5.4). The forward primer for the 
upstream region contained a BamHI restriction site, while the reverse primer of the 
downstream region contained an EcoRI restriction site. The PCR amplified products of the 
two regions (Material and Methods, Section 4.2.5) were each ligated into vector pGEM-T 
Easy (Table 5.2), separately, and the required changes within the two regions confirmed by 
DNA sequencing. These two regions inserted successfully in a single ligation reaction into 
the BamHI and EcoRI site of pAKE604 vector to create pAMK1 plasmid. Standard suicide 
vector strategy was followed for the construction of P. fluorescens with the new promoter 
upstream of mupU. PCR checking using external primers for the strains with the new 
promoter upstream mupU was not helpful as long as the changes were very specific and 
different from checking in-frame deletion. Therefore, PCR products out of the expected 
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isolates were gel purified and ligated into pGEM-T Easy vector for sequencing. Results out 
of sequencing confirmed two isolates as having the correct new promoter upstream of mupU 
perfectly. 
    Bioassay did show a reasonable increase in the production of mupirocin up to more than 
two fold by the strains with the new promoter (Figure 5.5 and 5.6, respectively) using B. 
subtilis 1604 as a sensitive organism and WT P. fluorescens as a control. This result confirms 
the significance of MupU in increasing the production of total mupirocin, however, it did not 
show whether there was a change in the ratio of PA-A to PA-B, which needed to be 
determined by HPLC analysis.   
 
 
 
 
 
 
 
 
  
Figure 5.4 Scheme showing the strategy for putting mupU under the control of a new 
promoter. The original DNA targeted sequence is shown in A, while the new promoter based 
on genetic manipulation is shown in B.  
A. Original sequence                                  
  mupT     →│                                    Deletion                                                                → mupU                                                                                                              
gtgcggtacgtgagcctgcttcgcctggcaccgcggctggcaatgtgcgtcttctatttttggtatggcaagggaatgtgagatggaacagtt 
 
B. Manipulated   
  mupT    →│                     -35   ←     17 nt       →   -10           tsp         rbs              → mupU  
gtgcggtacgtgagcctgcttcgcttgacaccgcggcaatgtgcgtctatcatttttggtatggcaagggaatgtgagatggaacagttgac 
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                   mupUp (1)                                   WT                                       mupUp (2)                    
                P. fluorescens                         P. fluorescens                          P. fluorescens                      
                              
 
Figure 5.5 Bioassay to determine the productivity of the isolates with a new promoter 
upstream of mupU relative to the WT. 
 
  
     
Figure 5.6 Quantitative bioassay of P. fluorescens isolates with a new promoter 
upstream of mupU in comparison to the WT using triplicate for each. 
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5.3.2 Quantitative analysis of PA-A and PA-B produced by strains with 
promoter upstream of mupU 
    HPLC analysis was performed to check whether over expression of mupU by isolates with 
a new promoter affects the yield of the different pseudomonic acids. According to our 
proposal for increasing the production of PA-A relative to PA-B we need more ACPs as well 
as more of the enzyme that transfers the intermediate to ACP. Therefore, as a first option to 
test this hypothesis, mupU was over-expressed via a new promoter inserted just upstream. 
WT P.fluorescens was used as control, also as 100% expression for both PA-A and PA-B. 
HPLC analysis (Figure 5.7) showed that over-expression of mupU did not abolish PA-B 
production. However, the production of PA-A (Figure 5.8) was increased by 3.1-fold in 
comparison to the wild type. 
    Quantitative HPLC analysis of isolates with the new promoter upstream of mupU showed 
an increase in the production of PA-A (Figure 5.9) by more than three fold in comparison to 
the wild type. Although of an increase in the production of PA-A by the new isolates, 
production of PA-B was not abolished, and even it increased by not less than two fold 
compare to the wild type PA-B. Barely, this might indicate that production of PA-B and PA-
A is concomitant. In addition, mass spectrometry analysis done in Bristol by Dr. Song, 
confirmed the production of more antibiotic (mupirocin) by isolates with the new promoter 
(Figure 5.10), in comparison to the WT, and about the same productivity of WT with in trans 
expression of mupR. Also, it did show an increase in the production of both PA-A and PA-B 
(Figure 5.11) to about 4 to 5 fold with the new isolates, but without a significant difference 
compare to those in the WT.  
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                                                                                                           Retention time (minutes)     
 
Figure 5.7 HPLC chromatograms of pseudomonic acids produced by P. fluorescens 
isolates with new promoter upstream of mupU, using WT strain as control.   
 
       
         
Figure 5.8 HPLC analysis of production of PA-A and PA-B by the WT P. fluorescens 
and strains with new promoter upstream of mupU. Samples were collected from 
cultures grown under similar conditions, and triplicates were used for each isolate.  
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Figure 5.9 Quantitative HPLC of PA-A and PA-B production by isolates with the new 
promoter upstream of mupU, in comparison to the WT strain of P.fluorescens. 
  
Figure 5.10 Diode array and LC-MS of mupirocin production by isolates of P. 
fluorescens with new promoter upstream of mupU (at the top), in comparison to the WT 
(bottom one) and WT with mupR (the transcriptional activator) expression in trans 
from pJH2 (pJH10) plasmid (in the middle). Analysis done by Dr. Song in Bristol.    
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Figure 5.11 Quantitative MS analysis of PA-A and PA-B production by isolates with the 
new promoter upstream of mupU, in comparison to the WT strain of P. fluorescens and 
WT with mupR provided in trans by pJH2 (pJH-mupR).  
 
 
5.3.3 Construction of  P.  fluorescens strain with ∆mupU and ∆macpE  
    Going back to our proposal that in order to increase the production of PA-A relative to 
PA-B, we need more ACPs as well as more of the enzyme that transfers the intermediate to 
ACP. Since the first attempt through increasing transcription of mupU (the acyl CoA 
synthase) gene did not have the desired effect of reducing PA-B production, it was decided to 
fuse mupU, and macpE to increase the efficiency of transfer. To test the function of such a 
hybrid, a double deletion strain was needed. NCIMB10586∆macpE was used for adding an 
in-frame deletion of mupU as well. To do so, two regions, upstream and downstream of 
mupU were PCR amplified using specific primers designed for that purpose. The forward 
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primer of the upstream arm and the reverse primer of the downstream arm contained BamHI, 
and EcoRI restriction endonuclease sites, respectively. However, both the reverse primer of 
the upstream arm, and the forward primer of the downstream arm contained an XbaI 
restriction endonuclease site. Both of those two arms were ligated into pGEM-T Easy vector 
(Table 5.2), separately, and the arms that did not show any mismatches from the DNA 
sequencing, were selected and inserted into the BamHI-EcoRI site of the suicide (pAKE604) 
vector to create pAMK2 vector. This new pAMK2 plasmid was used in the standard way to 
create strains with both ∆macpE and the additional in-frame deletion of mupU which was 
confirmed as successful by PCR, and designated as NCIMB10586∆mupU/∆macpE.     
    This new strain was used for both in trans expression of fused mupU(-STC)--
macpE(+STC) while looking for complementation study and atomic level surgery to insert 
fused mupU(-STC)--macpE(-STC) into different locations within the mupirocin gene cluster, 
described subsequently in this Chapter. 
 
5.3.4 Construction of a mupU-macpE expression plasmid   
    For expression of fused mupU-macpE in trans in NCIMB10586∆mupU/∆macpE, pAMH3 
plasmid was constructed (Figure 5.12). To create this plasmid, the oligonucleotide linker with 
20 amino acids shown in Table 5.4 was first inserted into KpnI-XbaI sites of pJH10 vector 
under the control of tac promoter, and the insertion confirmed by different digestion like, 
KpnI-MfeI, KpnI-XbaI, and ClaI-XbaI.  
    In order to create a fusion of mupU and macpE, the stop codon was removed from the 
mupU gene, and both of mupU and macpE were amplified by PCR using specific primers, 
which were then ligated into pGEM-T Easy vector for DNA sequencing (Table 5.2). 
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However, it should be mentioned that internal primers (Table 5.3) were used for further DNA 
sequencing of mupU because it has a long sequence (1.6 kb). PCR amplified mupU and 
macpE genes which were confirmed as not having any mismatches were cloned into EcoRI-
MfeI and ClaI-XbaI sites of the pJH10 vector with the oligonucleotide linker, respectively, 
creating pAMH3 plasmid, so that the orfs would be joined by the short orf encoded in the 
linker. Moreover, the reason for using this linker was to leave enough space to achieve the 
proper folding of fused proteins and to get translated into a functional polypeptide.      
 
5.3.5 Complementation analysis of mupU and macpE expressed from    
pAMH3 plasmid 
    Plate bioassay was used to check the expression and function of the fused mupU-macpE 
downstream from tac promoter. Plasmid pAMH3 carrying the fused mupU-macpE genes, 
was transferred to NCIMB10586∆mupU/∆macpE by bacterial conjugation. The inhibitory 
(clearance) zone around the spot of bacterial culture under investigation was used as an 
estimate of antibacterial activity against sensitive bacteria. Plates of L-agar, without induction 
as well as with 0.5 mM IPTG induction were used for performing the bioassay. The bioassay 
result showed that the fused genes were expressed from pAMH3 plasmid and were 
functional, and antibiotic production was restored in NCIMB10586∆mupU/∆macpE even 
without IPTG (Figure 5.13). Induction with 0.5 mM IPTG was found to improve antibiotic 
production significantly by about 15 %. However, induction with 0.5 mM IPTG decreased 
the antibiotic production (Figure 5.14) in NCIMB10586∆mupU/∆macpE, in the presence of 
empty pJH10 vector.   
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                     WT                   WT + pJH10              
       
     NCIMB10586∆macpE     ∆macpE + pJH10 
      
          
          ∆mupU/∆macpE          ∆U/∆E+ pJH10          ∆U/∆E+ pAMH3  
    
Figure 5.13 Bioassay to determine complementation of NCIMB10586∆mupU/∆macpE 
by the in trans expression of fused mupU/macpE genes from pAMH3 plasmid without 
IPTG.   
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Figure 5.14 Quantitative bioassay of NCIMB10586∆mupU/∆macpE strain expressing 
fused mupU/macpE in trans from pAMH3 plasmid in comparison to the wild type (WT) 
performed with and without 0.5 mM IPTG and with triplicates. 
 
5.3.6 Quantitative analysis of PA-A and PA-B produced by 
NCIMB10586∆mupU/∆macpE expressing fused mupU/macpE 
    More precise data about complementation of NCIMB10586∆mupU/∆macpE strain 
expressing fused mupU(-STC)-macpE from pAMH3 plasmid obtained via HPLC analysis. 
According to our hypothesis that MupU and mAcpE are working in succession, therefore, 
expression of fused mupU(-STC)-macpE in trans from pAMH3 plasmid should complement 
the strain with deletion in those two genes. HPLC chromatograms showed that without IPTG 
induction either there was about 50% PA-A, or much less compare to PA-B. However, full 
complementation and even production of a little more of both PA-A and PA-B was observed  
0 
20 
40 
60 
80 
100 
120 
wt Wt 
+pJH10 
 
∆E  ∆E 
+pJH10 
 
 ∆U-∆E ∆U-∆E 
+pAMH3 
 
∆U-∆E 
+pJH10 
 
A
re
a 
o
f 
in
h
ib
it
io
n
 a
s 
%
 o
f 
W
.T
. 
-IPTG 0.5 mM IPTG 
191 
 
   
           
     
                                                                                                         Retention time (minutes)                 
Figure 5.15 HPLC chromatograms of NCIMB10586∆mupU/∆macpE strain with 
pAMH3 plasmid expressed in trans. NCIMB10586 WT, NCIMB10586∆macpE, and 
NCIMB10586∆mupU/∆macpE strains with and without pJH10 are taken as controls.   
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compared to the wild type when the tac promoter induced with 0.5 mM IPTG (Figures 5.15, 
5.16, and 5.17). This might indicate that MupU and mAcpE are playing their role 
successively, and are able to work together when they get fused and translated into a single 
polypeptide. 
 
 
 
Figure 5.16 HPLC analysis of PA-A and PA-B production by the wild type strain of P. 
fluorescens, and strain of NCIMB10586∆mupU/∆macpE complemented through in trans 
expression of fused mupU/macpE by pAMH3. Triplicate samples were collected from 
induced cultures grown under similar conditions.   
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Figure 5.17 Quantitative HPLC of PA-A and PA-B production by 
NCIMB10586∆mupU/∆macpE strain, complemented through in trans expression of 
fused mupU/macpE from pAMH3, in comparison to the wild type strain with IPTG 
induction. 
 
5.3.7 Bioassay and HPLC analysis of NCIMB10586∆mupU/∆macpE strain 
with fused mupU/macpE insertion either after ACP7(Bc) of mmpB or after 
ACP4(A3b) of mmpA  
    Because we had been able to demonstrate that a fusion protein of MupU-mAcpE can 
complement NCIMB10586∆mupU/∆macpE strain through in trans expression of the fused 
mupU(-STC)-macpE, this added extra supportive evidence for the proposed role of MupU 
and mAcpE in the conversion of PA-B to PA-A. Also, the absence of an macpE homologue 
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in thiomarinol gene cluster and the presence of extra KS and ACP in TmpB (Figure 5.2b) 
before the TE domain, suggested that this extra non-elongating module could be responsible 
for all the late tailoring steps (Fukuda et al., 2011) in thiomarinol, just as mAcpE is 
implicated in during the production of mupirocin (Cooper et al., 2005a). In addition, results 
in Chapter 4 of this thesis demonstrated the probable role of this extra module in the removal 
of C8-OH group, and the release of thiomarinol PA-B analogue (HT-G or C and TH-H). 
Therefore, and as a third attempt to reduce PA-B, and to increase PA-A the highest level, we 
have planned to insert the fused mupU(-STC)-macpE(-STC) into mmpB in the linker region 
between ACP7 and the TE domain. This insertion might fit with the suggestion that both the 
C9 and C8 fatty acid side chains in mupirocin and thiomarinol respectively, seems to be built 
up on a PKS derived (monic acid and marinolic acid)  part by a successive elongations, rather 
than by the ligation of the fully assembled hydroxy acids (Murphy et al., 2011). However, the 
second insertion of the fused mupU(-STC)-macpE(-STC) was planned to be inserted before 
the stop codon of ACP4 of mmpA, which fits with the idea that monic acid in mupirocin 
might get loaded onto mAcpE first.      
    To create the suicide vectors for both of the two insertions, and to be certain that the fused 
mupU/macpE is going to be included and translated as a single functional polypeptide in each 
insertion, new primers were used for the PCR amplification of macpE without the stop codon 
as long as we had mupU(-STC). Those two genes were inserted into ClaI-XbaI and EcoRI-
MfeI of the pAMH1 (pJH10 plasmid with a 20 aa linker) plasmid, respectively, creating 
pAMH2-b and pAMH4 plasmids (Table 5.2). Upstream and downstream arms for both of the 
two insertions were amplified by PCR using specific primers designed for that purpose. The 
upstream arms (ACP7-linker, and ACP4, respectively) both had BamHI-EcoRI restriction 
sites and were cloned into pAMH4 plasmid separately using same restriction site to create 
pAMH5 and pAMH6 plasmids, respectively. However, downstream arms (linker-TE, and 
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mupB, respectively) contained XbaI-EcoRI restriction sites and were inserted into same 
restriction site in pAKE604 vector (Figure 5.18) separately to create pAMK3 and pAMK5, 
respectively. Then both pAMH5 and pAMH6 plasmids were digested with BamHI-XbaI 
restriction endonuclease to release the upstream arm, and fused with mupU(-STC)-macpE(-
STC) and ligated into pAMK3 and pAMK5 plasmids to create the final suicide vectors 
pAMK4 and pAMK6, respectively. However, it should be mentioned that all the PCR 
amplified genes were sequenced using pGEM-T Easy vector, labelled pAMG, which 
followed by a letter as a symbol for the gene (Table 5.2).  
 
                               
Figure 5.18 Plasmid pAKE604 that was used to create the suicide vectors pAMK4, and 
pAMK6, that were used for insertion mutation in the mupirocin cluster (El-Sayed et al., 
2001). 
   
    Plasmid pAMK4 was used as a suicide vector for the insertion of the fused mupU(-STC) –
macpE(-STC) into mmpB of NCIMB10586∆mupU∆macpE, and pAMK6 was used similarly 
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for the insertion after ACP4 of mmpA of the same NCIMB10586∆mupU/∆macpE strain. 
Selected bacterial isolates were tested by PCR to confirm the insertion of the fused mupU(-
STC)-macpE(-STC) into mupirocin genes cluster. Two mutants were obtained for each type 
insertion. The insertion into mmpB was in the linker region between ACP7 and TE. The 
mupU and macpE orfs had been joined by the short orf of linker and were kept in frame with 
the orf in mmpB so that they would get translated into a single functional polypeptide. 
However, it was discovered that the other insertion was after the stop codon of ACP4 of 
mmpA, which means it was not included into mmpA, and this was a mistake which would 
need to be rectified if there was more time.                                                   
                                                                                
                                        WT                           ∆mupU/∆macpE                                   
                              
                                                   ∆mupU/∆macpE                               
 
                                  + fused mupU (-STC)-macpE (-STC) inserted 
                                 After ACP4 of mmpA                  into mmpB 
                             
Figure 5.19 Bioassay to determine the effect of fused mupU(-STC)-macpE(-STC) 
insertion into either mmpB or after ACP4 of mmpA of NCIMB10586∆mupU/∆macpE 
using WT NCIMB10586 and NCIMB10586∆mupU/∆macpE strains as controls.   
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    Bioassay results did not show a significant difference between the 
NCIMB10586∆mupU/∆macpE strain and derivatives with fused mupU(-STC)-macpE(-STC) 
inserted into either mmpB or after mmpA with regard to the production of biologically active 
product (Figure 5.19 and 5.20). Moreover, the percent production was about 1/3 of the WT 
NCIMB10586. Therefore, this means that we did not achieve complementation, and this 
might be due to improper folding of the fused proteins in MmpB. However, the case is 
different with the second insertion as long as the insertion was not included into mmpA.   
    HPLC analysis (Figure 5.21) showed the production of PA-B by mutant strains with fused 
mupU(-STC)-macpE(-STC) inserted after ACP4 of mmpA, which was similar to the original 
NCIMB10586∆mupU/∆macpE. However, there was no clear cut evidence of a peak related to 
any biological compounds (PA-A or PA-B) with the insertion of the same fused genes into 
mmpB. Further mass spectrometry analysis confirmed HPLC results.    
 
Figure 5.20 Quantitative bioassay of NCIMB10586∆mupU/∆macpE with fused mupU(-
STC)-macpE(-STC) inserted into either mmpB or after ACP4 of mmpA using WT 
NCIMB10586 and NCIMB10586∆mupU/∆macpE strains as controls. Data was collected 
from more than triplicate samples.   
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Figure 5.21 HPLC chromatograms of NCIMB10586∆mupU/∆macpE with fused mupU(-
STC)-macpE(-STC) inserted into either mmpB or after mmpA using WT NCIMB10586 
and NCIMB10586∆mupU/∆macpE strains as controls.   
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5.4 Discussion  
    The idea of attempting to decrease the production of PA-B, as a minor product of 
mupirocin started when Cooper et al., (2005b) showed that in-frame deletion of mupO, 
mupU, mupV and macpE abolished PA-A production, which means they are essential for PA-
A. Also that two additional genes, mupC and mupF were proposed to be implicated in the 
conversion of PAB to PA-A (Hothersall et al., 2007). In this study we used three strategies 
for reaching that purpose. The first was to investigate the effect of increasing the expression 
of mupU, the gene that is proposed to be involved in the transfer of the intermediate to 
mAcpE, on the production of PA-A, through putting a new promoter upstream mupU . The 
second was to test the capability of over-expression of fused mupU(-STC)-macpE in trans in 
NCIMB10586∆mupU/∆macpE strain to complement the double deletion, and to divert the 
production away from PA-B in favour of PA-A. The third was to construct something like in 
TmpB (Figure 2b) of the thiomarinol cluster by inserting fused mupU(-STC)-macpE(-STC) 
into mmpB of NCIMB10586∆mupU/∆macpE strain once, and after ACP4 of mmpA as a 
second to reduce PA-B, which in turn should increase PA-A to the highest level. 
    Genetically manipulated strains of P. fluorescens with a new promoter upstream mupU 
were constructed successfully, and the effect on the production of pseudomonic acids was 
determined using HPLC analysis. While constructing these strains, all the positions within the 
consensus sequence (-35 region, spacer 17 nucleotide, and -10 region) were conserved. In 
addition, the transcriptional start point was kept as typical as possible within 7 bases 
downstream the -10 region of the promoter, and the natural RBS of mupU was conserved 
before the start codon in order to create the optimum conditions for translation. Results of 
bioassay showed a significant increase in the production of mupirocin up to more than two 
fold compare to the wild type strain. This increase in the production of mupirocin might be 
200 
 
due to increased expression of all the other genes downstream mupU as well. Therefore, this 
might be due to not only the role of MupU, but also it might be due to the role of other 
proteins including MupV, and MupR (the transcriptional activator). This is consistent with 
both Macioszek’s observation while over-expressing mupV in trans ((Macioszek, PhD thesis, 
University of Birmingham, 2009), and over-expression of mupR in trans (Hothersall et al., 
2011) in the WT NCIMB10586.            
     HPLC and LC-MS analysis showed that genetically improved strains did not abolish PA-
B production as predicted by our hypothesis. Even though, both PA-A and PA-B was 
increasing up to more than three fold in comparison to the WT NCIMB10586, and 
approximately the same productivity of WT strain expressing mupR in trans. Therefore, 
although this result represents a new approach to increase the production of total antibiotic, it 
does not provide a practical way to shutt down PA-B pathway. This result is consistent with 
the result of over expression of mupO/macpE/U/V/C/F in trans in the wild type of mupirocin 
producer (Macioszek, PhD thesis, University of Birmingham, 2009). One possible 
explanation for the inability to shut down the PA-B pathway by this approach might be due to 
the level of other rate-limiting proteins implicated in PA-A production. For example mAcpE, 
which receives the intermediates from MupU, that needs to be processed further by 
MupO/V/C/F for the production of PA-A. Therefore, in the availability of more MupU, there 
might be less mAcpE, which means less processing of the intermediate, and ultimately less 
conversion of PA-B to PA-A. This is consistent with the concept that to increase the flux 
from PA-B to PA-A, we need more ACP (represented by mAcpE) and the enzyme (MupU) 
essential to transfer the intermediates onto the ACP.                        
    To over express the fused mupU(-STC)-macpE in trans and to determine the influence on 
the level of pseudomonic acids by HPLC, both mupU(-STC) and macpE were fused together 
by a short orf encoded by a 20 aa linker while keeping their RBS intact with a successful 
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cloning into pAMH3 plasmid. Data from the bioassay of over-expression of fused mupU(-
STC)-macpE in trans from the tac promoter of pAMH3 plasmid showed that 
NCIMB10586∆mupU/∆macpE strain restored antibiotic production even without induction. 
However, full complementation and production of antibiotic to the wild type level were 
observed when 0.5 mM IPTG was used for induction. This results indicate that MupU, and 
mAcpE were able to complement NCIMB10586∆mupU/∆macpE strain when they were 
translated as a single functional polypeptide.  
    More precisely, HPLC analysis of in trans expression of fused mupU(-STC)-macpE from 
pAMH3 plasmid in NCIMB10586∆mupU/∆macpE strain showed production of both PA-A 
and PA-B either in similar quantities or very less PA-A without induction. Surprisingly, a 
smaller increase in the production of both PA-A and PA-B than the wild type level was 
observed while 0.5 mM IPTG used for the induction of tac promoter. The inability to achieve 
full complementation of NCIMB10586∆mupU/∆macpE strain and the production of PA-A as 
a major product without induction, might have been due to insufficient fused MupU, and 
mAcpE. However, although full complementation of the NCIMB10586∆mupU/∆macpE 
strain was achieved while over-expressing fused mupU(-STC)-macpE in trans, it does not 
provide a way to abolish PA-B. Presumably, this might have been due to the in trans 
expression of fused mupU(-STC)-macpE, which makes some difference if they are expressed 
in cis with the whole biosynthetic gene cluster. Therefore, it might be that there is inevitable 
release of a small amount of PA-B until the fused MupU/mAcpE starts playing its role in the 
biosynthetic pathway. 
    Atomic level surgery followed through inserting the fused mupU(-STC)-macpE(-STC) into 
mmpB of NCIMB10586∆mupU/∆macpE strain and exactly in the linker region between 
ACP7 and the thioesterase (TE). This is to test the expected position where MupU and 
mAcpE are proposed to work in the mupirocin system during the biosynthesis pathway, and 
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makes something similar to the KS
°
-ACP
° 
(2
nd
 TmpB module) in the thiomarinol system. 
Also it was proposed that this might shut down PA-B and divert the pathway to the major 
compound PA-A, as in the case of thiomarinol normally there is a release of a very tiny 
amount of PA-B analogue (TH-G). Concomitantly, fused mupU(-STC)-macpE(-STC) 
proposed to be inserted before the stop codon of ACP4 in mmpA of 
NCIMB10586∆mupU/∆macpE, as it was expected that the MA (PKS part) of mupirocin 
might be loaded onto mAcpE by MupU before the esterification with 9-HN, the fatty acid 
side chain of mupirocin. Unfortunately, the fused genes were inserted after the stop codon of 
ACP4, which means it was not included in mmpA. Bioassay result of mutants with the 
insertions did not show either complementation of NCIMB10586∆mupU/∆macpE strain by 
production of PA-A, or a remarkable increase in the biological activity compare to 
NCIMB10586∆mupU/∆macpE strain in either case against the sensitive bacteria tested. 
HPLC analysis confirmed production of PA-B, quite similar to the 
NCIMB10586∆mupU/∆macpE strain for the insertion after mmpA, indicate that the inserted 
genes are not interfering with the biosynthetic pathway in a major way. However, and 
surprisingly, no detectable compound was observed in mutants with the insertion of the fused 
genes in mmpB. This may indicate that MupU and mAcpE are normally not acting in the 
biosynthesis of mupirocin in this position, therefore, the whole biosynthesis blocked, or it 
might be simply be due to the disruption of the region between ACP7 and TE, that affects the 
action MmpB. However, we wanted to prevent disrupting the linker that join ACP7 to TE in 
mmpB, which consists of 160 amino acids by inserting the fused mupU(-STC)-macpE(-STC) 
in the middle of that linker while keeping the genetic codes conserved, and to keep both 
ACP7 and TE apart from the inserted genes. This result is consistent with the observation 
made by Tran et al., (2008), that there is no sequence conservation of the linker between 
ACP6 and TE in the DEBS system. However, it appears as if the amino acid sequence of the 
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linkers keeps the domains apart yet permits them moving about relative to each other, as they 
confer a degree of stiffness (Weissman, 2004).  
    Kira Weissman (Nancy University), Peter Leadlay (Cambridge University) and their 
colleagues suggested that the TE interacts more significantly with the ACP’s attached acyl 
moiety than the ACP itself, rather than the idea that phosphopantetheinylation and/or 
acylation makes some structural changes to the ACP that promotes its binding to TE (Tran et 
al., 2008). They also reported that DEBS TE interacts with the ACP in the erythromycin 
system through covalent linkage, and that both the transfer and the release of the chain will 
occur ideally if the proper architectural relationship is maintained and the substrate on the 
ACP contains suitable recognition features for the TE. Therefore, it might be that the mAcpE 
attached acyl group was facing the TE in case of mutants with fused mupU(-STC)-macpE(-
STC) insertion into mmpB before its loading onto MupV/C/F for the production of PA-A, and 
that the TE was not able to recognise the mAcpE’s attached acyl group in order to release it. 
Moreover, it is principally agreed that engineering experiments including altering domains 
(deletions, additions, and swaps) that alter the enzyme organization might translate into a 
predictable change in the structure of the polyketide. However, many of these experiments 
are not successful in giving the expected polyketides, and the yields are often too low even if 
they can be made, that are not useful for large scale production (drug synthesis), and trials to 
trace the problems are usually difficult (Weissman, 2004).       
    We have demonstrated that genetically manipulated strains of P. fluorescens with a new 
promoter upstream of mupU could have a very strong effect on increasing the production of 
total antibiotic, but not diverting one compound (PA-B) in favour of the other (PA-A). This 
might be due to the imbalance of the level of different proteins essential for a specific 
pathway (PA-A). Over-expression of fused mupU/macpE, the two important factors in PA-A 
production were able to restore antibiotic production in the mutant 
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NCIMB10586∆mupU/∆macpE when they were translated into a single polypeptide but they 
were unable to abolish the PA-B pathway by increasing the flux of the intermediates. This 
also might be due to low level of other rate limiting enzymes essential for PA-A production 
as long as it appears like normally Mup proteins are expressed at low levels. Genetically 
engineered NCIMB10586∆mupU/∆macpE with mupU/macpE fused into mmpB did not 
complement the deleted genes, which indicates that they are unable to act in that position. 
However, it might be a good idea of splicing the KS˚-ACP˚ and the TE from TmpB in 
thiomarinol with the tandem ACP of MmpB instead of the TE in mupirocin, which might be 
helpful to switch on the whole mupirocin biosynthesis into PA-A.     
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CHAPTER 6 
ATTEMPTS TO TRANSFER THIOMARINOL 
PRODUCTION PLASMID pTML1 TO INVESTIGATE 
EXPRESSION AND REGULATION OF THE 
BIOSYNTHETIC GENES   
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6.1 Introduction 
     Understanding the mechanisms or the aspects of the genetic regulation of antibiotic 
production by the bacteria that produce them will open a strong and rapid way of improving 
strains with higher productivity. In addition, it will facilitate both combinatorial biosynthesis 
and synthesis of novel compounds that are needed to overcome the critical problem of 
antibiotic resistance. Thiomarinol, the naturally hybrid antibiotic that we are working on, is 
encoded by a novel 97 kb circular plasmid designated pTML1, and is made up of two parts, 
the pyrrothine (holomycin) part of a dithiolopyrrolone class of antibiotic attached to 8-
hydroxyoctanoic acid side-chain, the mupirocin like component termed marinolic acid, via an 
amide linkage  (Fukuda et al., 2011). Although it is known that the biosynthesis of mupirocin 
is regulated via a quorum-sensing dependent system it is still not known how thiomarinol 
biosynthesis is regulated. Nevertheless, data in Chapter two of this thesis showed that the 
thiomarinol gene cluster appears to be regulated so as to give expression in late exponential 
or early stationary phase, and it would not make sense for genes to be on a plasmid and able 
to move between bacteria if they could not carry their regulatory system with them. 
Therefore, the hypothesis is to transfer pTML1 to a new host to see if the genes are expressed 
and can be regulated in the same way, or whether it needs one or more chromosomal genes 
from Pseudoalteromonas spp. SANK 73390 to allow activation and expression.  
     Different approaches have been used to determine the mechanism by which the regulatory 
system exerts global control over antibiotic gene expression. For example, AbrB protein, the 
repressor that is produced by Bacillus subtilis, was confirmed by gel mobility shift 
experiments to bind to the regulatory region for tyrocidine synthetase I of the tryrocidine 
biosynthetic pathway in Bacillus brevis (Robertson et al., 1989). Using quantitative real-time 
PCR for the number of transcripts, both in-frame deletion and insertion of a terminator 
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cassette into the biosynthetic gene cluster of novobiocin confirmed transcriptional regulation 
to be governed by two regulatory genes, novE and novG, which act in a cascade-like 
mechanism (Dangel et al., 2009). Although Geistlich et al., (1992) identified srmR (srm22) as 
a regulatory gene for the biosynthesis of spiramycin in Streptomyces ambofaciens, Karray et 
al., (2010) identified srm40 as being a pathway-specific activator that depends on srm22 for 
its expression using reverse transcription-PCR (RT-PCR) analysis for genes in the wild type 
and deletion mutants. Moreover, the aur1P gene upstream of the biosynthetic gene cluster of 
the polyketide auricin was identified as an essential gene that produces Aur1P regulator that 
activates expression of all the genes included in the auricin biosynthetic gene cluster 
(Novakova et al., 2005). In Streptomyces coelicolor, the producer of four genetically and 
structurally different antibiotics, AbsB protein (an RNase III homologue) was identified as 
having a role in stabilizing the pathway-specific transcription regulator (Price et al., 1999). 
However, the pathway specific regulator within each antibiotic cluster that is designated as a 
cluster situated regulator (CSRS) is found to have pleiotropic actions (cross-regulation) via 
controlling other antibiotic biosynthetic gene clusters in Streptomyces coelicolor, and the 
cross regulation activity is demonstrated to be modulated globally and differentially during 
the growth cycle by the RNase III homologue AbsB (Huang et al., 2005). 
     Heterologous expression of a cosmid carrying the entire gene cluster of medermycin from 
Streptomyces sp. AM-7161 in Streptomyces coelicolor CH999 was successful in proving the 
completeness of the clone (Ichinose et al., 2003). Two overlapping cosmids of Streptomyces 
clavuligerus, producer of a dithiolopyrrolone antibiotic, holomycin, was constructed using an 
integrative Streptomyces-E.coli shuttle vector, induced the production of holomycin when 
heterologously expressed in Streptomyces albus (Huang et al., 2011).   
    El-sayed et al., (2001) identified MupR, the transcriptional activator, and MupI the AHL 
producer in the soil gram-negative bacteria Pseudomonas fluorescens NCIMB 10856, as two 
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regulatory proteins regulating mupirocin production via quorum-sensing regulation. 
Surprisingly, production of AHLs signals, the quorum-sensing communication in marine 
snow bacteria such as Roseobacter spp. was reported for the first time by Gram et al., (2002) 
using well diffusion and thin-layer chromatography (TLC) assays, and it was found that 
AHLs are likely to govern a variety of phenotypic traits including antibiotic production. 
    Production of lankacidin and lankamycin, antibiotics encoded on a giant linear plasmid 
pSLA2-L, and morphological differentiation in Streptomyces rochei were found to be under 
the control of complex regulatory (γ-butyrolactone receptor) system including four different 
genes (Arakawa et al., 2007). Therefore, the purpose of this study is to identify how the 
thiomarinol system is regulated via capturing and mobilising pTML1 out of 
Pseudoalteromonas spp SANK 73390 to heterologous host. Three different strategies have 
been followed using different suicide vectors constructed according their ability to recombine 
with pTML1, and based on carrying a piece of DNA from pTML1 that is outside the 
thiomarinol biosynthetic gene cluster and not essential for replication or stability. One such 
strategy provided evidence of successful integration into pTML1 although we were not 
successful in recovering the hybrid in E.coli.  
    We have found that it is essential to give a brief description about the original plasmids 
that have been used for the construction of the suicide vectors during different strategies of 
this study. RK2 plasmid (Figure 6.1), a 60 kb broad-host-range replicon of the IncPα 
incompatibility group (Chikami et al., 1985), is not distinguishable from other isolates R18, 
R68, RP1 and RP4 of the same plasmid (Pansegrau et al., 1994). This plasmid was identified  
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Figure 6.1 Map of broad-host-range plasmid RK2 showing regions responsible for 
replication, partitioning and stable maintenance of the plasmid. (Top) Central control 
region of RK2. Genes korA and korB are encode repressor genes marked with arrows; incC1 
and kfrA are regulatory genes. (Right) Structure of RK2’s origin (oriV) containing motifs 
required for replication: four DnaA boxes (depicted in light grey) where host DnaA protein 
binds during replication initiation; eight repeated iteron sequences (dark grey), binding sites 
for RK2 initiator protein TrfA. (Bottom) Genes encoding replication proteins (trfA, ssb) and 
the gene for the global regulatory protein (trbA) (from Kolatka et al., 2010).    
 
originally as an agent conferring resistance to ampicillin, kanamycin and tetracycline (Meyer 
and Helinski, 1977) to the clinical isolates like Klebsiella sp. and Pseudomonas sp. isolated 
from burn patients in Birmingham Accident Hospital (Lowbury et al., 1969). RK2 plasmid 
replicates in Escherichia coli at a low number of four to eight copies per chromosome (Kues 
and StahI, 1989; Thomas and Helinski, 1989). Owing to the ability of RK2 to transfer by 
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conjugation, and its stable maintenance in almost all gram-negative bacteria (Thomas and 
Smith, 1987), with the exception of Bacterioides and Myxococcus (Thomas and Helinski, 
1989), it becomes an ideal vector for genetic manipulations in diverse bacterial species 
(Thomas and Smith, 1987). Different regions have been identified within the RK2 genome in 
addition to the antibiotic resistance genes, including oriV as a region for vegetative 
replication, the trfA gene encoding a replication initiation protein, (oriT, tra) as two regions 
for conjugal transfer, (mrs/psk) as an encoding region for both multimer resolution system 
and post-segregational killing function, respectively, and ccr (central control region), 
consisting of a region combining partitioning function with a region encoding for its 
regulation as well (from Kolatka, et al., 2010).  
      
Figure 6.2 Map of the antibiotic resistance plasmid R6K illustrating the 3 origins of 
DNA replication α, β, and γ, respectively. The asymmetric terminus of replication defined 
as ter. Essential restriction sites are indicated. 11.05 kb pRK353, is a self-replicating 
derivative of R6K. (from Stalker et al., 1982).    
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    R6K, a 39.9 kb (Figure 6.2) self-transmissible plasmid (Rakowski and Filutowicz, 2013) 
that occurs naturally in E.coli has a high copy number and specifies resistance to both 
ampicillin and streptomycin (Kolter and Helinski, 1978b) with a relaxed mode of replication 
(Kontomichalou et al., 1970). Three distinct origins, designated α, β, and γ, have been 
identified in vitro as regions from which initiation of DNA replication starts (Kolter and 
Helinski, 1978a; Crosa, 1980). However, smaller derivatives of R6K have been constructed, 
including pRK353, which identified a 2.5 kb segment of the plasmid DNA that provides 
sufficient information for autonomous replication in E.coli (Kolter and Helinski, 1978b). 
Further investigation confirmed this segment as a piece of DNA that contains both the γ-
origin of DNA replication and a structural gene (pir) that codes for the π- protein, that is 
essential for the initiation of DNA replication of R6K in vitro (Inuzuka and Helinski, 1978).  
    P15A plasmid is one of the smallest known naturally occurring replicons, which is able to 
replicate autonomously derived from E. coli 15 (Cozzarelli et al., 1968). Since P15A 
replication system was found to be a reasonable source for the construction of a variety of 
special-purpose plasmid cloning vehicles, a series of cloning vehicles derived from P15A 
have been constructed (Chang and Cohen, 1978). Construction of those plasmids including 
pACYC184 (Figure 6.3) carried out through attaching chloramphenicol and tetracycline as 
selectable “marker” genes to P15A, and those assayable genes contained cleavage sites for a 
number of commonly employed site-specific endonucleases. The ability of pACYC184 as an 
amplifiable, multicopy DNA cloning vehicle to co-exist compatibly with plasmids derived 
from ColE1 in the same bacterial cells, in addition to several other properties, makes it useful 
as a general and special-purpose cloning vehicle. The complete nucleotide sequence of 
pACYC184 has been reported by Rose, (1988) as 4245 bp nucleotide in length. However, 
Mok et al., (1991) discovered that the recognition site of the restriction endonuclease BsiYI 
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that recognizes 5' CCNNNNNNNGG 3' was wrongly sequenced in P15A, pACYC177, and 
pACYC184, respectively.  
     
Figure 6.3 Map of pACYC184 cloning vehicle. pACYC184 is an E.coli 15 plasmid cloning 
vector with a low copy number at about 15 copies per cell. Restriction enzymes are 
designated. pACYC184 includes a tetracycline resistance gene (Tc
R
), a chloramphenicol 
resistance gene (Cm
R
) and a P15A origion of replication (ori). (Figure from NEB; snapgene, 
and Chang and Cohen, 1978).  
    In this study, we used three different strategies for the purpose that has been mentioned 
earlier, and pACYC184 was really successful as a cloning vehicle for cloning DNA 
fragments whenever required. A suicide RK2 vector that depends on oriVRK2 and consisting 
of a piece of DNA from pTML1 outside the thiomarinol biosynthetic gene cluster has been 
used in the first strategy. The oriVRK2 in the first suicide vector has been replaced by the R6K 
replicon using R6K derivative pRK353 as a source of R6K replicon, and the constructed 
suicide vectors was used in the second strategy. In the third strategy, a suicide RK2 plasmid 
only with R6K γ-ori which was incapable of autonomous replication and required 
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chromosomal expression of π-protein was constructed in E. coli strains ECF529 and ECF530, 
respectively, and was successfully integrating into pTML1, but not successful in moving it 
outside Pseudoalteromonas spp SANK 73390.    
 
6.2 Materials and Methods 
6.2.1 Bacterial strains  
       In addition to E.coli DH5α that has been described in Chapter 3, all the other strains used 
during this study are listed in Table 6.1.  
 
6.2.2 Growth media and culture conditions 
       Media used were L-broth (LB) and L-agar for the growth of E.coli strains, M-agar and 
broth described in Chapter 4 used for the growth of Pseudoalteromonas spp. SANK 73390. 
These media were supplemented with antibiotics as listed in Table 6.2 whenever required. In 
addition, media were supplemented with 0.05% and 0.2% L-arabinose to induce π protein 
production under the control of PBAD promoter in ECF529 and ECF530 strains with the pir 
gene in the chromosome. However, when those two strains were transformed with ligation 
reactions, transformants were incubated in LB with 0.005% arabinose for 1 hour before 
plating (Bowers et al., 2004). M9 Histidine medium was used for the growth of C2110 
(PolAI
ˉ
), and M9 Casamino acids medium (Kahn et al., 1979) was used for the growth of 
MV10 whenever carrying plasmids with trpE
+
. The procedure described in section 4.2.8 (the 
conjugation part) of Chapter 4 was used for conjugation with Pseudoalteromonas spp. SANK 
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73390 whenever required. E.coli strains were grown at 37
o
C, while strains of 
Pseudoalteromonas spp. SANK 73390 were grown at 23
o
C.  
Table 6.1 Bacterial strains used during this study. 
Bacterial strain Genotype Reference 
Escherichia coli C600 F
ˉ 
tonA21 thi-1 thr-1 leuB6 lacY1 glnV44 rfbC1  
fhuA1 λˉ 
Bachmann, 
1987 
Escherichia coli K12 
(MV10) 
C600 ∆trpE5 Hershfield et 
al., 1974 
Escherichia coli C2110 K-12 polA1 his rha  Stachel et al., 
1985 
WM2949 lacI
Q
, ∆araBAD ∆rhaBAD ∆araFGH ∆araE J. Cronan: 
(Datsenko and 
Wanner, 2000) 
ECF529 
with  wt pir gene 
 
WM2949:attB_::PBAD-pir rrnBPI(CTC-AGA) 
-lacYA177C 
M. Filutowicz; 
Sheryl. A. 
Rakowski, 
University of 
Wisconsin-
Madison 
(Bowers et al., 
2004) 
ECF530 
With hyperactive 
variant of pir gene 
WM2949:attB_::PBAD-pirP106LᶺF107S 
rrnBPI(CTC-AGA)-lacYA177C 
Pseudoalteromonas sp 
SANK 73390 
Wild type (W.T) strain which produces 
thiomarinol (yellow strain) 
Fukuda et al., 
2011 
Pseudoalteromonas sp 
SANK 73390 
pTML1 (thiomarinol gene cluster removed) 
cured (white strain) 
Fukuda et al., 
2011 
 
  Table 6.2 Antibiotics used in this study. 
Antibiotic Stock solution (mg/ml) Working solution (µg/ml) 
Ampicillin 100 100 
Kanamycin sulphate 50 50 
Chloramphenicol  34 34 
Ampicillin 25 25 
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 Table 6.3 Primers used in this study. 
Gene Primer Length 
(bp) 
         Primer sequence, 5’→3’ Purpose Rerstriction 
      sites 
 
pTML1 
-Junk 
DNA 
FPJunk DNA    17 AGGGATCCGCTGTGTTT  
Junk DNA 
Construc- 
tion 
    BamHI 
RPJunk DNA    21 AGAAGCTTTTTTACTTGGTCA    HindIII 
RK6 
gamma 
   (γ) 
region 
 
FPR6K-γ- 
     origin 
   24 GAATTCTGTCAGCCGTTAAGTGTT R6K 
Gamma 
 origin 
construc- 
tion 
    EcoRI 
RPR6K-γ- 
     origin 
   24 TCTAGAGTCCATCATGACCTTGAG     XbaI 
  
klaC- 
RK2 
FPklaC-RK2    42 AAGCTTCGAGATCTCGTGTACACGG 
GTTCGTGCGATCCGTCT 
 
 
klaC con- 
struction 
 
   HindIII, 
   BglII 
   BsrGI 
RPklaC-RK2    26 TCTAGACCAGCCCAACAAAGCCGG 
TT 
    XbaI 
 
 
 
 
pTML1 
capture 
FP(A)-pTML1 
           -Junk 
   27 GGTACCCATTAACAACGCAGCAAT 
ATA 
 
For check- 
   ing the 
integration 
 of suicide 
   vector 
  without 
  pir gene 
into pTML1 
 
  BamHI  
RP(B)-pTML1 
           -Junk 
   27 CTGCAGGTTGGGCAGAATCTAATTA 
TT 
     PstI 
FP(D)-R6K- 
            Junk 
   27 CTGCAGGAGGCTATTTAAGTTGCTG 
AT 
    PstI 
RP(C)-tet
R
- 
           Junk 
   27 GGTACCCAGAGCCATGTAGACAAC 
ATC 
   KpnI 
  
 
 
 
 
Table 6.4 Plasmids used or constructed during this study. 
 
Plasmid  
  
Size 
(kb) 
 
Relevant properties 
 
Reference or source 
 
pACYC184 
 
4.245 
 
Mob
-
, cat(CmR), TcR , P15A_replicon 
 
 
Chang and Cohen, 
1978 and NEB 
 
RK2 
 
60.0 
 
TcR , Ap R, Km R, oriV replication 
 
Jobanputra and 
Datta, 1974 
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pRK353 
 
11.05 
 
TrpE 
+
, R6K replicon 
 
Kolter and Helinski, 
1978b 
 
pGEM-T 
Easy 
 
3.0 
 
Ap
R
, lacZα (PCR cloning vector) 
 
Promega 
 
pGEM-T 
Easy -Junk 
 
3.5 
 
0.5 kb BamHI-HindIII PCR fragment of 
pTML1-Junk DNA cloned into pGEM-T Easy 
vector   
 
Anthony. S. Haines 
 
pACYC184 
-Junk 
 
4.745 
 
0.5 kb BamHI-HindIII PCR fragment of 
pTML1-Junk DNA cloned into pACYC184 
 
Anthony. S. Haines 
 
pAM01 
 
6.045 
  
1.3 kb BamHI-SalI TcR gene from RK2 cloned 
into BglII-SalI sites of pACYC184-Junk 
 
This study (Fig. 6.4) 
 
pAM02 
 
66.04 
 
60.0 kb RK2 with pAM01 (RK2- pACYC184 
derivative or hybrid) 
 
This study (Fig. 6.6) 
 
pAM03 
 
49.7 
 
EcoRI deletion of pAM02 plasmid (RK2- 
pACYC184 derivative or hybrid)  
 
This study (Fig. 6.6) 
 
pAM04 
 
60.75 
 
pAM03 plasmid with R6K replicon-pRK353 
(RK2-pACYC184-R6K derivative)  orientation I 
 
This study (Fig. 6.8) 
 
pAM05 
 
60.75 
 
pAM03 plasmid with R6K replicon-pRK353 
(RK2-pACYC184-R6K derivative) orientation II 
 
This study (Fig. 6.8) 
 
pAM06 
 
6.55 
 
0.51 kb HindIII,BglII,BsrGI-XbaI PCR fragment 
of klaC-RK2 cloned into pAM01 (pACYC184 
derivative) 
 
This study (Fig. 
6.11) 
 
pAM07 
 
7.02 
 
0.47 kb BglII-BsrGI fragment of  γ-region 
digested from R6K replicon and cloned into 
pAM06 (pACYC184 derivative) 
 
 
This study (Fig. 
6.11) 
 
pAM08 
 
67.02 
 
60.0 kb RK2 with pAM07 (RK2-R6K- 
pACYC184 derivative). HR via klaC 
 
This study (Fig. 
6.11) 
 
pAM09 
 
67.02 
 
60.0 kb RK2 with pAM07 (RK2-R6K- 
pACYC184 derivative). HR via Tc
R
 gene 
 
This study (Fig. 6.11 
and 6.13) 
 
pAM10 
 
62.75 
 
 
EcoRI deletion of pAM08; ( plasmid with 
oriVRK2 & P15A replicon ) (- Junk DNA) 
 
This study (Fig. 
6.11) 
 
pAM11 
 
 
50.72 
 
EcoRI deletion of pAM09; (non self-replicating 
plasmid (depends on chromosomally expressed 
pir gene) ) (suicide vector) 
 
This study (Fig. 
6.13) 
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6.3 Results 
6.3.1 Construction of a suicide RK2 derived vector depending on the 
pACYC184   plasmid 
    For mobilising pTML1 plasmid carrying the biosynthetic genes of thiomarinol, and as a 1st 
attempt, a suicide vector was designed that would have lost oriVRK2 constructed through a 
series planned steps to capture pTML1 plasmid and move it out of the original host 
Pseudoalteromonas spp. SANK 73390 to strains like E.coli and Pseudomonas putida.    
 
6.3.1.1 Cloning a non-essential DNA segment from pTML1 and RK2 tetR 
gene into pACYC184 plasmid 
    A piece of DNA (0.5 kb) designated “junk DNA” because it does not appear to encode an 
essential part of the plasmid pTML1 (that carries the thiomarinol biosynthetic genes) was 
amplified and sequenced using vector pGEM-T Easy. The junk DNA was then cloned into 
BamHI-HindIII sites of pACYC184 using DH5α as a host and selecting CmR. The new 
plasmid was designated pACYC184-Junk (Figures 6.4 and 6.5A). This part of the project was 
completed by Dr. Anthony Haines and Prof. C. M. Thomas. However, I used the primers 
designed for the junk DNA later on to confirm junk DNA in the wild type 
Pseudoalteromonas spp. SANK73390, and its absence in pTML1 cured mutant strain.  
     DNA of broad host range vector RK2 plasmid was prepared by Maxi- prep as described in 
part 3.2.3.1 of Chapter 3 of this thesis. Then DNA of this plasmid was digested with BglII-
SalI to release 1.3 kb fragment of tetR from Tc
R 
(tetracycline resistance) gene (Figure 6.5B). 
This DNA was ligated with DNA of pACYC184-Junk that was digested with BamHI-SalI 
and transformed into DH5α selecting CmR. A number of CmR plasmids were isolated by this 
method. One such plasmid, pAM01 plasmid (Figure 6.4), had the tetR fragment inserted  
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Figure 6.4 Construction of pACYC184-Junk, and pAM01. pGEM-T Easy-Junk and 
pACYC184 were digested with BamHI-HindIII to clone the junk fragment into pACYC184 
and then ligated. BHR RK2 vector was digested with BglII-SalI to clone tetR into BamHI-
SalI of pACYC184-Junk and then ligated.  
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downstream of the Junk region, while others possible clones did not. This result was 
confirmed by SalI-HindIII digestion which released a DNA fragment of 1.8-2.0 kb (Figure 
6.5C).   
 
 
 
Figure 6.5 Construction of pACYC184 (pAM01) plasmid carrying the junk fragment 
and RK2-tetR. Junk fragment cloned into HindIII-BamHI of pACYC184 in A, the release of 
1.3kb tetR from RK2 by BglII-SalI digestion and BamHI-SalI digested pACYC184-Junk in 
B, and HindIII- SalI digestion confirmed pACYC184 carrying both  junk DNA and RK-tetR 
in C.  
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6.3.1.2 Recombination of pAM01 plasmid with RK2 in C600 and 
construction of pAM02 in C2110  
     Transformation of pAM01 plasmid (with RK2-tetR) into E.coli C600 harbouring RK2 
selecting CmR and KmR to allow low frequency homologous recombination to take place to 
create pAM02 (Figure 6.6) was performed. However, pAM01 plasmid is able to replicate in 
this strain because C600 is polA1
+
. This strain was used for conjugation with C2110 (polA1ˉ) 
selecting CmR and KmR in order to isolate pure pAM02 plasmid and to exclude the possibility 
of having pAM01 plasmid as well (plasmids without HR), in which the later one is (polA1ˉ) 
and unable to replicate in C2110.              
     To confirm the right organisation, pAM02 plasmid was digested using single EcoRI 
digestion and different combinations of restriction endonucleases, such as EcoRI-BamHI, 
EcoRI-BamHI-XbaI, EcoRI-BglII, EcoRI-BglII-XbaI, BamHI-BglII and EcoRI-HindIII 
(Figure 6.7). In order to remove oriVRK2, pAM02 plasmid digested with EcoRI, was heat 
treated at 80
o
C for 20 minutes to inactivate the enzyme, and then ligated back to construct 
pAM03 (under the control of P15A replicon) plasmid (Figure 6.6). This trial was repeated 
several times, but they were not successful to construct pAM03 plasmid at this stage since 
EcoRI digestion did not give the plasmid. However, this plasmid (pAM03) was constructed 
later on and confirmed as Km R, Ap S, CmS in section 6.3.3 of this Chapter when combined 
with pRK353 (with R6K replicon) for the construction of pAM04 and pAM05 plasmids.  
 
6.3.2 Attempt to capture and mobilise pTML1 using pAM02 plasmid under 
the control of oriVRK2 
     As a 1st attempt to mobilise pTML1, C2110 carrying the confirmed pAM02 plasmid, the 
co-integrant with the Junk DNA was used for conjugation with Pseudoalteromonas spp. 
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SANK 73390 carrying pTML1 plasmid. Selecting KmR and CmR. C600 with RK2 was used 
for conjugation as a control selecting KmR. Since both of the two plasmids, pAM02 and RK2, 
transferred to Pseudoalteromonas spp. SANK 73390 similarly with a high frequency, the fact 
which indicates that there is no need for pAM02 plasmid to integrate into pTML1 plasmid in 
the new host in order to be replicated. Plasmids were isolated out of Pseudoalteromonas spp. 
SANK 73390 for both of the two cases and checked by comparing with pAM02 plasmid. 
Although the isolated plasmids looked different in size, there was no clear evidence for the 
integration of the suicide pAM02 plasmid into pTML1, as most of the plasmids were faint 
and smeary. Also it was difficult to conclude that the larger sized plasmids are the suicide 
vector with pTML1. Therefore, to determine whether pTML1 plasmid was captured or not, 
the same Pseudoalteromonas spp. SANK 73390 isolates which had been used previously for 
plasmid isolation were re-used for conjugation with DH5α and C2110 selecting KmR, and 
KmR, CmR, respectively, moving out the suicide vector possibly with pTML1 captured. The 
same hosts with KmR selection had been used for moving the control RK2 plasmid out of 
Pseudoalteromonas spp. SANK 73390. In order to determine whether pTML1 was captured 
and moved out of the original host (Pseudoalteromonas spp. SANK 73390), plasmids 
isolated from DH5α and C2110 were compared with control RK2 vector isolated from same 
strains as well. Although plasmids with possible pTML1 captured should look quite different 
from RK2 vector, there was no indication of pTML1 with the suicide vector that was used for 
mobilising it. Therefore, this result indicates that our suicide vector was unable to mobilise 
the plasmid (pTML1) carrying thiomarinol biosynthetic genes cluster, and this is mostly due 
to the fact that oriVRK2 and trfA must still be functional in this host and makes it able to 
replicate in Pseudoalteromonas spp. SANK 73390, so that there is no need for it to integrate 
into pTML1 in order to replicate.  
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Figure 6.6 Construction of pAM03 (-oriVRK2) vector. Plasmid pAM01 with RK2-tetAʹ tetR 
was used for HR with RK2 in C600. Plasmid pAM02 isolated from C2110 was digested with 
EcoRI to remove oriVRK2 for the construction of pAM03.   
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Figure 6.7 Confirmation of the right orientation (I) of pAM02 plasmid recombined with 
RK2 (HR). Orientation I would give plasmid with only oriVRK2 located between the two 
EcoRI sites, while both oriVRK2 and P15A replicon will be located between the two EcoRI 
sites with orientation II and EcoRI digestion will remove oriTRK2. EcoRI and BamHI-BglII 
digestion in A, and digestion with different combinations of EcoRI-BglII/XbaI and EcoRI-
BamHI/XbaI in B. These digestions would release fragments smaller than these in case of 
orientation II and that is based on the position of the junk DNA within the plasmids 
(orientation I and II).  
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6.3.3 Construction of a suicide vector depending on R6K replicon 
     An alternative strategy adopted to demonstrate whether it could be feasible to capture 
pTML1 and mobilise it out of Pseudoalteromonas spp. SANK 73390, is to put the suicide 
pAM03 plasmid under the control of another replicon. This strategy was achieved by 
replacing the oriVRK2 by the R6K (PolA-independent) replicon because it was thought that the 
R6K replicon had a narrower host range and therefore may not function in 
Pseudoalteromonas spp.   
     The 11.05 kb pRK353 (TrpE 
+
) plasmid (Figure 6.8) with R6K replicon isolated from 
MV10 was precisely confirmed by digestion with HindIII in addition to EcoRI, and EcoRI-
BamHI digestion (Figure 6.9B). DNA of this molecule was digested with EcoRI to produce a 
single cut per plasmid DNA molecule. This DNA was ligated with plasmid DNA of pAM02 
that had been digested with EcoRI (deleting oriVRK2 and Ap
R gene to produce pAM03 
plasmid) and transformed into MV10 selecting KmR (Figure 6.9C). Several KmR plasmids 
were isolated by this method. Although the orientation is not a problem with these plasmids, 
HindIII digestion of those plasmids confirmed that there were plasmids with both orientations 
(Figures 6.8 and 6.9D) designated pAM04 and pAM05, respectively. Those two new 
plasmids with the R6K replicon were confirmed as Km R, Ap S, CmS.  
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Figure 6.8 Construction of hybrid RK2-R6K vector. pAM03 (-oriVRK2) and pRK353 (self-
replicating R6K derivative) were digested with EcoRI and then ligated. KmR colonies 
obtained by transformation of MV10 with this DNA were screened for ApS and CmS, while 
colonies with KmR, ApS and CmS were examined for plasmid DNA. Two sorts of plasmids 
differing by orientation of pRK353 with R6K replicon were constructed. These plasmids 
designated as pAM04 and pAM05, respectively.  
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Figure 6.9 pRK353, a derivative of R6K plasmid and the construction of pAM04 and 
pAM05 plasmids. A, intact pRK353 presented and confirmed by HindIII and EcoRI-BamHI 
digestion in B. EcoRI digestion of pAM02 plasmid (C), and pAM04 and pAM05 plasmids 
with R6K replicon confirmed by HindIII digestion (D).   
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6.3.4 Attempt to capture and mobilise pTML1 using suicide pAM04 and 
pAM05 vector with R6K replicon 
      The new suicide vector (pAM04 and pAM05) with the R6K replicon, rather than oriVRK2 
from the (BHR) RK2 plasmid was used for the attempted integration into pTML1. MV10 
with either of those two vectors separately was used for bacterial conjugation with 
Pseudoalteromonas spp. SANK 73390 carrying pTML1 and SANK 73390 cured of pTML1, 
respectively, selecting KmR. Surprisingly, growth was detected for both strains, which 
indicate that the suicide vectors with the R6K replicon are able to replicate in the SANK 
strains. Most of the plasmid DNA preparations isolated out of bacteria resulting from the 
conjugation were smeary. However, a few of them were better, but still did not provide any 
evidence of integration with pTML1. Moreover, plasmid DNA isolated from the pTML1 
cured strain were also smeary and even heat treatment of plasmid DNA did not help to clarify 
them. This might indicate that the suicide vector was able to replicate autonomously, and 
replication in bacteria cured of pTML1 could be taken as good evidence for that. 
Furthermore, it should be noted that the DNA molecules isolated from the pTML1 cured 
bacteria were not looking like chromosomal DNA, but rather were plasmid DNA. 
Additionally, the presence of the “junk DNA” in the wild type Pseudoaltermonas spp. SANK 
73390 carrying pTML1 plasmid, suicide vector (with R6K replicon), and the trans-conjugant 
of the wild type SANK 73390 with suicide vector, and its absence in SANK 73390 strain that 
is cured of pTML1 was confirmed by PCR (Figure 6.10). It therefore appears that the R6K 
replicon can function in Pseudoalteromonas spp and therefore this plasmid is not suitable to 
be used as a suicide plasmid.    
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Figure 6.10 PCR for presence of 0.5 kb “junk DNA”. Lanes from left to right; M: 1 kb 
marker ladder, Lane 1 and 2: Pseudoalteromonas spp. SANK 73390 with pTML1, Lane 3: 
SANK 73390 cured of pTML1, Lane 4: suicide RK2-R6K hybrid (PAM05) plasmid, Lane 5, 
6 and 7: conjugant of WT SANK 73390 with the suicide vector, and Lane 8: control negative.  
  
 
 6.3.5 Construction of RK2 suicide vector with junk DNA depending on 
chromosomal expression of π-protein for replication and maintenance  
     Because neither of the previous strategies to capture pTML1, based on replacement of the 
oriVRK2 with the P15A replicon or the R6K replicon, had worked for different reasons an 
alternative approach was devised. This involved constructing a suicide vector that depends on 
induction of chromosomally expressed π-protein which is essential for replication from the 
R6K replication origin using strains from Marcin Filutowicz as described in Table 6.1. These 
strains have the pir (encoding the R6K π-protein) gene inserted in the chromosome. In order 
to construct that vector, two different routes were followed.  
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6.3.5.1 Substituting R6K and P15A replicons in pAM05 vector with R6K γ-
origin  
    The key requirement for this new strategy was to have the R6K replication origin separate 
from the gene, pir, encoding the essential replication protein. According to the map of R6K 
plasmid, the location of the pir gene spans the region between two HindIII fragments 
designated as 9 and 15, while that of the γ-origin was specified to the junction of HindIII 
fragments 4 and 9 (Stalker et al., 1982). It has also been demonstrated that in trans 
expression of pir gene (encoding π- protein) and γ-origin supports the replication of R6K 
derivatives that only have γ-origin (Kolter et al., 1978), in contrast to derivatives with either 
α or β origins, respectively (Shafferman et al., 1981). Therefore, the γ-origin was PCR 
amplified using the R6K sequence available from Sanger Institute and using pRK353 (R6K 
derivative) plasmid as a template without including pir gene. The forward primer contained 
an EcoRI site while the reverse primer contained an XbaI. To construct a plasmid with γ-
origin only (depending on chromosomal expression of π- protein), pAM05 plasmid DNA was 
digested with EcoRI-XbaI to remove both R6K and P15A replicons. This DNA was ligated 
with the amplified DNA of the γ-origin that has the same sticky ends and transformed into 
ECF529 and ECF530 (with pir gene in the chromosome) strains, using wild type WM2949 as 
control, selecting KmR with arabinose. Plasmid DNA was isolated from ECF529 and ECF530 
(with hyperactive pir gene), but these plasmid bands were faint and could not be digested 
with EcoRI-XbaI. This step was carried out so as to clone RK2-klaC subsequently into XbaI-
HindIII sites of pAM05 plasmid downstream the R6K γ-origin. However, since cloning of 
R6K γ-origin apparently was not successful, and we found that HindIII is cutting within the 
sequence of the R6K γ-origin if we try to clone RK2-klaC into XbaI-HindIII sites, therefore, 
we moved to an alternative plan.       
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  6.3.5.2 Construction and characteristics of the γ-ori expression vector 
     The first attempt to replace the R6K and P15A replicons in pAM05 plasmid with γ-origin 
was unsuccessful as mentioned in the previous section. The alternative plan was to use a 
linker to clone RK2-klaC first into pAM01 plasmid to avoid HindIII cutting within γ- origin, 
then cloning the γ-ori of R6K replicon (Figure 6.11). A 0.51 kb segment of klaC of RK2, one 
of the genes in the kilA operon was amplified and sequenced (Figure 6.12A) and then cloned 
into the HindIII-XbaI sites of pAM01 (Figure 6.12B) using a small linker HindIII, BglII, 
BsrGI- XbaI selecting CmR. Isolated plasmids were confirmed as having klaC, and designated 
as pAM06. DNA of this plasmid was digested with BglII-BsrGI and ligated with BglII-BsrGI 
fragment (γ-origin) of pRK353 with the R6K replicon (Figure 6.12C) and transformed into 
DH5α selecting CmR. Transformants were confirmed as carrying plasmid pAM07 (Figures 
6.11 and 6.12D) having both klaC and R6K γ-origin cloned accurately. As pAM01 plasmid 
had the tetR gene from RK2, therefore, pAM07 plasmid is deliberately carrying two DNA 
fragments from RK2, tetR and klaC genes, allowing sequential double recombination which 
should give the plasmid that we wished to construct.  
    For recombination with RK2 via one of the RK2 fragments, C600 was transformed with 
pAM07 selecting KmR and CmR. XbaI–SalI digestion of plasmids isolated from transformants 
of C600 confirmed klaC and R6K γ-origin in pAM07 vector with preliminary evidence of 
recombination, using RK2 as a control (Figure 6.12E). The transformants were used for 
conjugation with the strains ECF529 and ECF530 that provide the R6K replication protein 
and would therefore allow the product of resolution to survive if they carry the R6K 
replication origin. KmR and CmR were selected and 0.05% arabinose was added to induce 
expression of the pir gene. EcoRI digestion of isolated plasmids showed that both possible 
recombinations of the component segments had been obtained and these were designated 
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pAM08 and pAM09 (Figure 6.11). In theory, EcoRI digestion and re-ligation of these two 
plasmid should give pAM10 (Figure 6.11) and pAM11 (Figure 6.13) plasmids, respectively. 
The recombinant releasing a 4.4-4.8 kb EcoRI fragment (pAM08) is not the required plasmid 
because deletion of the small EcoRI fragment would generate a plasmid without either the 
junk DNA or the R6K γ-origin (pAM10) (Figure 6.12F). By contrast, the plasmid that 
released an EcoRI fragment of 16.0-16.3 kb (pAM09) was the preferred recombinant because 
EcoRI deletion would generate a plasmid (pAM11) that would depend on the π- protein 
(Figure 6.14A). Therefore, plasmids that release a fragment of about 16.0-16.3 kb were 
digested with EcoRI, the enzyme heat-inactivated and ligation then performed followed by 
transformation of ECF530 selecting KmR and CmR; KmR; and CmR, respectively. 
Transformants resistant to kanamycin were confirmed as chloramphenicol sensitive. 
Unfortunately, the isolated plasmids out of ECF530 were still able to replicate in WM2949 (-
pir), and even in C2110 which excluded the possibility of replicating via the P15A replicon. 
Further EcoRI, and EcoRI-SalI digestions showed the 16.0 kb EcoRI fragment re-ligated back 
to the vector.   
     The gel purified and ligated plasmid resulting from the EcoRI digestion of the plasmid 
pAM09 was another trial to construct plasmid pAM11, which it did not replicate in the WT 
WM2949, but it did replicate in ECF530 as required. However, this was also not helpful, 
because EcoRI digestion of the isolated plasmids did not give an intact plasmid DNA. 
Therefore, 10 of the plasmids (pAM09) isolated out of ECF529 and ECF530 described 
previously, that were confirmed having the 16.0 kb EcoRI fragment, were digested with 
EcoRI, the enzyme heat-inactivated and ligation performed in a larger volume (100 µl), then 
followed by transformation of ECF529 and ECF530 selecting KmR with 0.05% arabinose 
only, since these plasmids were confirmed as chloramphenicol sensitive. From the isolated 
plasmids digested with EcoRI, two of them had lost the 16.0 kb fragment, which means they 
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should have no oriVRK2-Tn1 region (Figures 6.14C). Further digestion using EcoRI-BsrGI, 
XbaI-BsrGI, BsrGI-BglII, confirmed both of these two plasmids as having the γ-origin 
(Figure 6.14B), and EcoRI-BamHI showed that they have lost the AmpR gene. Moreover, 
digestion with EcoRI, EcoRV, EcoRI-EcoRV (Figure 6.14C, D and E), more accurately 
confirmed that they are the right suicide vector (pAM11) using RK2 plasmid, and plasmids 
from both C600 and C2110 as controls. Faint growth of ECF530 (with PBAD promoter and pir 
gene) strain with these plasmids in broth culture without arabinose was observed, while better 
growth was observed with 0.05% arabinose. This is consistent with Bowers et al., (2004) 
observation that PBAD promoter is leaky enough to give support of maintenance of γ-ori 
plasmids even in the absence of arabinose by supplying sufficient levels of π-protein.     
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Figure 6.11 Scheme for the construction of the suicide vector (hybrid of RK2-R6K γ-ori) 
but showing the undesired plasmids. Plasmid pRK353 digested with BglII-BsrGI released a 
0.47 kb γ-ori fragment which was ligated between the BglII-BsrGI sites of pAM06 to give 
pAM07 plasmid. EcoRI digestion of pAM08 plasmid out of recombination of pAM07 
plasmid with RK2 via klaC region (HRI) would give plasmid pAM10 which does not have 
the desired properties and was not constructed.   
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Figure 6.12 Cloning klaC and R6K γ-ori into pAM01 plasmid for recombination with 
RK2. Using RK2 and pAM05 plasmids 0.51 kb klaC amplified (A) and cloned into pAM01 
for the construction of pAM06 (B) which was digested with BglII-BsrGI to clone 0.47 kb 
R6K γ-ori out of pAM05 plasmid (C). Construction was confirmed by XbaI-HindIII (D) and 
XbaI-SalI (E) digestions. EcoRI digestion of pAM08 plasmid out of recombination of 
pAM07 with RK2 via RK2-klaC (HRI) released 4.8 kb designated as pAM10.     
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Figure 6.13 Construction of suicide vector (hybrid of RK2-R6K γ-ori). Plasmid pRK353 
digested with BglII-BsrGI released a 0.47 kb γ-ori fragment which was ligated between the 
BglII-BsrGI sites of pAM06 to give pAM07 plasmid. EcoRI digestion of pAM09 plasmid out 
of recombination of pAM07 plasmid with RK2 via tetR region (HRII) of tetracycline 
resistance gene gave the suicide vector pAM11 with R6K γ-ori.    
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Figure 6.14 Confirmation of the construction of the pAM11 suicide vector (RK2-R6K γ-
ori hybrid) with the junk DNA. EcoRI digestion of pAM09 plasmid out of recombination of 
pAM07 with RK2 via RK2-tetR (HRII) released 16.3 kb designated as pAM11 (A) which 
had been digested with BsrGI/EcoRI, BsrGI/XbaI and BsrGI/BglII, respectively (B), and 
confirmed by EcoRI, EcoRV, and EcoRI/EcoRV digestions (C, D and E) using RK2 and 
plasmids out of C600 and C2110 as controls.       
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6.3.6 Successful integration but not mobilisation of pTML1 by suicide 
vector RK2 with R6K γ-ori depending on chromosomal expression of π- 
protein      
     The suicide vector based on RK2 with R6K γ-ori and without oriVRK2-Tn1 region 
constructed in section 6.3.5.2 in ECF530 with pir gene in the chromosome was next used for 
conjugation with Pseudoalteromonas spp SANK 73390 selecting KmR, using pTML1 cured 
SANK 73390 as a control. The experiment was performed more than in triplicate, and the 
result showed transconjugants on plates with both the wild type SANK 73390 and the 
pTML1 cured strain as well. However, growth of typical colonies of SANK 73390 with 
optimum numbers was seen only on plates from the conjugation with the wt carrying pTML1. 
In contrast, mostly small to tiny colonies were seen on plates from the conjugation with 
pTML1 cured strain, and those might have been just the donor E. coli ECF530 (Table 6.5).   
 
 
Transconjugation  
replicates 
 
WT SANK 73390 
 
 
pTML1 cured SANK 73390 
 
Numbers and description of colonies on plates with different 
dilutions 
 
1 Typical colonies up to 10
-5 
(a 
few colonies on 10
-4 
and
 
10
-5
) 
Mixed of S and M colonies up to 10
-
4 
(3-4 colonies on 10
-4
)  
2 Typical colonies up to 10
-5 
(3-4 
colonies on 10
-4 
and 10
-5
) 
S and M colonies up to 10
-3 
(no 
colonies on 10
-4 
and 10
-5
) 
3 Typical and small colonies up to 
10
-5
 
90% tiny colonies up 10
-4
 
4 Typical and small colonies up to 
10
-5
 
Tiny colonies on some of the plates 
5 Typical colonies on 10
-2
 and 10
-3 
only  
90% tiny colonies up to 10
-2 
only 
6 Typical colonies up to 10
-5
 S and M colonies up to 10
-4 
 
 
Table 6.5 Showing number of the colonies on plates of different dilutions out of 
transconjugation of the suicide (RK2-R6K-γ-ori hybrid) vector with the WT and the 
pTML1 cured strains of SANK 73390. 
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     To check for suicide vector integration into pTML1 in the WT SANK 73390, PCR was 
performed using primers labelled A to D described in Table 6.3 and designed to give a 1.0 kb 
product. Suicide vector (RK2 with R6K γ-ori), WT SANK73390, SANK 73390 (-pTML1 
cured) without and with suicide vector (trans-conjugant) were used as controls. Ideally, 
primers A and B should amplify a fragment running through the junk DNA in the WT 
carrying pTML1, and should give 1.0 kb product in case of the WT strain but not in the 
pTML1 cured strain. Primers C and D should amplify a fragment of RK2-tetR and a fragment 
of R6K γ-ori while running across the junk DNA in the suicide vector pAM11 (a hybrid of 
RK2-R6K γ-ori) to give 1.0 kb product (Figure 6.15). PCR using A and B primers gave a 1.0 
kb product in case of WT with pTML1, but not with pTML1 cured strain and the negative 
control. In addition, PCR using C and D primers gave a 1.0 kb product with suicide vector 
(RK2 -R6K γ-ori hybrid), but not with the negative control (Figure 6.16). These results are 
exactly what we were expecting for two reasons, first it confirmed the presence of pTML1 in 
the WT SANK 73390, and its absence in pTML1 cured strain; second it indicates the 
presence of the junk DNA and R6K γ-ori in the suicide vector. Therefore, and based on 
recombination between the suicide vector and pTML1 in the WT SANK 73390, PCR was 
performed using combinations of primers, A with D and B with C to check for suicide 
integration into pTML1 of WT strain (Figure 6.15). Trans-conjugants with the pTML1 cured 
strain which cannot undergo recombination with pTML1 were used as a negative control. The 
1.0 kb PCR product (Figure 6.16) observed with both combinations of primers in case of 
trans-conjugant with WT (carrying pTML1), indicated the correct integration of the suicide 
vector into pTML1. The first combination of primers did not give PCR product in case of 
trans-conjugant with the pTML1 cured strain, which is expected, however, and surprisingly, a 
faint 1.0 kb product observed with the second combination of primers (B and C). This is rele- 
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Figure 6.15 Investigation of the suicide (RK2-R6K γ-ori hybrid) vector integration into 
pTML1 in the WT SANK 73390. Primers A and B designed to amplify a 1.0 kb fragment 
running across the junk DNA in the WT carrying pTML1, and primers C and D designed to 
amplify a 1.0 kb fragment in the suicide vector running through the junk DNA including part 
of RK2-tetR in one side and part of R6K γ-ori in the other side.  
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vant with primer C since it normally amplifies part of RK2-tetR before running through the 
junk DNA in the suicide vector, which it might be able to replicate in the pTML1 cured 
strain. However, it is peculiar with primer B, since we precisely confirmed that SANK 
pTML1 cured strain is lacking pTML1, but it might be due to annealing of primer B 
somewhere else within the vector as the PCR product looks different in size compare to the 
1.0 kb product of trans-conjugant with WT.      
 
 
Figure 6.16 Confirmation of the suicide vector integration into pTML1 plasmid. Top 
lanes from left: M, 1 kb marker ladder; lane1, WT SANK 73390; lane 2, SANK 73390 
pTML1-cured; lane 3 and 6, negative controls; lane 4 and 5, suicide vector with R6K γ-ori; 
lanes 7 to 13, suicide integration into pTML1 of WT SANK; lanes 14 to 18 at the top, 19 and 
20 at the bottom left, SANK pTML1-cured. Bottom lanes from left: 1 to 7, suicide integration 
into pTML1 of WT SANK; unused lane 8; lanes 9 to 13, SANK pTML1-cured. 
 
      In order to be certain about the correct direction of the primers, for example primers A in 
the WT SANK with pTML1 and primer C in the suicide vector that are running through the 
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BamHI site of the junk DNA, the fact which provides good evidence to the previous result of 
the suicide integration into pTML1. PCR was performed using normal combination of 
primers (A+B and C+D) to check the trans-conjugant. Results showed a 1.0 kb product with 
both combination of primers in case of trans-conjugant with WT carrying pTML1, and only 
with the combination of C and D primers in the case of trans-conjugants with pTML1 cured, 
while no product was observed when A and B primers were used for trans-conjugant with 
pTML1 cured (Figure 6.17). The presence of products with C and D might indicate the 
possibility of having different copies of the plasmid in the trans-conjugant with WT, such as 
pTML1, suicide vector (RK2 with R6K γ-ori), and suicide vector integrated into pTML1, but 
only the presence of the suicide vector in the trans-conjugant with pTML1 cured strain. Since 
these results were encouraging, therefore, conjugation with E. coli strains ECF529 and 
ECF530 were performed to move the hybrid plasmid (RK2 with R6K γ-ori) possibly with 
pTML1 captured out of trans-conjugant of WT SANK 73390 selecting KmR with 0.05% 
arabinose. Unfortunately, plasmids isolated out of ECF strains looked similar to the suicide 
vector (RK2 with R6K γ-ori).   
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Figure 6.17 PCR checking of vector integration into pTML1 plasmid. Top and bottom 
lanes from left: M, 1 kb marker ladder; lanes 1 to 7, WT SANK 73390; lanes 8 to 12, SANK 
73390 pTML1-cured; lane 13, control negative.  
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6.4 Discussion 
     Regulation of thiomarinol biosynthetic genes carried on pTML1 plasmid, are predicted to 
be encoded by gene(s) located on the plasmid itself. This prediction was based on preliminary 
data in Chapter 2 of this thesis showing that thiomarinol production appears to be regulated 
so as to give expression in late exponential or early stationary phase. Moreover, if the 
plasmid is able to replicate autonomously in the cytoplasm of the host cell, and able to 
transfer to a recipient cell through the mode of conjugation, as two fundamental properties of 
transmissible plasmids (Willetts, 1972), then it should carry its own regulator. However, 
although the majority of essential requirements for a typical mobile DNA including 
replication, partitioning, transposition and integration were identified on five orfs, occupying 
only 7.6 kb of pTML1 DNA molecule, there was no evidence of conjugation transfer function 
(Fukuda et al., 2011). In addition, plasmids that are not self-transmissible can often be 
mobilised by other replicons, allowing them to adapt and colonize new bacterial species (del 
Solar and Espinosa, 2000). More specifically, and at the level of gene, Thomas and Nielsen 
(2005) showed the probability and usefulness of broad-host-range plasmids for the spread of 
a gene between bacteria in case the gene moves onto the vector. Therefore, the purpose of the 
study described in this Chapter was different attempts to mobilise pTML1 plasmid out of 
Pseudoalteromonas spp. SANK 73390 to investigate expression and regulation of 
thiomarinol biosynthetic genes.   
     The first attempt to capture and mobilise pTML1 plasmid was by utilising RK2 vector. 
For this plasmid to be able to integrate into pTML1 through homologous recombination (HR) 
it needs to have some homology with its target. Therefore, a suicide RK2 (pAM02) vector 
under the control of oriVRK2 with a piece of DNA, designated as ‘junk’, out of the 
biosynthetic gene cluster of thiomarinol has been constructed using plasmid pACYC184 as 
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an intermediate vector. Data from using this vector to capture and mobilise pTML1 showed 
the inefficiency of this vector to do so while using RK2 vector as a control. This might be due 
to the ability of pAM02 plasmid to replicate in Pseudoalteromonas spp. SANK 73390, which 
minimised the possibility of integration into pTML1 plasmid via the junk DNA.    
      To overcome the problem of the suicide vector replication in SANK73390, pRK353 
plasmid (Figure 6.18), a derivative of R6K replicon was used to replace the oriVRK2 in 
pAM02 plasmid when pAM03 plasmid constructed. pRK353 plasmid with R6K replicon had 
been selected according to three characteristics that made it preferable vehicle in molecular 
cloning (Kolter and Helinski, 1978b). The most relevant one is the absence of selectable  
         
Figure 6.18 Map of autonomously replicating pRK353. Restriction sites for EcoRI, 
BamHI, HindIII, BsrGI, BglII, and HaeII are shown. Sufficient R6K replicon present in this 
plasmid represented by γ-origin and pri gene and the size indicated. ptrpE, and trpE refers to 
tryptophan E gene and the promoter region.  
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 markers (antibiotic resistance) in pRK353 makes it a reasonable plasmid for cloning DNA 
fragments with BamHI, EcoRI, or BamHI-EcoRI. Therefore, suicide RK2 vector with R6K 
replicon with two orientations (pAM04 and pAM05) was constructed, and both were used for 
conjugation with Pseudoalteromonas spp. SANK 73390, using SANK pTML1 cured strain as 
a control. Apparently, these new suicide vectors with R6K replicon were also able to replicate 
both in the wild type carrying pTML1 and pTML1 cured strain as well, which excluded the 
possibility of capturing and mobilising pTML1.     
      Because the initially constructed suicide vectors were unable to mobilise pTML1, another 
suicide vector with R6K γ-ori (pAM11) was constructed so that it could not replicate without 
an exogenous source of π protein. This type of vector has been confirmed as a valuable tool 
in molecular applications (Bowers et al., 2004), including recombination studies (Alexeyev 
and Shokolenko, 1995; Metcalf et al., 1996). E.coli strains with chromosomally inserted pir 
gene, ECF529 (with wt pir gene) and ECF530 (with hyperactive pir gene) has been used for 
providing enough π protein for the initiation of replication from γ-ori of the suicide vector, 
and maintaining the plasmid copy number at an accurate levels in the cell. This is in 
agreement with Bowers et al., (2004) since a supply of π protein from the chromosome is 
preferable over provision from another helper plasmid encoding π protein. One of the 
approaches used to identify whether this new suicide vector with R6K γ-ori was able to 
integrate into pTML1 and mobilise it, was specific PCR primers designed to identify the 
suicide integration into pTML1. Results of using different combinations of PCR primers 
(A+D and C+B) indicated the suicide integration into pTML1 in case of transconjugants of 
WT Pseudoalteromonas spp. SANK 73390. Suicide (RK2-R6K- γ-ori) vector, WT SANK 
73390, and pTML1 cured strain were used as controls. This result was encouraging and 
provides a preliminary evidence of possible mobilisation of pTML1 out of the WT SANK 
73390. Using the same combination of primers for the transconjugants with the SANK 
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pTML1 cured, primers A with D did not produce any product which was as expected, 
however, primers B with C gave a faint product which looks different compare to the 1.0 kb 
product of transconjugants with WT SANK with pTML1. Presumably, this might be due to 
the annealing of primer B somewhere else within the suicide vector since there is no pTML1 
to anneal with. When the usual combination of primers (A+B) was used, only transconjugants 
with the WT SANK 73390 showed a 1.0 kb product since the primers run across the junk 
DNA, which was as expected. However, and unexpectedly, both of the transconjugants with 
the WT SANK and pTML1 cured showed a 1.0 kb product while using primers C and D, 
which usually runs across the junk DNA in the suicide (RK2-R6K γ-ori) vector. The presence 
of different copies of plasmids including the suicide (RK2-R6K γ-ori hybrid) vector and the 
suicide vector integrated into pTML1 in the transconjugant of WT SANK may be the 
possible explanation. However, the presence of suicide (RK2-R6K γ-ori hybrid) vector in the 
transconjugants of SANK pTML1 cured strain can be the only possible explanation for the 
1.0 kb product. Since we confirmed accurately the absence of oriVRK2 in this suicide vector, 
but dependence on oriTRK2 for conjugal transfer, survival of the plasmid in these strains 
might be due to the presence of P15A replicon when there is no obvious exogenous source of 
π protein. Also it might be due to the host-encoded integration host factor (IHF), if there is 
any, which has been demonstrated to permit the replication from γ-ori through the binding to 
one IHF site (ihf1) only, but not the second IHF site (ihf2) within the γ-ori when the level of π 
protein is inhibitory (Dellis et al., 1996).     
   Subsequently, and as the other side of the previous approach, plasmids isolated from 
ECF529 and ECF530 when suicide RK2 derivative (RK2-R6K γ-ori hybrid) possibly with 
pTML1 moved out of SANK strains to E. coli strains by conjugation. Unfortunately, the 
plasmids seem to be similar to the suicide vector. Therefore, although previous data in SANK 
73390 with pTML1 and pTML1 cured strains did show the suicide integration into pTML1 
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was which was really encouraging, however, the reason for not been able to mobilise pTML1 
might be due to the size of both pTML1 (97 kb) and the suicide vector pAM11 (50.72 KB), 
respectively.     
      Overall, this study demonstrated the ability to integrate with pTML1 plasmid carrying the 
biosynthetic gene cluster of thiomarinol using suicide RK2-R6K (γ-ori only) hybrid vector. 
However, the reason why attempts to mobilise pTML1 were unsuccessful is unclear. Further 
experiments need to be performed to identify possible problems and explore associated 
solutions. One possibility is that the plasmid does transfer to E. coli but then rapidly breaks 
down by recombination. In this case a recombination deficient recipient might overcome the 
problem. It might also be worth trying to make this suicide vector smaller if it is possible, 
then using it for the mobilisation. 
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7.1 General comments 
    Over the last fifty years, a huge number of diverse polyketides (PKs) was found, some of 
which are given as examples in Chapter 1.  Among them, a good number have entered 
clinical use, serving medicine via different ways, acting as anti-bacterial (antibiotics), anti-
fungal, anti-parasitic and anti-cancer agents as well as various immunological purposes and 
lowering cholesterol levels. In addition, various other compounds including non-ribosomal 
peptides (NRPSs) and of PKS-NRPS hybrids were discovered, which added extra power and 
interest to this field, although some are still underway to be used medicinally. Understanding 
the assembly lines of modular polyketides and the synthesis pattern of type II and type III 
PKSs, has already provided a critical path to genetically engineering pathways of various 
specific PKs, to produce compounds with the required alterations (Weissman and Leadlay, 
2005). However, all the way through, combinatorial biosynthesis is still under development, 
aiming to improve the process of manipulation by overcoming some key steps, which will 
facilitate different strategies. These include attempts to develop a set of universal 
‘interdomain’ and ‘intermodular’ linkers that could be used successfully for joining any 
pieces of PKS together, even if they are different based on their sequences, so as to make 
(reprogramming) a functional assembly line (Weissman, 2004). It also includes attempts to 
develop a set of orthogonal pairs of docking domains (normally located at the ends of PKS 
proteins which resist forming incorrect associations) that can simply be attached to the ends 
of the newly assembled (engineered) PKS proteins from different pathways to make sure that 
the reprogramming of the assembly line joined together in a functional and correct order 
(Weissman, 2004). The outcome of engineering the PKS and NRPS is hoped to give 
compounds with stronger activity, less toxicity, high production and various other desirable 
properties. Erythromycin is given as a model example for understanding the biosynthetic 
pathway, partly because it was the first studied in detail but also because the order of the PKS 
250 
 
genes in the cluster is colinear with its structure. However, in the mupirocin system, there are 
several interesting features which made it of a significant value. These features includes the 
order of the genes in mup cluster which is not colinear with mupirocin structure, a tran-AT 
domains, tandem ACP and a system which includes a set of reductive (tailoring) enzymes.  In 
addition to further other interesting specificities, this clearly indicates that the system is really 
valuable and very important to understand biosynthesis and adds further realistic and valuable 
engineering mechanisms to combinatorial biology. These critical tools may provide a way to 
develop mupirocin so that it could be used systemically. Thiomarinol, the hybrid of PKS 
(pseudomonic acid) and NRPS (pyrrothine) is another more interesting antibiotic, with a high 
potency (broad spectrum activity) against a wide range of bacterial groups. However, it still 
has not yet been used clinically, since more things need to be solved or discovered, including 
the way that the system is regulated. All these might be helpful in removing the toxic effect 
of this antibiotic to eukaryotic cells, if there is any, and further important aspects which needs 
to be taken into consideration, when it comes to be used in the clinic. In addition, creation of 
novel compounds through successful mutasynthesis is one of the most interesting features of 
thiomarinol, which suggests a great future with diverse and strong novel compounds that 
could be used not only for the treatment of MRSA as the case with mupirocin, or thiomarinol, 
that can overcome mupirocin resistance, but expansion to more than that.                    
 
7.2 Discussion of key conclusions  
7.2.1 Thiomarinol production is regulated, its extraction improved by adjusting the pH to 
acidic conditions and using acetone in combination with ethyl acetate   
    Production of thiomarinol by Pseudoalteromonas spp SANK 73390 after 9 h of growth, 
which is late logarithmic phase, is an indicator that the production is under regulation. 
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Logarithmic phase was confirmed as the period from 3 to 9 h after inoculation followed by 
stationary phase where the production of thiomarinol fluctuated to give a higher level at 18 h 
(the first 24 h) and 36 h (the second 24 h). Removing thiomarinol that was already produced 
in the seed culture before carrying on the growth and production in fresh medium was 
essential for the accurate designation of the initial point of thiomarinol production. In 
agreement with Shiozawa et al., (1993), a combination of acetone with ethyl acetate was 
found to give efficient extraction of the majority of the thiomarinol. Also acidic conditions 
gave improved extraction, possibly through stabilising the compound, which is consistent 
with Takahashi et al., (1995) that thiomarinol compounds can be extracted by organic 
solvents under neutral or acidic conditions. In addition, since thiomarinol is hydrophobic 
(Takahashi et al., 1995), 35% acetonitrile and 65% water were typical for the detection and 
discrimination of thiomarinol by HPLC analysis.          
 
7.2.2 TmlU, the thiomarinol amide ligase, interferes with mupirocin biosynthetic pathway 
through making pseudomonic acids with shorter fatty acid side chain (C5 PA-B and PA-A) 
    TmlU, the amide ligase in the thiomarinol system acts by linking marinolic acid 
(mupirocin analogue) and pyrrothine via an amide linkage. It was also proposed to play an 
additional role equivalent to the role of MupU in the mupirocin system, in transferring the 
growing PK chain (intermediate) to mAcpE, based on the weak similarity between them 
(Fukuda et al., 2011). However, the inability of tmlU to cross-complement mupU indicates 
that TmlU is responsible for a quite distinct and specific function. Comparison of amino acid 
sequence of TmlU with its homologues, SimL from simocyclinone (Luft et al., 2005; 
Pacholec et al., 2005) and NovL in novobiocin biosynthesis (Steffensky et al., 2000), 
suggested that it creates the amide linkage during the biosynthesis, which has been confirmed 
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tentatively and mentioned earlier by Fukuda et al., (2011). Not only did tmlU not 
complement mupU but it also interferes with the biosynthesis of mupirocin to cause the 
accumulation of a C5-pseudomonic acid A and B depending on the level of induction of 
tmlU. It therefore appears to block the second (C5-C7) and the third (C7-C9) round of 
elongation for the synthesis of 9HN (which is predicted to be the product of MmpB with 
tandem ACPs/-Ba, -Bb and -Bc (El-Sayed et al., 2003), without affecting the first 
condensation step (C3-C5). This was also the case with the wild type P. fluorescens NCIMB 
10586 and 10586∆mupX, since it was expected that MupX (amidase) in the WT counteracts 
TmlU function, which in turn caused the truncation of mupirocin. Further analysis confirmed 
that TmlU is not working like an abnormal acyl hydrolase to release the PK chain when it 
was expressed in NCIMB10586∆TE. Expression of tmlU in 10586 strains with the active site 
serine of the ACPs of MmpB mutated to alanine showed that TmlU is not targeting the active 
site. Additional data indicates that TmlU may interact with all the ACPs of MmpB, when 
tmlU was expressed in NCIMB10586 strains with single or double deletion of these ACPs. 
However, the deletion of ACP6 (Bb) significantly reduced the sensitivity of mupirocin 
biosynthesis to the negative effect of TmlU. These observations are important, since they 
provide the first evidence that MmpB is involved in the production of 9HN. But they also 
indicate that while the second and the third elongation steps happen on MmpB, it is possible 
that the first round of condensation might happen on a protein other than MmpB. It also adds 
another indication to the idea that the saturated acyl side chain in the case of mupirocin and 
thiomarinol are built up through successive elongations of the PKS derived product, rather 
than via the ligation of fully assembled fatty acids (C9 or C8, respectively) (Murphy et al., 
2011) with the PK part.     
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7.2.3 The extra KS-B2/ACP-B2 (2
nd
 module) of TmpB represents a non-elongating module in 
thiomarinol biosynthesis pathway, and the ACP-B2 has a role in the removal of C8-OH.  
    In the mupirocin cluster, macpE, which has an essential role in the last steps in the 
production of pseudomonic acid A but not pseudomonic acid B (Cooper et al., 2005a), is one 
of the genes (along with mupU and mupV) that has no equivalent in the thiomarinol 
biosynthetic cluster. However, the presence of the extra KS-B2/ACP-B2 in TmpB of the 
thiomarinol biosynthesis pathway, and its absence in MmpB of mupirocin, suggests that all 
the last tailoring steps in the production of thiomarinol might happen on TmpB (Fukuda et 
al., 2011). In-frame deletion of this extra module in TmpB minimised the production of 
thiomarinol A and B but did not eliminate thiomarinol production. This is a good indication 
that this extra KS-B2/ACP-B2 works as a non-elongating module, and that the KS-B2 
functions as a transferase, since it is not implicated in a Claisen condensation. The deletion 
also revealed the accumulation of thiomarinol molecules with an extra OH at C8, indicating 
that the ACP-B2 might be implicated in this tailoring step. Accumulation of thiomarinol C, 
which lacks OH at C4 is also interesting which might indicate a link between the removal of 
OH at C4 and hydroxylation at C8 as a result of KS-B2/ACP-B2 deletion.   
 
7.2.4 Genetic manipulation increased mupirocin production but does not reduce PA-B in 
favour of PA-A. Fused MupU-mAcpE expressed in trans as a single functional protein is able 
to convert PA-B to PA-A, does not function when inserted into mmpB 
    The proposed pathway which includes the transfer of the intermediate by MupU to 
mAcpE, following by further processing via MupO, V, C and MupF, is predicted to be 
sufficient for the conversion of PA-B to PA-A (Hothersall et al., 2007). In trans expression of 
those genes in the WT NCIMB 10586 was successful in increasing total mupirocin (PA-A 
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and PA-B) by about two fold, but did not achieve its primary goal of shutting down PA-B in 
favour of PA-A (Macioszek, PhD thesis, University of Birmingham, 2009). This was 
predicted to be as a result of the release of the ACP bound acyl intermediate (PA-B) in the 
pathway, catalysed by the thioesterase (TE) at the end of MmpB and because of a limit in the 
onward flux of the intermediate. Over-expression of mupU through genetic manipulation to 
increase the onward flux of the intermediate in the PA-A pathway, was demonstrated to 
increase the production of mupirocin by about three to four fold, but without reducing the 
level of PA-B. The increase in production might be due to an increase in the expression of the 
other genes downstream of mupU, including mupR (transcription activator), which was 
shown by Hothersall et al., (2011) to have a profound role in increasing the yield of 
mupirocin. Fusion of mupU and macpE via a small linker was performed, so that the two 
functions would be translated into a single functional polypeptide. Complementation 
achieved while expressing in trans the fused mupU-macpE in NCIMB10586∆mupU∆macpE, 
confirmed that they were translated into a polypeptide that retained both functions. In 
contrast, most of the hybrid pikAI complementation plasmids were not detectably functional 
to restore pikromycin production in a pikAI deletion mutant (Kim et al., 2004). However, 
complementation was not achieved with the insertion of the fused mupU-macpE into mmpB 
of NCIMB10586∆mupU∆macpE to make something like the extra KS-ACP of tmpB in 
thiomarinol. Indeed, the insertion blocked the biosynthetic pathway. This might indicate that 
MupU and mAcpE are not working normally at this point in the pathway, i.e after full 
elongation of the 9HN moiety. It could also indicate that the whole segment between ACP-Bc 
and TE needs to be kept intact so that TE could hydrolase and release the compound. 
However, when various reductive domains (KR, DH and ER), either singly or in 
combinations, were inserted into the second module of DEBS 1-TE version between the AT 
and the ACP by either of two linkers, production of a triketide by most of the hybrids 
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indicates that the reductive loop was treated as a single functional unit (Kellenberger et al., 
2008). Also, since the second insertion of the fused mupU-macpE was not included in mmpA 
of NCIMB10586∆mupU∆macpE, PA-B was the sole product, indicating that no alteration in 
the enzyme organisation of the biosynthesis pathway had been achieved.  
 
7.2.5 Creation of a hybrid of RK2-R6K γ-ori suicide vector depending on chromosomal 
expression of the pir gene integrates into pTML1 but did not succeed in recovering it to E. 
coli  
    The demonstration that the thiomarinol biosynthetic genes cluster is located on plasmid 
pTML1 of Pseudoalteromonas spp SANK 73390, was really interesting, but, the ambiguity 
of the regulatory gene and the absence of the conjugative transfer functions (Fukuda et al., 
2011) makes the search for the regulation complicated. Attempts to mobilise pTML1 plasmid 
to another host using different suicide vectors carrying a non essential DNA segment of 
pTML1 were implemented. The first suicide vector constructed depends on oriVRK2 has been 
constructed and used for capturing pTML1, but since the vector was able to replicate 
independently in SANK 73390, it ruled out the possibility of the integration into pTML1 and 
the mobilisation. In addition, when the oriVRK2 of the suicide vector was replaced with the 
R6K replicon for the construction of the second vector, no changes could be detected, due 
once again to the ability of the vector to replicate again. However, when a new vector 
constructed devoid of both oriVRK2 and R6K replicon, but only with the γ-origin of R6K, 
which depends on chromosomal expression of π-protein (E. coli strains ECF529 and 
ECF530) for replication, a great improvement was made. It was demonstrated that this new 
vector was successfully integrated into pTML1 plasmid but unfortunately it was not possible 
to recover the suicide vector with pTML1 in the E. coli strains ECF529 and ECF530 with 
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chromosomally integrated pir gene. The reason for why pTML1 mobilisation was 
unsuccessful is unclear. However, one possibility is that the plasmid does transfer to E. coli 
strain but it rapidly breaks down by recombination. Non-mobilised (non-conjugative) 
plasmids were transmitted at high frequencies between strains of Lacococcus lactis, when a 
specific fragment, minimal mobilisation (mob) locus of pIP501 cloned into the target 
plasmids and the transfer (tra) functions were provided in trans by a pIP501 derivative 
(Langella et al., 1993). pHel4, and pHel12, are examples of plasmids identified in many 
strains of Helicobacter pylori (Hp), which contain a mobilisation region, but are deficient in 
cognate type IV secretion system (T4SS), essential for conjugative transfer. However, certain 
Hp strains, e.g. strain P12 carrying plasmid pHel12, can harbour up to four types of T4SSs in 
their genome, and comB T4SS identified as the major mediator of plasmid DNA transfer 
between strains of Hp, in addition to providing evidence which indicates the existence of a 
T4SS-independent mechanism of DNA transfer (Rohrer et al., 2012) .    
 
7.3 Future work 
    One of the biggest issue that still needs more input, is switching on mupirocin biosynthesis 
pathway totally into pseudomonic acid A (PA-A) since the enzymes essential for this specific 
pathway have been elucidated, and the specific role determined. Manipulating the ribosome 
binding site of mupU could be useful in this regard, since it will be translated from the same 
amount of mRNA. Fused mupU-macpE has been cloned into an expression vector and can be 
utilised in future work via different strategies. Over-expression of fused mupU-macpE in the 
WT NCIMB 10586 could be really useful, since over-expression in 
NCIMB10586∆mupU∆macpE was complemented. Insertion of the fused mupU-macpE into 
mmpB by avoiding the sequence of the linker which connects ACP7 (Bc) with thioesterase 
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(TE) using two different options; the first insertion before the linker and the second after, 
could be successful. It might also be worth trying to insert the fused mupU-macpE after ACP-
A3b (before the stop codon) of mmpA. Over-expression of Malgorzata Macioszek’s plasmid 
(pMMH6), which consists of all the six genes found to be sufficient to convert PA-B to PA-
A, in NCIMB10586∆mupU∆macpE may give what is being sought. 
    The effect of TmlU on the biosynthesis of mupirocin, and the clue that has been given 
about the biosynthesis of the 9HN part should also be continued. Inactivation of TmlU by 
point mutation, then over-expression in WT NCIMB 10586 would be very useful in the 
process of investigating the negative effect of TmlU, to see whether it is still able to interact 
with mupirocin biosynthesis. Since it appears as if TmlU is targeting MmpB, and 
NCIMB10586∆ACP6 (Bb) showed less sensitivity, it could be useful to develop 
NCIMB10586 strains with all the possible options of swapping the ACPs (Ba, -Bb and –Bc) 
of MmpB and then testing the effect of TmlU. Substituting the tandem ACPs of MmpB in the 
WT NCIMB 10586 with the last three ACPs of TmpB, followed by the expression of TmlU 
in-trans would be another opportunity. An attempt to co-purify TmlU once with TmpB (from 
thiomarinol), and second with MmpB, would also serve as a proof that TmlU is targeting 
MmpB in mupirocin system. This could be achieved by expression and purification of cloned 
His-tagged TmlU, TmpB and MmpB, respectively, removing the His-tag from TmlU possibly 
then trying to elute TmlU with TmpB and MmpB, separately. While the first step of 
elongation (unaffected by TmlU) in the biosynthesis of 9HN is expected to happen outside 
MmpB, and based on the prediction that MupS, MupQ and mAcpD are implicated in the 
biosynthesis of 3HP, the starter unit of 9HN, it might be worth trying to express TmlU in  
NCIMB10586∆mupS, NCIMB10586∆mupQ and NCIMB10586∆macpD, respectively.  
    The ability of suicide (hybrid of RK2 and R6K γ-ori) vector to integrate into pTML1 
plasmid, but still allow recovery in E. coli strains ECF529 and ECF530 with chromosomally 
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integrated pir gene, needs further work to be performed to identify the possible problems and 
to explore the associated solutions. Since it has been proposed that the plasmid does transfer 
to E. coli but rapidly undergoes degradation as a result of recombination, therefore, using 
another recipient with a recombination deficiency might be useful to overcome the problem. 
Also dealing with the size of the suicide vector to make it smaller might be helpful for the 
mobilisation. Since the main goal is looking for the regulation of the thiomarinol biosynthesis 
pathway, if it is possible, it could be reasonable to construct a cosmid library of biosynthetic 
genes cluster of thiomarinol from pTML1 using an integrative shuttle vector. Introducing the 
cosmid into a strain like Streptomyces albus, fermentation and then checking the antibacterial 
activity to explore thiomarinol production. The demonstration of the initial point of 
thiomarinol production relative to growth could be useful for studying the gene expression 
via quantifying the level of RNA using the available techniques. In addition, identifying 
promoters within the thiomarinol cluster and studying the inverted repeats located in the 
space between the two divergent transcriptional units, which are predicted to be the operator 
sequences through which the genes are regulated, could be another meaningful path.  
    Regardless of all the future projects which have been mentioned earlier, leading from this 
project there are still some additional logistic steps about mupirocin which need to be 
understood, and more than that about thiomarinol needs to be discovered. In case of 
mupirocin, resolving all the critical points related to the biosynthesis of the 9HN moiety and 
the esterification with the monic acid moiety can solve the problem of mupirocin dissociation 
in the human blood circulation, which then could be used systemically. This might also 
improve combinatorial biosynthesis in mupirocin. Since there are still quite a few genes in 
the thiomarinol cluster that need to be investigated, it might be helpful to find additional gene 
(s) that confers resistance to the pyrrothine element, if there is any. It is hoped that 
NCIMB10586∆AT1 could be complemented with the type II TEs from other PKSs including 
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those encoded by the NRPS gene clusters, since they apparently are not playing an essential 
role in the biosynthesis. Complementation with the editing hydrolases (AHs) described by 
Jensen et al., (2012) might also be useful, or even insertion of these acyl hydrolases into the 
biosynthetic pathway of mupirocin might be useful to release the ACPs bound stalled 
intermediates from the blocked modules.            
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